



**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS**

Approved Formulary File Submission ID: 00022473, Version 11

This formulary was updated on 04/18/2022. For more recent information or other questions, please contact Alterwood Advantage at 1-866-267-3144 or, for TTY users, 711, 24 hours a day, 7 days a week, or visit [www.AlterwoodAdvantage.com](http://www.AlterwoodAdvantage.com).

## **Alterwood Advantage Choice 2022 Formulary (List of Covered Drugs)**

# **Alterwood Advantage Choice (HMO)**

## **2022 Formulary**

### **List of Covered Drugs**

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION  
ABOUT THE DRUGS WE COVER IN THIS PLAN**

HPMS Approved Formulary File Submission ID: 00022473, Version 11

This formulary was updated on 04/18/2022. For more recent information or other questions, please contact Alterwood Advantage Choice Member Service at 1-866-267-3144 toll-free (TTY users should call 711), 24 hours 7 days a week, or visit [www.alterwoodadvantage.com](http://www.alterwoodadvantage.com).

When this drug list (formulary) refers to “we,” “us”, or “our,” it means Alterwood Advantage, Inc. When it refers to “plan” or “our plan,” it means Alterwood Advantage Choice.

This document includes an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.

May 2022

H9306\_22\_DRS\_0106\_001\_OE\_C

## What is the Alterwood Advantage Choice Formulary?

A formulary is a list of covered drugs selected by Alterwood Advantage Choice in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Alterwood Advantage Choice will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a Alterwood Advantage Choice network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

For a complete listing of all prescription drugs covered by Alterwood Advantage Choice, please visit our website or call us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

## Can the Formulary (drug list) change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes.

**Changes that can affect you this year:** In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
  - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can find information in the section below titled “How do I request an exception to the Alterwood Advantage Choice’s Formulary?”
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary; or add new restrictions to the brand name drug or move it to a different cost sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, [or] add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.

May 2022

H9306\_22\_DRS\_0106\_001\_OE\_C

- If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Alterwood Advantage Choice’s Formulary?”

**Changes that will not affect you if you are currently taking the drug.** Generally, if you are taking a drug on our 2022 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2022 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of 04/18/2022. To get updated information about the drugs covered by Alterwood Advantage Choice, please contact us. Our contact information appears on the front and back cover pages.

## **How do I use the Formulary?**

There are two ways to find your drug within the formulary:

### **Medical Condition**

The formulary begins on page 11. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, Cardiovascular Agents. If you know what your drug is used for, look for the category name in the list that begins on page 9. Then look under the category name for your drug.

### **Alphabetical Listing**

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 102. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

## **What are generic drugs?**

Alterwood Advantage Choice covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs cost less than brand name drugs.

## **Are there any restrictions on my coverage?**

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

May 2022

H9306\_22\_DRS\_0106\_001\_OE\_C

- **Prior Authorization:** Alterwood Advantage Choice requires you [or your physician] to get prior authorization for certain drugs. This means that you will need to get approval from Alterwood Advantage Choice before you fill your prescriptions. If you don't get approval, Alterwood Advantage Choice may not cover the drug.
- **Quantity Limits:** For certain drugs, Alterwood Advantage Choice limits the amount of the drug that Alterwood Advantage Choice will cover. For example, Alterwood Advantage Choice provides 90 tablets per prescription for VALSARTAN TABLET 80 mg. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, Alterwood Advantage Choice requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Alterwood Advantage Choice may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Alterwood Advantage Choice will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 11. You can also get more information about the restrictions applied to specific covered drugs by visiting our Web site. We have posted online a document that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask Alterwood Advantage Choice to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the Alterwood Advantage Choice's formulary?" on page 4 for information about how to request an exception.

## **What if my drug is not on the Formulary?**

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered. For more information, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you learn that Alterwood Advantage Choice does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by Alterwood Advantage Choice. When you receive the list, show it to your doctor and ask him or her to prescribe a similar drug that is covered by Alterwood Advantage Choice.
- You can ask Alterwood Advantage Choice to make an exception and cover your drug. See below for information about how to request an exception.

## **How do I request an exception to the Alterwood Advantage Choice's Formulary?**

You can ask Alterwood Advantage Choice to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

May 2022

H9306\_22\_DRS\_0106\_001\_OE\_C

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier. If approved, this would lower the amount you must pay for your drug.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, Alterwood Advantage Choice limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, Alterwood Advantage Choice will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug or additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, tier, or utilization restriction exception. **When you request a formulary, tier, or utilization restriction exception you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

## **What do I do before I can talk to my doctor about changing my drugs or requesting an exception?**

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. After your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

If you experience a level of care change such as a move from a hospital to a home setting or a move from a skilled nursing facility to a home setting, we may cover a one-time temporary supply of drug(s) not on our formulary when filled at a network pharmacy. This temporary one-time supply must be for a up to 30-day supply (or up to a 31-day supply if you reside in a long-term care facility) within 90 days of your enrollment.

May 2022

H9306\_22\_DRS\_0106\_001\_OE\_C

You and your provider will receive a letter in the mail indicating that you have received a temporary supply. Please discuss with your provider the drugs listed in the Alterwood Advantage Choice formulary. You or your provider may request continuation of coverage for the temporary drug supply through the plan's exception process before you run out drug(s).

## For more information

For more detailed information about your Alterwood Advantage Choice prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about Alterwood Advantage Choice, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or, visit <http://www.medicare.gov>.

## Alterwood Advantage Choice Formulary

The formulary below provides coverage information about the drugs covered by Alterwood Advantage Choice. If you have trouble finding your drug in the list, turn to the Index that begins on page 102.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., DIGITEK ORAL TABLET 125 MCG) and generic drugs are listed in lower-case italics (e.g., *digoxin oral tablet 125 mcg*).

The information in the Requirements/Limits column tells you if Alterwood Advantage Choice has any special requirements for coverage of your drug.

Your 2022 Part D copays and the Alterwood Advantage Choice formulary tiers are described below.

| Formulary Tier                           | Retail<br>(up to a 30<br>days supply) | Retail<br>(up to a 90<br>days supply) | Mail Order<br>(up to a 30<br>days supply) | Mail Order<br>(up to a 90<br>days supply) | Long-Term<br>Care (LTC)<br>(up to a 31<br>days supply) | Out-of-<br>Network<br>(up to a 10<br>days supply) |
|------------------------------------------|---------------------------------------|---------------------------------------|-------------------------------------------|-------------------------------------------|--------------------------------------------------------|---------------------------------------------------|
| Tier 1<br><i>Preferred Generics</i>      | \$3                                   | \$0                                   | \$3                                       | \$0                                       | \$3                                                    | \$3                                               |
| Tier 2<br><i>Generics</i>                | \$8                                   | \$8                                   | \$8                                       | \$8                                       | \$8                                                    | \$8                                               |
| Tier 3<br><i>Preferred Brand</i>         | \$47                                  | \$94                                  | \$47                                      | \$94                                      | \$47                                                   | \$47                                              |
| Tier 4<br><i>Non-Preferred<br/>Brand</i> | \$100                                 | \$300                                 | \$100                                     | \$300                                     | \$100                                                  | \$100                                             |
| Tier 5<br><i>Specialty</i>               | 33%                                   | Not<br>Covered                        | 33%                                       | Not<br>Covered                            | 33%                                                    | 33%                                               |

Note: LTC drugs greater than a 31-day supply and OON drugs greater than a 10-day supply are not covered.

May 2022

H9306\_22\_DRS\_0106\_001\_OE\_C

If you receive “Extra Help,” your copay will vary by the type of drug (i.e., generic drugs or all other drugs). Also, the allowed drug days supply varies depending on where you get your drug(s) – see table below.

| <b>For generic drugs (including brand drugs treated as a generic):</b>                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| <b><i>Copays*</i></b>                                                                                                                                                                                                                                                                                                                                                                                                                            | <b><i>Drug Days Supply**</i></b>                                                                                   |
| \$0, \$1.35, or \$3.95                                                                                                                                                                                                                                                                                                                                                                                                                           | Retail and Mail Order: Up to 90 days<br>Long Term Care (LTC): Up to 31 days<br>Out-of-Network (OON): Up to 10 days |
| <b>For all other drugs:</b>                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                    |
| <b><i>Copays*</i></b>                                                                                                                                                                                                                                                                                                                                                                                                                            | <b><i>Drug Days Supply**</i></b>                                                                                   |
| \$0, \$4.00, or \$9.85                                                                                                                                                                                                                                                                                                                                                                                                                           | Retail and Mail Order: Up to 90 days<br>LTC: Up to 31 days<br>OON: Up to 10 days                                   |
| <p>*Copay varies based on the “Extra Help” you receive. You will pay the lower of the cost of your prescription or your copay described above. Once you reach the Catastrophic Coverage stage, you will pay \$0 or the greater of 5%, \$3.95 for generics, including brands treated as generics, and \$9.85 for all other drugs.</p> <p>**LTC drugs greater than a 31-day supply and OON drugs greater than a 10-day supply are not covered.</p> |                                                                                                                    |



The following abbreviations can be found in the Alterwood Advantage Choice formulary:

| Abbreviation/Symbol | Definition                                                                                                                                                                                                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BvD                 | Part B vs. Part D- This prescription drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.                                                                                                 |
| PA                  | Prior Authorization- You (or your physician) are required to get prior authorization before you fill your prescription for this drug. Without prior approval, we may not cover this drug.                                                                                                                                        |
| PA2                 | Prior Authorization (New Starts Only) - You (or your physician) are required to get prior authorization before you fill your prescription for this drug unless you are a previous user of the drug. If you have a history of using this medication, you will not need prior authorization.                                       |
| QL                  | Quantity Limit- There is a limit on the amount of this drug that is covered per prescription, or within a specific time frame.                                                                                                                                                                                                   |
| ST2                 | Step Therapy (New Starts Only)- In some cases, you may be required to first try certain drugs to treat your medical condition before we will cover another drug for that condition unless you are a previous user of the drug. If you have a history of using this medication, you will not need to try other medications first. |
| NMO                 | This prescription is not available via mail order.                                                                                                                                                                                                                                                                               |
| MO                  | This prescription may also be available via mail order.                                                                                                                                                                                                                                                                          |

## **Alterwood Advantage Choice 2022 (List of Covered Drugs)**

### **List of Drugs by Medical Condition**

|                                                                                 |           |
|---------------------------------------------------------------------------------|-----------|
| <b>ANALGESICS</b>                                                               | <b>11</b> |
| <b>ANESTHETICS</b>                                                              | <b>13</b> |
| <b>ANTI-ADDICTION/ SUBSTANCE ABUSE TREATMENT AGENTS</b>                         | <b>13</b> |
| <b>ANTIBACTERIALS</b>                                                           | <b>14</b> |
| <b>ANTICONVULSANTS</b>                                                          | <b>21</b> |
| <b>ANTIDEMENTIA AGENTS</b>                                                      | <b>24</b> |
| <b>ANTIDEPRESSANTS</b>                                                          | <b>25</b> |
| <b>ANTIEMETICS</b>                                                              | <b>27</b> |
| <b>ANTIFUNGALS</b>                                                              | <b>28</b> |
| <b>ANTIGOUT AGENTS</b>                                                          | <b>30</b> |
| <b>ANTIMIGRAINE AGENTS</b>                                                      | <b>30</b> |
| <b>ANTIMYASTHENIC AGENTS</b>                                                    | <b>31</b> |
| <b>ANTIMYCOBACTERIALS</b>                                                       | <b>31</b> |
| <b>ANTINEOPLASTICS</b>                                                          | <b>32</b> |
| <b>ANTIPARASITICS</b>                                                           | <b>39</b> |
| <b>ANTIPARKINSON AGENTS</b>                                                     | <b>40</b> |
| <b>ANTIPSYCHOTICS</b>                                                           | <b>41</b> |
| <b>ANTISPASTICITY AGENTS</b>                                                    | <b>45</b> |
| <b>ANTIVIRALS</b>                                                               | <b>45</b> |
| <b>ANXIOLYTICS</b>                                                              | <b>49</b> |
| <b>BIPOLAR AGENTS</b>                                                           | <b>50</b> |
| <b>BLOOD GLUCOSE REGULATORS</b>                                                 | <b>51</b> |
| <b>BLOOD PRODUCTS AND MODIFIERS</b>                                             | <b>54</b> |
| <b>CARDIOVASCULAR AGENTS</b>                                                    | <b>56</b> |
| <b>CENTRAL NERVOUS SYSTEM AGENTS</b>                                            | <b>64</b> |
| <b>DENTAL AND ORAL AGENTS</b>                                                   | <b>66</b> |
| <b>DERMATOLOGICAL AGENTS</b>                                                    | <b>66</b> |
| <b>ELECTROLYTES/MINERALS/METALS/VITAMINS</b>                                    | <b>70</b> |
| <b>GASTROINTESTINAL AGENTS</b>                                                  | <b>73</b> |
| <b>GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT</b> | <b>75</b> |
| <b>GENITOURINARY AGENTS</b>                                                     | <b>76</b> |
| <b>HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL)</b>             | <b>77</b> |

|                                                                                           |            |
|-------------------------------------------------------------------------------------------|------------|
| <b>HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (PITUITARY) .....</b>               | <b>78</b>  |
| <b>HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS) .....</b> | <b>78</b>  |
| <b>HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (THYROID) .....</b>                 | <b>84</b>  |
| <b>HORMONAL AGENTS, SUPPRESSANT (PITUITARY) .....</b>                                     | <b>85</b>  |
| <b>HORMONAL AGENTS, SUPPRESSANT (THYROID).....</b>                                        | <b>86</b>  |
| <b>IMMUNOLOGICAL AGENTS .....</b>                                                         | <b>86</b>  |
| <b>INFLAMMATORY BOWEL DISEASE AGENTS.....</b>                                             | <b>92</b>  |
| <b>METABOLIC BONE DISEASE AGENTS .....</b>                                                | <b>92</b>  |
| <b>OPHTHALMIC AGENTS .....</b>                                                            | <b>93</b>  |
| <b>OTIC AGENTS .....</b>                                                                  | <b>96</b>  |
| <b>RESPIRATORY TRACT/ PULMONARY AGENTS.....</b>                                           | <b>96</b>  |
| <b>SKELETAL MUSCLE RELAXANTS .....</b>                                                    | <b>100</b> |
| <b>SLEEP DISORDER AGENTS.....</b>                                                         | <b>101</b> |

| Drug Name                                                               | Drug Tier | Requirements/Limits         |
|-------------------------------------------------------------------------|-----------|-----------------------------|
| <b>ANALGESICS</b>                                                       |           |                             |
| <b><i>Analgesics</i></b>                                                |           |                             |
| <i>butalbital-apap-caffeine oral capsule 50-300-40 mg, 50-325-40 mg</i> | 4         | MO; QL (180 EA per 30 days) |
| <i>butalbital-apap-caffeine oral tablet 50-325-40 mg</i>                | 2         | MO; QL (180 EA per 30 days) |
| <i>butalbital-asa-caff-codeine oral capsule 50-325-40-30 mg</i>         | 4         | MO; QL (180 EA per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40 mg</i>            | 2         | MO; QL (180 EA per 30 days) |
| <b><i>Nonsteroidal Anti-Inflammatory Drugs</i></b>                      |           |                             |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i>             | 2         | MO                          |
| <i>diclofenac potassium oral tablet 50 mg</i>                           | 2         | MO                          |
| <i>diclofenac sodium er oral tablet extended release 24 hour 100 mg</i> | 1         | MO                          |
| <i>diclofenac sodium external gel 1 %</i>                               | 2         | MO                          |
| <i>diclofenac sodium oral tablet delayed release 25 mg</i>              | 2         | MO                          |
| <i>diclofenac sodium oral tablet delayed release 50 mg, 75 mg</i>       | 1         | MO                          |
| <i>diflunisal oral tablet 500 mg</i>                                    | 2         | MO                          |
| <i>etodolac oral capsule 200 mg, 300 mg</i>                             | 2         | MO                          |
| <i>etodolac oral tablet 400 mg, 500 mg</i>                              | 2         | MO                          |
| <i>flurbiprofen oral tablet 100 mg</i>                                  | 1         | MO                          |
| <i>IBU ORAL TABLET 600 MG, 800 MG</i>                                   | 1         | MO                          |
| <i>ibuprofen oral suspension 100 mg/5ml</i>                             | 1         | MO                          |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i>                     | 1         | MO                          |
| <i>indomethacin er oral capsule extended release 75 mg</i>              | 2         | MO                          |
| <i>indomethacin oral capsule 25 mg, 50 mg</i>                           | 1         | MO                          |
| <i>ketorolac tromethamine oral tablet 10 mg</i>                         | 1         | MO                          |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i>                              | 1         | MO                          |
| <i>nabumetone oral tablet 500 mg, 750 mg</i>                            | 1         | MO                          |
| <i>naproxen oral suspension 125 mg/5ml</i>                              | 2         | MO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                                                                        | <b>Drug Tier</b> | <b>Requirements/Limits</b>       |
|-----------------------------------------------------------------------------------------------------------------------------------------|------------------|----------------------------------|
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i>                                                                                      | 1                | MO                               |
| <i>naproxen oral tablet delayed release 375 mg, 500 mg</i>                                                                              | 2                | MO                               |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i>                                                                                       | 2                | MO                               |
| <i>oxaprozin oral tablet 600 mg</i>                                                                                                     | 2                | MO                               |
| <i>piroxicam oral capsule 10 mg, 20 mg</i>                                                                                              | 2                | MO                               |
| <i>sulindac oral tablet 150 mg, 200 mg</i>                                                                                              | 1                | MO                               |
| <b>Opioid Analgesics, Long-Acting</b>                                                                                                   |                  |                                  |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr</i> | 4                | PA2; MO; QL (10 EA per 30 days)  |
| <i>methadone hcl oral tablet 10 mg, 5 mg</i>                                                                                            | 2                | MO; QL (240 EA per 30 days)      |
| <i>morphine sulfate er oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i>                                             | 2                | MO; QL (90 EA per 30 days)       |
| <i>oxycodone hcl er oral tablet er 12 hour abuse-deterrent 10 mg, 20 mg, 40 mg, 80 mg</i>                                               | 4                | MO                               |
| <b>Opioid Analgesics, Short-Acting</b>                                                                                                  |                  |                                  |
| <i>acetaminophen-codeine #3 oral tablet 300-30 mg</i>                                                                                   | 2                | MO; QL (360 EA per 30 days)      |
| <i>acetaminophen-codeine oral solution 120-12 mg/5ml</i>                                                                                | 2                | MO; QL (5000 ML per 30 days)     |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-60 mg</i>                                                                           | 2                | MO; QL (360 EA per 30 days)      |
| <i>codeine sulfate oral tablet 15 mg, 30 mg, 60 mg</i>                                                                                  | 2                | MO; QL (180 EA per 30 days)      |
| <i>fentanyl citrate buccal lozenge on a handle 1200 mcg, 1600 mcg, 600 mcg, 800 mcg</i>                                                 | 5                | PA; NMO; QL (120 EA per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg, 400 mcg</i>                                                                     | 4                | PA; MO; QL (120 EA per 30 days)  |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15ml</i>                                                                          | 2                | MO; QL (5500 ML per 30 days)     |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i>                                                            | 2                | MO; QL (360 EA per 30 days)      |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg</i>                                                                                      | 2                | MO; QL (150 EA per 30 days)      |
| <i>hydrocodone-ibuprofen oral tablet 5-200 mg, 7.5-200 mg</i>                                                                           | 2                | MO; QL (180 EA per 30 days)      |
| <i>hydromorphone hcl oral liquid 1 mg/ml</i>                                                                                            | 4                | MO; QL (1920 ML per 30 days)     |
| <i>hydromorphone hcl oral tablet 2 mg, 4 mg</i>                                                                                         | 2                | MO; QL (360 EA per 30 days)      |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                       | <b>Drug Tier</b> | <b>Requirements/Limits</b>   |
|----------------------------------------------------------------------------------------|------------------|------------------------------|
| <i>hydromorphone hcl oral tablet 8 mg</i>                                              | 2                | MO; QL (240 EA per 30 days)  |
| <i>morphine sulfate (concentrate) oral solution 100 mg/5ml</i>                         | 2                | MO; QL (600 ML per 30 days)  |
| <i>morphine sulfate oral solution 10 mg/5ml</i>                                        | 2                | MO; QL (1800 ML per 30 days) |
| <i>morphine sulfate oral solution 20 mg/5ml</i>                                        | 2                | MO; QL (1500 ML per 30 days) |
| <i>morphine sulfate oral tablet 15 mg, 30 mg</i>                                       | 2                | MO; QL (180 EA per 30 days)  |
| <i>oxycodone hcl oral concentrate 100 mg/5ml</i>                                       | 4                | MO; QL (180 ML per 30 days)  |
| <i>oxycodone hcl oral solution 5 mg/5ml</i>                                            | 4                | MO; QL (1080 ML per 30 days) |
| <i>oxycodone hcl oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i>                      | 2                | MO; QL (180 EA per 30 days)  |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg</i> | 2                | MO; QL (360 EA per 30 days)  |
| <i>tramadol hcl oral tablet 100 mg</i>                                                 | 1                | MO; QL (120 EA per 30 days)  |
| <i>tramadol hcl oral tablet 50 mg</i>                                                  | 1                | MO; QL (240 EA per 30 days)  |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i>                                  | 2                | MO; QL (240 EA per 30 days)  |

## **ANESTHETICS**

### **Local Anesthetics**

|                                                        |   |                                |
|--------------------------------------------------------|---|--------------------------------|
| <i>lidocaine external patch 5 %</i>                    | 4 | PA; MO; QL (90 EA per 30 days) |
| <i>lidocaine hcl external solution 4 %</i>             | 2 | MO; QL (50 ML per 30 days)     |
| <i>lidocaine viscous hcl mouth/throat solution 2 %</i> | 4 | MO                             |
| <i>lidocaine-prilocaine external cream 2.5-2.5 %</i>   | 2 | MO; QL (30 GM per 30 days)     |

## **ANTI-ADDICTION/ SUBSTANCE ABUSE TREATMENT AGENTS**

### **Alcohol Deterrents/Anti-Craving**

|                                                               |   |     |
|---------------------------------------------------------------|---|-----|
| <i>acamprosate calcium oral tablet delayed release 333 mg</i> | 2 | MO  |
| <i>disulfiram oral tablet 250 mg</i>                          | 2 | MO  |
| <i>naltrexone hcl oral tablet 50 mg</i>                       | 2 | MO  |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MG        | 5 | NMO |

### **Opioid Dependence**

|                                                                                     |   |    |
|-------------------------------------------------------------------------------------|---|----|
| <i>buprenorphine hcl sublingual tablet sublingual 2 mg, 8 mg</i>                    | 2 | MO |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg, 8-2 mg</i> | 2 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                         | Drug Tier | Requirements/Limits |
|-------------------------------------------------------------------------------------------------------------------|-----------|---------------------|
| SUBOXONE SUBLINGUAL FILM 12-3 MG, 2-0.5 MG, 4-1 MG, 8-2 MG                                                        | 4         | MO                  |
| <b>Opioid Reversal Agents</b>                                                                                     |           |                     |
| KLOXXADO NASAL LIQUID 8 MG/0.1ML                                                                                  | 3         | MO                  |
| <i>naloxone hcl injection solution 0.4 mg/ml</i>                                                                  | 2         | MO                  |
| <i>naloxone hcl injection solution cartridge 0.4 mg/ml</i>                                                        | 2         | MO                  |
| <i>naloxone hcl injection solution prefilled syringe 2 mg/2ml</i>                                                 | 2         | MO                  |
| <i>naloxone hcl nasal liquid 4 mg/0.1ml</i>                                                                       | 2         | MO                  |
| NARCAN NASAL LIQUID 4 MG/0.1ML                                                                                    | 3         | MO                  |
| <b>Smoking Cessation Agents</b>                                                                                   |           |                     |
| <i>bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg</i>                                 | 1         | MO                  |
| CHANTIX CONTINUING MONTH PAK ORAL TABLET 1 MG                                                                     | 3         | MO                  |
| CHANTIX STARTING MONTH PAK ORAL TABLET 0.5 MG X 11 & 1 MG X 42                                                    | 3         | MO                  |
| NICOTROL INHALATION INHALER 10 MG                                                                                 | 3         | MO                  |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg</i>                                                              | 3         | MO                  |
| <b>ANTIBACTERIALS</b>                                                                                             |           |                     |
| <b>Aminoglycosides</b>                                                                                            |           |                     |
| <i>amikacin sulfate injection solution 500 mg/2ml</i>                                                             | 4         | BvD; MO             |
| ARIKAYCE INHALATION SUSPENSION 590 MG/8.4ML                                                                       | 4         | PA; MO              |
| <i>gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%, 1-0.9 mg/ml-%, 1.2-0.9 mg/ml-%, 1.6-0.9 mg/ml-%</i> | 2         | MO                  |
| <i>gentamicin sulfate external cream 0.1 %</i>                                                                    | 2         | MO                  |
| <i>gentamicin sulfate external ointment 0.1 %</i>                                                                 | 2         | MO                  |
| <i>gentamicin sulfate injection solution 40 mg/ml</i>                                                             | 2         | MO                  |
| <i>neomycin sulfate oral tablet 500 mg</i>                                                                        | 2         | MO                  |
| <i>paromomycin sulfate oral capsule 250 mg</i>                                                                    | 4         | MO                  |
| <i>tobramycin sulfate injection solution 10 mg/ml, 80 mg/2ml</i>                                                  | 4         | BvD; MO             |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                      | Drug Tier | Requirements/Limits |
|------------------------------------------------------------------------------------------------|-----------|---------------------|
| ZEMDRI INTRAVENOUS SOLUTION 500 MG/10ML                                                        | 5         | NMO                 |
| <b>Antibacterials, Other</b>                                                                   |           |                     |
| AZACTAM INJECTION SOLUTION RECONSTITUTED 2 GM                                                  | 4         | BvD; MO             |
| <i>aztreonam injection solution reconstituted 1 gm</i>                                         | 2         | MO                  |
| <i>clindamycin hcl oral capsule 150 mg, 75 mg</i>                                              | 1         | MO                  |
| <i>clindamycin hcl oral capsule 300 mg</i>                                                     | 2         | MO                  |
| <i>clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml</i>                         | 4         | MO                  |
| <i>clindamycin phosphate in d5w intravenous solution 300 mg/50ml, 600 mg/50ml, 900 mg/50ml</i> | 4         | MO                  |
| <i>clindamycin phosphate injection solution 300 mg/2ml, 600 mg/4ml, 900 mg/6ml</i>             | 4         | BvD; MO             |
| <i>clindamycin phosphate vaginal cream 2 %</i>                                                 | 2         | MO                  |
| <i>colistimethate sodium (cba) injection solution reconstituted 150 mg</i>                     | 4         | BvD; MO             |
| <i>daptomycin intravenous solution reconstituted 350 mg</i>                                    | 4         | MO                  |
| <i>daptomycin intravenous solution reconstituted 500 mg</i>                                    | 5         | NMO                 |
| FIRVANQ ORAL SOLUTION RECONSTITUTED 25 MG/ML, 50 MG/ML                                         | 4         | MO                  |
| <i>linezolid intravenous solution 600 mg/300ml</i>                                             | 4         | PA; MO              |
| <i>linezolid oral tablet 600 mg</i>                                                            | 4         | PA; MO              |
| <i>methenamine hippurate oral tablet 1 gm</i>                                                  | 2         | MO                  |
| <i>metronidazole external cream 0.75 %</i>                                                     | 2         | MO                  |
| <i>metronidazole external gel 0.75 %, 1 %</i>                                                  | 2         | MO                  |
| <i>metronidazole external lotion 0.75 %</i>                                                    | 2         | MO                  |
| <i>metronidazole in nacl intravenous solution 5-0.79 mg/ml-%</i>                               | 2         | BvD; MO             |
| <i>metronidazole oral tablet 250 mg, 500 mg</i>                                                | 2         | MO                  |
| <i>metronidazole vaginal gel 0.75 %</i>                                                        | 3         | MO                  |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i>                           | 2         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                                                            | Drug Tier | Requirements/Limits |
|--------------------------------------------------------------------------------------|-----------|---------------------|
| <i>nitrofurantoin monohyd macro oral capsule 100 mg</i>                              | 2         | MO                  |
| <i>tigecycline intravenous solution reconstituted 50 mg</i>                          | 5         | BvD; NMO            |
| <i>tinidazole oral tablet 250 mg, 500 mg</i>                                         | 2         | MO                  |
| <i>trimethoprim oral tablet 100 mg</i>                                               | 1         | MO                  |
| <i>vancomycin hcl intravenous solution reconstituted 1 gm, 10 gm, 500 mg, 750 mg</i> | 4         | MO                  |
| <i>vancomycin hcl oral capsule 125 mg, 250 mg</i>                                    | 4         | MO                  |
| <i>vancomycin hcl oral solution reconstituted 250 mg/5ml</i>                         | 4         | MO                  |
| XIFAXAN ORAL TABLET 200 MG, 550 MG                                                   | 4         | MO                  |
| <b>Beta-Lactam, Cephalosporins</b>                                                   |           |                     |
| <i>cefaclor er oral tablet extended release 12 hour 500 mg</i>                       | 4         | MO                  |
| <i>cefaclor oral capsule 250 mg, 500 mg</i>                                          | 2         | MO                  |
| <i>cefaclor oral suspension reconstituted 125 mg/5ml, 250 mg/5ml, 375 mg/5ml</i>     | 4         | MO                  |
| <i>cefadroxil oral capsule 500 mg</i>                                                | 1         | MO                  |
| <i>cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml</i>               | 2         | MO                  |
| <i>cefadroxil oral tablet 1 gm</i>                                                   | 2         | MO                  |
| <i>cefazolin sodium injection solution reconstituted 1 gm, 10 gm, 500 mg</i>         | 4         | MO                  |
| <i>cefdinir oral capsule 300 mg</i>                                                  | 2         | MO                  |
| <i>cefdinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i>                 | 2         | MO                  |
| <i>cefepime hcl injection solution reconstituted 1 gm, 2 gm</i>                      | 4         | MO                  |
| <i>cefixime oral capsule 400 mg</i>                                                  | 4         | MO                  |
| <i>cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i>                 | 4         | MO                  |
| <i>cefotetan disodium injection solution reconstituted 1 gm, 2 gm</i>                | 4         | BvD; MO             |
| <i>cefoxitin sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm</i>         | 4         | BvD; MO             |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                                                                  | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|-----------------------------------------------------------------------------------------------------------------------------------|------------------|----------------------------|
| <i>cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml</i>                                                   | 4                | MO                         |
| <i>cefpodoxime proxetil oral tablet 100 mg, 200 mg</i>                                                                            | 4                | MO                         |
| <i>cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i>                                                             | 2                | MO                         |
| <i>cefprozil oral tablet 250 mg, 500 mg</i>                                                                                       | 2                | MO                         |
| <i>ceftazidime injection solution reconstituted 1 gm, 6 gm</i>                                                                    | 4                | MO                         |
| <i>ceftazidime intravenous solution reconstituted 2 gm</i>                                                                        | 4                | MO                         |
| <i>ceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg</i>                                             | 4                | MO                         |
| <i>ceftriaxone sodium intravenous solution reconstituted 10 gm</i>                                                                | 4                | MO                         |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i>                                                                               | 2                | MO                         |
| <i>cefuroxime sodium injection solution reconstituted 750 mg</i>                                                                  | 4                | BvD; MO                    |
| <i>cefuroxime sodium intravenous solution reconstituted 1.5 gm</i>                                                                | 4                | BvD; MO                    |
| <i>cephalexin oral capsule 250 mg, 500 mg</i>                                                                                     | 1                | MO                         |
| <i>cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i>                                                            | 2                | MO                         |
| <i>cephalexin oral tablet 250 mg, 500 mg</i>                                                                                      | 2                | MO                         |
| TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400 MG, 600 MG                                                                         | 5                | BvD; NMO                   |
| <b>Beta-Lactam, Penicillins</b>                                                                                                   |                  |                            |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i>                                                                                    | 1                | MO                         |
| <i>amoxicillin oral suspension reconstituted 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml</i>                                   | 1                | MO                         |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i>                                                                                     | 1                | MO                         |
| <i>amoxicillin oral tablet chewable 125 mg, 250 mg</i>                                                                            | 1                | MO                         |
| <i>amoxicillin-pot clavulanate er oral tablet extended release 12 hour 1000-62.5 mg</i>                                           | 4                | MO                         |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml, 600-42.9 mg/5ml</i> | 2                | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                               | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|------------------------------------------------------------------------------------------------|------------------|----------------------------|
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i>              | 2                | MO                         |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5 mg, 400-57 mg</i>                 | 2                | MO                         |
| <i>ampicillin oral capsule 500 mg</i>                                                          | 1                | MO                         |
| <i>ampicillin sodium injection solution reconstituted 1 gm, 125 mg</i>                         | 4                | BvD; MO                    |
| <i>ampicillin sodium intravenous solution reconstituted 10 gm</i>                              | 4                | BvD; MO                    |
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm</i> | 4                | MO                         |
| <i>ampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm</i>             | 4                | MO                         |
| BICILLIN L-A INTRAMUSCULAR<br>SUSPENSION 1200000 UNIT/2ML, 2400000<br>UNIT/4ML, 600000 UNIT/ML | 4                | MO                         |
| <i>dicloxacillin sodium oral capsule 250 mg, 500 mg</i>                                        | 2                | MO                         |
| <i>nafcillin sodium injection solution reconstituted 1 gm, 2 gm</i>                            | 4                | BvD; MO                    |
| <i>nafcillin sodium intravenous solution reconstituted 10 gm</i>                               | 4                | BvD; MO                    |
| <i>oxacillin sodium in dextrose intravenous solution 1 gm/50ml, 2 gm/50ml</i>                  | 4                | BvD; MO                    |
| <i>oxacillin sodium injection solution reconstituted 1 gm, 2 gm</i>                            | 4                | BvD; MO                    |
| <i>oxacillin sodium intravenous solution reconstituted 10 gm</i>                               | 4                | BvD; MO                    |
| <i>penicillin g pot in dextrose intravenous solution 40000 unit/ml, 60000 unit/ml</i>          | 4                | MO                         |
| <i>penicillin g potassium injection solution reconstituted 20000000 unit</i>                   | 4                | BvD; MO                    |
| <i>penicillin g procaine intramuscular suspension 600000 unit/ml</i>                           | 4                | MO                         |
| <i>penicillin g sodium injection solution reconstituted 5000000 unit</i>                       | 4                | BvD; MO                    |
| <i>penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml</i>               | 2                | MO                         |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i>                                       | 1                | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                                                              | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|-------------------------------------------------------------------------------------------------------------------------------|------------------|----------------------------|
| <i>piperacillin sod-tazobactam so intravenous solution reconstituted 2.25 (2-0.25) gm, 3.375 (3-0.375) gm, 4.5 (4-0.5) gm</i> | 4                | MO                         |
| <b>Carbapenems</b>                                                                                                            |                  |                            |
| <i>ertapenem sodium injection solution reconstituted 1 gm</i>                                                                 | 4                | MO                         |
| <i>imipenem-cilastatin intravenous solution reconstituted 250 mg, 500 mg</i>                                                  | 4                | MO                         |
| <i>meropenem intravenous solution reconstituted 1 gm, 500 mg</i>                                                              | 4                | MO                         |
| <b>Macrolides</b>                                                                                                             |                  |                            |
| <i>azithromycin intravenous solution reconstituted 500 mg</i>                                                                 | 2                | BvD; MO                    |
| <i>azithromycin oral packet 1 gm</i>                                                                                          | 2                | MO                         |
| <i>azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i>                                                      | 2                | MO                         |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack)</i>                                                                       | 1                | MO                         |
| <i>azithromycin oral tablet 500 mg, 500 mg (3 pack), 600 mg</i>                                                               | 2                | MO                         |
| <i>clarithromycin er oral tablet extended release 24 hour 500 mg</i>                                                          | 2                | MO                         |
| <i>clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i>                                                    | 2                | MO                         |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i>                                                                              | 2                | MO                         |
| ERYTHROCIN LACTOBIONATE<br>INTRAVENOUS SOLUTION<br>RECONSTITUTED 500 MG                                                       | 4                | BvD; MO                    |
| <i>erythromycin base oral capsule delayed release particles 250 mg</i>                                                        | 4                | MO                         |
| <i>erythromycin base oral tablet 250 mg, 500 mg</i>                                                                           | 4                | MO                         |
| <i>erythromycin base oral tablet delayed release 333 mg, 500 mg</i>                                                           | 4                | MO                         |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200 mg/5ml, 400 mg/5ml</i>                                       | 4                | MO                         |
| <i>erythromycin ethylsuccinate oral tablet 400 mg</i>                                                                         | 4                | MO                         |
| <i>erythromycin oral tablet delayed release 250 mg</i>                                                                        | 4                | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                  | Drug Tier | Requirements/Limits |
|----------------------------------------------------------------------------|-----------|---------------------|
| <b>Quinolones</b>                                                          |           |                     |
| <i>ciprofloxacin hcl ophthalmic solution 0.3 %</i>                         | 1         | MO                  |
| <i>ciprofloxacin hcl oral tablet 100 mg</i>                                | 4         | MO                  |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg</i>                        | 1         | MO                  |
| <i>ciprofloxacin hcl oral tablet 750 mg</i>                                | 2         | MO                  |
| <i>ciprofloxacin in d5w intravenous solution 200 mg/100ml</i>              | 4         | BvD; MO             |
| <i>levofloxacin in d5w intravenous solution 500 mg/100ml, 750 mg/150ml</i> | 4         | MO                  |
| <i>levofloxacin intravenous solution 25 mg/ml</i>                          | 4         | MO                  |
| <i>levofloxacin oral solution 25 mg/ml</i>                                 | 4         | MO                  |
| <i>levofloxacin oral tablet 250 mg, 750 mg</i>                             | 2         | MO                  |
| <i>levofloxacin oral tablet 500 mg</i>                                     | 1         | MO                  |
| <i>moxifloxacin hcl in nacl intravenous solution 400 mg/250ml</i>          | 4         | BvD; MO             |
| <i>moxifloxacin hcl oral tablet 400 mg</i>                                 | 4         | MO                  |
| <i>ofloxacin oral tablet 300 mg, 400 mg</i>                                | 2         | MO                  |
| <b>Sulfonamides</b>                                                        |           |                     |
| <i>sulfacetamide sodium (acne) external lotion 10 %</i>                    | 2         | MO                  |
| <i>sulfadiazine oral tablet 500 mg</i>                                     | 2         | MO                  |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml</i>         | 2         | MO                  |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i>     | 1         | MO                  |
| <b>Tetracyclines</b>                                                       |           |                     |
| <b>DOXY 100 INTRAVENOUS SOLUTION RECONSTITUTED 100 MG</b>                  | 4         | BvD; MO             |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i>                      | 2         | MO                  |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i>                       | 2         | MO                  |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i>                  | 1         | MO                  |
| <i>doxycycline monohydrate oral tablet 100 mg, 50 mg, 75 mg</i>            | 2         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                               | Drug Tier | Requirements/Limits              |
|---------------------------------------------------------------------------------------------------------|-----------|----------------------------------|
| <i>minocycline hcl oral capsule 100 mg, 50 mg, 75 mg</i>                                                | 2         | MO                               |
| <i>minocycline hcl oral tablet 100 mg, 50 mg, 75 mg</i>                                                 | 2         | MO                               |
| <i>tetracycline hcl oral capsule 250 mg, 500 mg</i>                                                     | 2         | MO                               |
| <b>ANTICONVULSANTS</b>                                                                                  |           |                                  |
| <b><i>Anticonvulsants, Other</i></b>                                                                    |           |                                  |
| BRIVIACT ORAL SOLUTION 10 MG/ML                                                                         | 4         | MO; QL (600 ML per 30 days)      |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG                                                 | 4         | MO; QL (60 EA per 30 days)       |
| DIACOMIT ORAL CAPSULE 250 MG, 500 MG                                                                    | 4         | PA2; MO                          |
| DIACOMIT ORAL PACKET 250 MG, 500 MG                                                                     | 4         | PA2; MO                          |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML                                                                       | 4         | PA2; MO                          |
| <i>felbamate oral suspension 600 mg/5ml</i>                                                             | 5         | NMO                              |
| <i>felbamate oral tablet 400 mg, 600 mg</i>                                                             | 4         | MO                               |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML                                                                        | 4         | PA2; MO                          |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML                                                                       | 4         | ST2; MO; QL (720 ML per 30 days) |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG                                                            | 5         | ST2; NMO; QL (30 EA per 30 days) |
| FYCOMPA ORAL TABLET 2 MG, 8 MG                                                                          | 4         | ST2; MO; QL (30 EA per 30 days)  |
| <i>lamotrigine er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | 4         | MO                               |
| <i>lamotrigine oral kit 25 &amp; 50 &amp; 100 mg</i>                                                    | 2         | MO                               |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i>                                            | 1         | MO                               |
| <i>lamotrigine oral tablet chewable 25 mg, 5 mg</i>                                                     | 2         | MO                               |
| <i>lamotrigine oral tablet dispersible 100 mg, 200 mg, 25 mg, 50 mg</i>                                 | 4         | MO                               |
| <i>lamotrigine starter kit-blue oral kit 35 x 25 mg</i>                                                 | 2         | MO                               |
| <i>lamotrigine starter kit-green oral kit 84 x 25 mg &amp; 14x100 mg</i>                                | 2         | MO                               |
| <i>lamotrigine starter kit-orange oral kit 42 x 25 mg &amp; 7 x 100 mg</i>                              | 2         | MO                               |
| <i>levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg</i>                             | 2         | MO                               |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                                               | <b>Drug Tier</b> | <b>Requirements/Limits</b>       |
|----------------------------------------------------------------------------------------------------------------|------------------|----------------------------------|
| <i>levetiracetam oral solution 100 mg/ml</i>                                                                   | 2                | MO                               |
| <i>levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg</i>                                               | 1                | MO                               |
| <i>phenobarbital oral elixir 20 mg/5ml</i>                                                                     | 2                | MO; QL (1500 ML per 30 days)     |
| <i>phenobarbital oral tablet 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg</i>                                    | 2                | MO; QL (90 EA per 30 days)       |
| <i>phenobarbital oral tablet 15 mg, 60 mg</i>                                                                  | 2                | MO; QL (120 EA per 30 days)      |
| <i>phenobarbital oral tablet 30 mg</i>                                                                         | 2                | MO; QL (300 EA per 30 days)      |
| <i>primidone oral tablet 250 mg, 50 mg</i>                                                                     | 1                | MO                               |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000 MG                                                             | 4                | ST2; MO; QL (90 EA per 30 days)  |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 250 MG, 500 MG, 750 MG                                              | 4                | ST2; MO; QL (120 EA per 30 days) |
| <i>valproic acid oral capsule 250 mg</i>                                                                       | 2                | MO                               |
| <i>valproic acid oral solution 250 mg/5ml</i>                                                                  | 2                | MO                               |
| XCOPRI (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 & 150 MG                                               | 4                | MO; QL (56 EA per 28 days)       |
| XCOPRI (350 MG DAILY DOSE) ORAL TABLET THERAPY PACK 150 & 200 MG                                               | 4                | MO; QL (56 EA per 28 days)       |
| XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG                                                               | 4                | MO; QL (60 EA per 30 days)       |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG, 14 X 150 MG & 14 X 200 MG, 14 X 50 MG & 14 X 100 MG | 4                | MO; QL (28 EA per 28 days)       |
| <b>Calcium Channel Modifying Agents</b>                                                                        |                  |                                  |
| CELONTIN ORAL CAPSULE 300 MG                                                                                   | 4                | ST2; MO                          |
| <i>ethosuximide oral capsule 250 mg</i>                                                                        | 2                | MO                               |
| <i>ethosuximide oral solution 250 mg/5ml</i>                                                                   | 2                | MO                               |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i>                                                            | 2                | MO                               |
| <b>Gamma-Aminobutyric Acid (Gaba) Augmenting Agents</b>                                                        |                  |                                  |
| <i>clobazam oral suspension 2.5 mg/ml</i>                                                                      | 4                | MO; QL (480 ML per 30 days)      |
| <i>clobazam oral tablet 10 mg, 20 mg</i>                                                                       | 4                | MO; QL (60 EA per 30 days)       |
| <i>diazepam rectal gel 10 mg, 2.5 mg, 20 mg</i>                                                                | 4                | MO                               |
| <i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i>                                                          | 1                | MO; QL (270 EA per 30 days)      |
| <i>gabapentin oral solution 250 mg/5ml</i>                                                                     | 2                | MO                               |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                            | Drug Tier | Requirements/Limits               |
|--------------------------------------------------------------------------------------|-----------|-----------------------------------|
| <i>gabapentin oral tablet 600 mg, 800 mg</i>                                         | 1         | MO; QL (180 EA per 30 days)       |
| NAYZILAM NASAL SOLUTION 5 MG/0.1ML                                                   | 4         | MO                                |
| SYMPAZAN ORAL FILM 10 MG, 20 MG                                                      | 5         | ST2; NMO; QL (60 EA per 30 days)  |
| SYMPAZAN ORAL FILM 5 MG                                                              | 4         | ST2; MO; QL (60 EA per 30 days)   |
| <i>tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i>                            | 4         | MO                                |
| VALTOCO 10 MG DOSE NASAL LIQUID 10 MG/0.1ML                                          | 4         | ST2; MO                           |
| VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 7.5 MG/0.1ML                            | 4         | ST2; MO                           |
| VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 10 MG/0.1ML                             | 4         | ST2; MO                           |
| VALTOCO 5 MG DOSE NASAL LIQUID 5 MG/0.1ML                                            | 4         | ST2; MO                           |
| <i>vigabatrin oral packet 500 mg</i>                                                 | 5         | PA2; NMO; QL (180 EA per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i>                                                 | 5         | PA2; NMO; QL (180 EA per 30 days) |
| <b>Sodium Channel Agents</b>                                                         |           |                                   |
| APTOM ORAL TABLET 200 MG, 400 MG, 800 MG                                             | 5         | ST2; NMO; QL (30 EA per 30 days)  |
| APTOM ORAL TABLET 600 MG                                                             | 5         | ST2; NMO; QL (60 EA per 30 days)  |
| <i>carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg</i> | 2         | MO                                |
| <i>carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg</i>  | 2         | MO                                |
| <i>carbamazepine oral suspension 100 mg/5ml</i>                                      | 2         | MO                                |
| <i>carbamazepine oral tablet 200 mg</i>                                              | 2         | MO                                |
| <i>carbamazepine oral tablet chewable 100 mg</i>                                     | 1         | MO                                |
| DILANTIN ORAL CAPSULE 30 MG                                                          | 4         | ST2; MO                           |
| EPITOL ORAL TABLET 200 MG                                                            | 2         | MO                                |
| <i>oxcarbazepine oral suspension 300 mg/5ml</i>                                      | 4         | MO                                |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i>                              | 1         | MO                                |
| <i>phenytoin oral suspension 125 mg/5ml</i>                                          | 1         | MO                                |
| <i>phenytoin oral tablet chewable 50 mg</i>                                          | 1         | MO                                |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg</i>                         | 1         | MO                                |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| <b>Drug Name</b>                                                                            | <b>Drug Tier</b> | <b>Requirements/Limits</b>    |
|---------------------------------------------------------------------------------------------|------------------|-------------------------------|
| <i>phenytoin sodium extended oral capsule 300 mg</i>                                        | 2                | MO                            |
| <i>rufinamide oral suspension 40 mg/ml</i>                                                  | 5                | NMO; QL (2760 ML per 30 days) |
| <i>rufinamide oral tablet 200 mg</i>                                                        | 5                | NMO; QL (480 EA per 30 days)  |
| <i>rufinamide oral tablet 400 mg</i>                                                        | 5                | NMO; QL (240 EA per 30 days)  |
| VIMPAT ORAL SOLUTION 10 MG/ML                                                               | 4                | MO; QL (1395 ML per 30 days)  |
| VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG                                            | 4                | MO; QL (60 EA per 30 days)    |
| <b>ANTIDEMENTIA AGENTS</b>                                                                  |                  |                               |
| <b><i>Antidementia Agents, Other</i></b>                                                    |                  |                               |
| <i>memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg</i>     | 3                | MO; QL (30 EA per 30 days)    |
| <i>memantine hcl oral solution 2 mg/ml</i>                                                  | 2                | MO; QL (360 ML per 30 days)   |
| <i>memantine hcl oral tablet 10 mg, 5 mg</i>                                                | 2                | MO; QL (60 EA per 30 days)    |
| <i>memantine hcl oral tablet 28 x 5 mg &amp; 21 x 10 mg</i>                                 | 2                | MO; QL (49 EA per 28 days)    |
| NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG                       | 3                | PA; MO                        |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG        | 3                | PA; MO                        |
| <b><i>Cholinesterase Inhibitors</i></b>                                                     |                  |                               |
| <i>donepezil hcl oral tablet 10 mg</i>                                                      | 1                | MO; QL (60 EA per 30 days)    |
| <i>donepezil hcl oral tablet 23 mg</i>                                                      | 2                | MO; QL (30 EA per 30 days)    |
| <i>donepezil hcl oral tablet 5 mg</i>                                                       | 1                | MO; QL (30 EA per 30 days)    |
| <i>donepezil hcl oral tablet dispersible 10 mg</i>                                          | 1                | MO; QL (60 EA per 30 days)    |
| <i>donepezil hcl oral tablet dispersible 5 mg</i>                                           | 1                | MO; QL (30 EA per 30 days)    |
| <i>galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg</i> | 2                | MO; QL (30 EA per 30 days)    |
| <i>galantamine hydrobromide oral solution 4 mg/ml</i>                                       | 2                | MO; QL (180 ML per 30 days)   |
| <i>galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg</i>                               | 2                | MO; QL (60 EA per 30 days)    |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i>                        | 2                | MO; QL (60 EA per 30 days)    |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24hr, 4.6 mg/24hr, 9.5 mg/24hr</i>        | 2                | MO; QL (30 EA per 30 days)    |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                   | Drug Tier | Requirements/Limits              |
|-------------------------------------------------------------------------------------------------------------|-----------|----------------------------------|
| <b>ANTIDEPRESSANTS</b>                                                                                      |           |                                  |
| <b>Antidepressants, Other</b>                                                                               |           |                                  |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg</i>                                    | 1         | MO; QL (120 EA per 30 days)      |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 150 mg</i>                                    | 1         | MO; QL (90 EA per 30 days)       |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 200 mg</i>                                    | 1         | MO; QL (60 EA per 30 days)       |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg</i>                                    | 2         | MO; QL (60 EA per 30 days)       |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 300 mg</i>                                    | 2         | MO; QL (90 EA per 30 days)       |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 450 mg</i>                                    | 2         | MO; QL (30 EA per 30 days)       |
| <i>bupropion hcl oral tablet 100 mg</i>                                                                     | 1         | MO; QL (180 EA per 30 days)      |
| <i>bupropion hcl oral tablet 75 mg</i>                                                                      | 1         | MO; QL (120 EA per 30 days)      |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg</i>                                                          | 1         | MO; QL (30 EA per 30 days)       |
| <i>mirtazapine oral tablet 7.5 mg</i>                                                                       | 1         | MO; QL (45 EA per 30 days)       |
| <i>mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg</i>                                              | 2         | MO; QL (30 EA per 30 days)       |
| <i>olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 6-50 mg</i>                                   | 4         | MO; QL (30 EA per 30 days)       |
| <i>olanzapine-fluoxetine hcl oral capsule 3-25 mg, 6-25 mg</i>                                              | 4         | MO; QL (90 EA per 30 days)       |
| <b>Monoamine Oxidase Inhibitors</b>                                                                         |           |                                  |
| <i>EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 6 MG/24HR, 9 MG/24HR</i>                                     | 5         | ST2; NMO; QL (30 EA per 30 days) |
| <i>MARPLAN ORAL TABLET 10 MG</i>                                                                            | 4         | ST2; MO; QL (180 EA per 30 days) |
| <i>phenelzine sulfate oral tablet 15 mg</i>                                                                 | 2         | MO                               |
| <i>tranylcypromine sulfate oral tablet 10 mg</i>                                                            | 4         | MO                               |
| <b>Ssris/Snris (Selective Serotonin Reuptake Inhibitor/Serotonin And Norepinephrine Reuptake Inhibitor)</b> |           |                                  |
| <i>citalopram hydrobromide oral capsule 30 mg</i>                                                           | 1         | MO; QL (30 EA per 30 days)       |
| <i>citalopram hydrobromide oral solution 10 mg/5ml</i>                                                      | 2         | MO; QL (600 ML per 30 days)      |
| <i>citalopram hydrobromide oral tablet 10 mg, 40 mg</i>                                                     | 1         | MO; QL (30 EA per 30 days)       |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                             | <b>Drug Tier</b> | <b>Requirements/Limits</b>  |
|----------------------------------------------------------------------------------------------|------------------|-----------------------------|
| <i>citalopram hydrobromide oral tablet 20 mg</i>                                             | 1                | MO; QL (60 EA per 30 days)  |
| <i>desvenlafaxine er oral tablet extended release 24 hour 100 mg, 50 mg</i>                  | 4                | MO; QL (30 EA per 30 days)  |
| <i>desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg</i> | 4                | MO; QL (30 EA per 30 days)  |
| DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG           | 3                | MO; QL (60 EA per 30 days)  |
| <i>duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 40 mg, 60 mg</i>      | 2                | MO; QL (60 EA per 30 days)  |
| <i>escitalopram oxalate oral solution 5 mg/5ml</i>                                           | 2                | MO; QL (600 ML per 30 days) |
| <i>escitalopram oxalate oral tablet 10 mg</i>                                                | 1                | MO; QL (45 EA per 30 days)  |
| <i>escitalopram oxalate oral tablet 20 mg</i>                                                | 1                | MO; QL (60 EA per 30 days)  |
| <i>escitalopram oxalate oral tablet 5 mg</i>                                                 | 1                | MO; QL (30 EA per 30 days)  |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 20 MG, 40 MG, 80 MG                    | 3                | MO; QL (30 EA per 30 days)  |
| FETZIMA TITRATION ORAL CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG                            | 3                | MO; QL (28 EA per 28 days)  |
| <i>fluoxetine hcl oral capsule 10 mg, 20 mg, 40 mg</i>                                       | 1                | MO; QL (60 EA per 30 days)  |
| <i>fluoxetine hcl oral solution 20 mg/5ml</i>                                                | 2                | MO; QL (600 ML per 30 days) |
| <i>fluoxetine hcl oral tablet 10 mg</i>                                                      | 2                | MO; QL (60 EA per 30 days)  |
| <i>fluoxetine hcl oral tablet 20 mg</i>                                                      | 2                | MO; QL (120 EA per 30 days) |
| <i>fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg</i>                                  | 2                | MO; QL (90 EA per 30 days)  |
| <i>nefazodone hcl oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i>                      | 4                | MO                          |
| <i>paroxetine hcl oral suspension 10 mg/5ml</i>                                              | 4                | MO; QL (900 ML per 30 days) |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg</i>                                               | 1                | MO; QL (30 EA per 30 days)  |
| <i>paroxetine hcl oral tablet 30 mg, 40 mg</i>                                               | 1                | MO; QL (60 EA per 30 days)  |
| <i>sertraline hcl oral capsule 150 mg, 200 mg</i>                                            | 2                | MO; QL (30 EA per 30 days)  |
| <i>sertraline hcl oral concentrate 20 mg/ml</i>                                              | 1                | MO; QL (300 ML per 30 days) |
| <i>sertraline hcl oral tablet 100 mg</i>                                                     | 1                | MO; QL (60 EA per 30 days)  |
| <i>sertraline hcl oral tablet 25 mg, 50 mg</i>                                               | 1                | MO; QL (90 EA per 30 days)  |
| <i>trazodone hcl oral tablet 100 mg, 150 mg, 50 mg</i>                                       | 1                | MO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022. Last updated 04/18/2022.

| Drug Name                                                                              | Drug Tier | Requirements/Limits             |
|----------------------------------------------------------------------------------------|-----------|---------------------------------|
| <i>trazodone hcl oral tablet 300 mg</i>                                                | 2         | MO                              |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG                                              | 4         | ST2; MO; QL (30 EA per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg, 75 mg</i> | 1         | MO; QL (60 EA per 30 days)      |
| <i>venlafaxine hcl er oral tablet extended release 24 hour 150 mg, 37.5 mg, 75 mg</i>  | 2         | MO; QL (30 EA per 30 days)      |
| <i>venlafaxine hcl er oral tablet extended release 24 hour 225 mg</i>                  | 4         | MO; QL (30 EA per 30 days)      |
| <i>venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i>                | 1         | MO; QL (90 EA per 30 days)      |
| VIIBRYD ORAL TABLET 10 MG, 20 MG, 40 MG                                                | 3         | MO; QL (30 EA per 30 days)      |
| VIIBRYD STARTER PACK ORAL KIT 10 & 20 MG                                               | 3         | MO; QL (30 EA per 30 days)      |
| <b>Tricyclics</b>                                                                      |           |                                 |
| <i>amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i>        | 2         | MO                              |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i>                              | 2         | MO                              |
| <i>clomipramine hcl oral capsule 25 mg, 50 mg, 75 mg</i>                               | 4         | MO                              |
| <i>desipramine hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i>          | 2         | MO                              |
| <i>doxepin hcl oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i>             | 2         | MO                              |
| <i>doxepin hcl oral concentrate 10 mg/ml</i>                                           | 2         | MO                              |
| <i>imipramine hcl oral tablet 10 mg, 25 mg</i>                                         | 1         | MO                              |
| <i>imipramine hcl oral tablet 50 mg</i>                                                | 2         | MO                              |
| <i>nortriptyline hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i>                       | 1         | MO                              |
| <i>nortriptyline hcl oral solution 10 mg/5ml</i>                                       | 2         | MO                              |
| <i>protriptyline hcl oral tablet 10 mg, 5 mg</i>                                       | 4         | MO                              |
| <i>trimipramine maleate oral capsule 100 mg, 25 mg, 50 mg</i>                          | 4         | MO                              |

## ANTIEMETICS

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                           | Drug Tier | Requirements/Limits             |
|---------------------------------------------------------------------|-----------|---------------------------------|
| <b>Antiemetics, Other</b>                                           |           |                                 |
| <i>meclizine hcl oral tablet 12.5 mg, 25 mg</i>                     | 1         | MO                              |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i>             | 1         | BvD; MO                         |
| <i>prochlorperazine rectal suppository 25 mg</i>                    | 4         | MO                              |
| <i>promethazine hcl oral syrup 6.25 mg/5ml</i>                      | 2         | MO                              |
| <i>promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg</i>           | 1         | MO                              |
| <i>promethazine hcl rectal suppository 12.5 mg, 25 mg</i>           | 2         | MO                              |
| <i>scopolamine transdermal patch 72 hour 1 mg/3days</i>             | 4         | MO                              |
| TRANSDERM-SCOP TRANSDERMAL PATCH 72 HOUR 1 MG/3DAYS                 | 4         | MO                              |
| <b>Emetogenic Therapy Adjuncts</b>                                  |           |                                 |
| <i>aprepitant oral capsule 125 mg, 40 mg, 80 mg</i>                 | 4         | BvD; MO; QL (30 EA per 30 days) |
| <i>aprepitant oral capsule 80 &amp; 125 mg</i>                      | 4         | BvD; MO; QL (12 EA per 30 days) |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i>                  | 4         | PA; MO; QL (60 EA per 30 days)  |
| <i>granisetron hcl oral tablet 1 mg</i>                             | 4         | BvD; MO; QL (60 EA per 30 days) |
| <i>ondansetron hcl oral solution 4 mg/5ml</i>                       | 2         | BvD; MO                         |
| <i>ondansetron hcl oral tablet 24 mg, 4 mg, 8 mg</i>                | 1         | BvD; MO                         |
| <i>ondansetron oral tablet dispersible 4 mg, 8 mg</i>               | 2         | BvD; MO                         |
| VARUBI (180 MG DOSE) ORAL TABLET THERAPY PACK 2 X 90 MG             | 3         | BvD; MO                         |
| <b>ANTIFUNGALS</b>                                                  |           |                                 |
| <b>Antifungals</b>                                                  |           |                                 |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML                              | 4         | BvD; MO                         |
| AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50 MG                 | 5         | BvD; NMO                        |
| <i>amphotericin b intravenous solution reconstituted 50 mg</i>      | 4         | BvD; MO                         |
| <i>caspofungin acetate intravenous solution reconstituted 50 mg</i> | 5         | NMO                             |
| <i>caspofungin acetate intravenous solution reconstituted 70 mg</i> | 4         | MO                              |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                                           | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|------------------------------------------------------------------------------------------------------------|------------------|----------------------------|
| <i>ciclopirox olamine external cream 0.77 %</i>                                                            | 2                | MO                         |
| <i>ciclopirox olamine external suspension 0.77 %</i>                                                       | 2                | MO                         |
| <i>clotrimazole external cream 1 %</i>                                                                     | 1                | MO                         |
| <i>clotrimazole external solution 1 %</i>                                                                  | 2                | MO                         |
| <i>clotrimazole mouth/throat troche 10 mg</i>                                                              | 2                | MO                         |
| <i>econazole nitrate external cream 1 %</i>                                                                | 2                | MO                         |
| ERAXIS INTRAVENOUS SOLUTION<br>RECONSTITUTED 100 MG                                                        | 5                | BvD; NMO                   |
| ERAXIS INTRAVENOUS SOLUTION<br>RECONSTITUTED 50 MG                                                         | 4                | BvD; MO                    |
| <i>fluconazole in sodium chloride intravenous<br/>solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml-<br/>%</i> | 2                | BvD; MO                    |
| <i>fluconazole oral suspension reconstituted 10<br/>mg/ml, 40 mg/ml</i>                                    | 2                | MO                         |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg,<br/>50 mg</i>                                           | 2                | MO                         |
| <i>flucytosine oral capsule 250 mg, 500 mg</i>                                                             | 5                | NMO                        |
| <i>griseofulvin microsize oral suspension 125 mg/5ml</i>                                                   | 2                | MO                         |
| <i>griseofulvin microsize oral tablet 500 mg</i>                                                           | 2                | MO                         |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250<br/>mg</i>                                          | 2                | MO                         |
| <i>itraconazole oral capsule 100 mg</i>                                                                    | 4                | PA; MO                     |
| <i>itraconazole oral solution 10 mg/ml</i>                                                                 | 4                | PA; MO                     |
| JUBLIA EXTERNAL SOLUTION 10 %                                                                              | 4                | MO                         |
| <i>ketoconazole external cream 2 %</i>                                                                     | 2                | MO                         |
| <i>ketoconazole external shampoo 2 %</i>                                                                   | 1                | MO                         |
| <i>ketoconazole oral tablet 200 mg</i>                                                                     | 1                | MO                         |
| NOXAFIL ORAL SUSPENSION 40 MG/ML                                                                           | 5                | PA; NMO                    |
| NYAMYC EXTERNAL POWDER 100000<br>UNIT/GM                                                                   | 3                | MO                         |
| <i>nystatin external cream 100000 unit/gm</i>                                                              | 1                | MO                         |
| <i>nystatin external ointment 100000 unit/gm</i>                                                           | 1                | MO                         |
| <i>nystatin external powder 100000 unit/gm</i>                                                             | 2                | MO                         |
| <i>nystatin mouth/throat suspension 100000 unit/ml</i>                                                     | 2                | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                              | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|---------------------------------------------------------------|------------------|----------------------------|
| <i>nystatin oral tablet 500000 unit</i>                       | 2                | MO                         |
| NYSTOP EXTERNAL POWDER 100000 UNIT/GM                         | 3                | MO                         |
| <i>posaconazole oral tablet delayed release 100 mg</i>        | 4                | PA; MO                     |
| <i>terbinafine hcl oral tablet 250 mg</i>                     | 2                | MO                         |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i>                 | 2                | MO                         |
| <i>terconazole vaginal suppository 80 mg</i>                  | 2                | MO                         |
| <i>voriconazole intravenous solution reconstituted 200 mg</i> | 5                | PA; NMO                    |
| <i>voriconazole oral suspension reconstituted 40 mg/ml</i>    | 5                | PA; NMO                    |
| <i>voriconazole oral tablet 200 mg, 50 mg</i>                 | 4                | PA; MO                     |

## ANTIGOUT AGENTS

### Antigout Agents

|                                                     |   |        |
|-----------------------------------------------------|---|--------|
| <i>allopurinol oral tablet 100 mg, 300 mg</i>       | 1 | MO     |
| <i>colchicine oral tablet 0.6 mg</i>                | 4 | MO     |
| <i>colchicine-probenecid oral tablet 0.5-500 mg</i> | 3 | MO     |
| <i>febuxostat oral tablet 40 mg, 80 mg</i>          | 3 | PA; MO |
| MITIGARE ORAL CAPSULE 0.6 MG                        | 3 | MO     |
| <i>probenecid oral tablet 500 mg</i>                | 2 | MO     |

## ANTIMIGRAINE AGENTS

### Ergot Alkaloids

|                                                          |   |                            |
|----------------------------------------------------------|---|----------------------------|
| <i>dihydroergotamine mesylate nasal solution 4 mg/ml</i> | 5 | NMO                        |
| <i>ergotamine-caffeine oral tablet 1-100 mg</i>          | 2 | MO; QL (40 EA per 28 days) |

### Prophylactic

|                                                                       |   |        |
|-----------------------------------------------------------------------|---|--------|
| EMGALITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 120 MG/ML                | 3 | PA; MO |
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML            | 3 | PA; MO |
| EPRONTIA ORAL SOLUTION 25 MG/ML                                       | 3 | MO     |
| <i>propranolol hcl er oral capsule extended release 24 hour 80 mg</i> | 2 | MO     |
| <i>propranolol hcl oral tablet 80 mg</i>                              | 2 | MO     |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022. Last updated 04/18/2022.

| Drug Name                                                                                  | Drug Tier | Requirements/Limits            |
|--------------------------------------------------------------------------------------------|-----------|--------------------------------|
| <i>topiramate er oral capsule er 24 hour sprinkle 100 mg, 150 mg, 200 mg, 25 mg, 50 mg</i> | 4         | MO                             |
| <i>topiramate oral capsule sprinkle 15 mg, 25 mg</i>                                       | 2         | MO                             |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i>                                 | 1         | MO                             |
| UBRELVY ORAL TABLET 100 MG, 50 MG                                                          | 4         | PA; MO; QL (16 EA per 30 days) |
| <b>Serotonin (5-Ht) Receptor Agonist</b>                                                   |           |                                |
| <i>naratriptan hcl oral tablet 1 mg, 2.5 mg</i>                                            | 2         | MO; QL (9 EA per 30 days)      |
| <i>rizatriptan benzoate oral tablet 10 mg, 5 mg</i>                                        | 2         | MO; QL (12 EA per 30 days)     |
| <i>rizatriptan benzoate oral tablet dispersible 10 mg</i>                                  | 2         | MO; QL (12 EA per 30 days)     |
| <i>rizatriptan benzoate oral tablet dispersible 5 mg</i>                                   | 2         | MO; QL (24 EA per 30 days)     |
| <i>sumatriptan nasal solution 20 mg/act, 5 mg/act</i>                                      | 4         | MO; QL (18 EA per 30 days)     |
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i>                              | 1         | MO; QL (9 EA per 30 days)      |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 4 mg/0.5ml, 6 mg/0.5ml</i> | 2         | MO; QL (10 ML per 30 days)     |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5ml</i>                              | 2         | MO; QL (8 ML per 30 days)      |
| <i>sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml</i>                | 2         | MO; QL (4.5 ML per 30 days)    |
| <i>sumatriptan succinate subcutaneous solution auto-injector 6 mg/0.5ml</i>                | 2         | MO; QL (4 ML per 30 days)      |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i>                                               | 2         | MO; QL (6 EA per 30 days)      |
| <i>zolmitriptan oral tablet dispersible 2.5 mg, 5 mg</i>                                   | 2         | MO; QL (6 EA per 30 days)      |
| <b>ANTIMYASTHENIC AGENTS</b>                                                               |           |                                |
| <b>Parasympathomimetics</b>                                                                |           |                                |
| <i>pyridostigmine bromide oral solution 60 mg/5ml</i>                                      | 2         | MO                             |
| <i>pyridostigmine bromide oral tablet 30 mg, 60 mg</i>                                     | 2         | MO                             |
| <b>ANTIMYCOBACTERIALS</b>                                                                  |           |                                |
| <b>Antimycobacterials, Other</b>                                                           |           |                                |
| <i>dapsone oral tablet 100 mg, 25 mg</i>                                                   | 2         | MO                             |
| PRIFTIN ORAL TABLET 150 MG                                                                 | 4         | MO                             |
| <i>rifabutin oral capsule 150 mg</i>                                                       | 4         | MO                             |
| <b>Antituberculars</b>                                                                     |           |                                |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                                 | Drug Tier | Requirements/Limits               |
|-----------------------------------------------------------|-----------|-----------------------------------|
| <i>ethambutol hcl oral tablet 100 mg, 400 mg</i>          | 2         | MO                                |
| <i>isoniazid oral syrup 50 mg/5ml</i>                     | 1         | MO                                |
| <i>isoniazid oral tablet 100 mg, 300 mg</i>               | 1         | MO                                |
| PASER ORAL PACKET 4 GM                                    | 4         | MO                                |
| <i>pyrazinamide oral tablet 500 mg</i>                    | 2         | MO                                |
| <i>rifampin intravenous solution reconstituted 600 mg</i> | 4         | MO                                |
| <i>rifampin oral capsule 150 mg, 300 mg</i>               | 2         | MO                                |
| SIRTURO ORAL TABLET 100 MG, 20 MG                         | 5         | PA; NMO                           |
| TRECTOR ORAL TABLET 250 MG                                | 4         | MO                                |
| <b>ANTINEOPLASTICS</b>                                    |           |                                   |
| <b><i>Alkylating Agents</i></b>                           |           |                                   |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i>         | 4         | BvD; MO                           |
| <i>cyclophosphamide oral tablet 25 mg, 50 mg</i>          | 2         | BvD; MO                           |
| LEUKERAN ORAL TABLET 2 MG                                 | 4         | MO                                |
| MATULANE ORAL CAPSULE 50 MG                               | 5         | PA2; NMO                          |
| VALCHLOR EXTERNAL GEL 0.016 %                             | 5         | PA2; NMO; QL (60 GM per 14 days)  |
| <b><i>Antiandrogens</i></b>                               |           |                                   |
| <i>abiraterone acetate oral tablet 250 mg, 500 mg</i>     | 5         | PA2; NMO; QL (120 EA per 30 days) |
| <i>bicalutamide oral tablet 50 mg</i>                     | 1         | MO                                |
| ERLEADA ORAL TABLET 60 MG                                 | 5         | PA2; NMO; QL (120 EA per 30 days) |
| <i>flutamide oral capsule 125 mg</i>                      | 2         | MO                                |
| LYSODREN ORAL TABLET 500 MG                               | 5         | NMO                               |
| <i>nilutamide oral tablet 150 mg</i>                      | 5         | NMO; QL (60 EA per 30 days)       |
| NUBEQA ORAL TABLET 300 MG                                 | 5         | PA2; NMO; QL (120 EA per 30 days) |
| XTANDI ORAL CAPSULE 40 MG                                 | 5         | PA2; NMO; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 40 MG                                  | 5         | PA2; NMO; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 80 MG                                  | 5         | PA2; NMO; QL (90 EA per 30 days)  |
| YONSA ORAL TABLET 125 MG                                  | 5         | PA2; NMO; QL (120 EA per 30 days) |
| <b><i>Antiangiogenic Agents</i></b>                       |           |                                   |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG              | 5         | PA2; NMO; QL (21 EA per 28 days)  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                          | Drug Tier | Requirements/Limits               |
|--------------------------------------------------------------------|-----------|-----------------------------------|
| REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG     | 5         | PA2; NMO; QL (28 EA per 28 days)  |
| THALOMID ORAL CAPSULE 100 MG, 200 MG, 50 MG                        | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| THALOMID ORAL CAPSULE 150 MG                                       | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| <b>Antiestrogens/Modifiers</b>                                     |           |                                   |
| EMCYT ORAL CAPSULE 140 MG                                          | 3         | MO                                |
| SOLTAMOX ORAL SOLUTION 10 MG/5ML                                   | 4         | PA2; MO                           |
| <i>tamoxifen citrate oral tablet 10 mg, 20 mg</i>                  | 1         | MO                                |
| <i>toremifene citrate oral tablet 60 mg</i>                        | 5         | PA2; NMO                          |
| <b>Antimetabolites</b>                                             |           |                                   |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG                         | 4         | MO                                |
| <i>hydroxyurea oral capsule 500 mg</i>                             | 1         | MO                                |
| INQOVI ORAL TABLET 35-100 MG                                       | 5         | PA2; NMO                          |
| <i>mercaptopurine oral tablet 50 mg</i>                            | 2         | MO                                |
| ONUREG ORAL TABLET 200 MG, 300 MG                                  | 5         | PA2; NMO                          |
| PURIXAN ORAL SUSPENSION 2000 MG/100ML                              | 4         | MO                                |
| TABLOID ORAL TABLET 40 MG                                          | 4         | PA2; MO                           |
| <b>Antineoplastics, Other</b>                                      |           |                                   |
| IDHIFA ORAL TABLET 100 MG                                          | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| IDHIFA ORAL TABLET 50 MG                                           | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| KISQALI FEMARA (400 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5         | PA2; NMO                          |
| KISQALI FEMARA (600 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5         | PA2; NMO                          |
| KISQALI FEMARA(200 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG  | 5         | PA2; NMO                          |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 5 mg</i>           | 2         | MO                                |
| <i>leucovorin calcium oral tablet 25 mg</i>                        | 4         | MO                                |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG                         | 5         | PA2; NMO                          |
| LYNPARZA ORAL TABLET 100 MG                                        | 5         | PA2; NMO; QL (180 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                  | Drug Tier | Requirements/Limits               |
|------------------------------------------------------------|-----------|-----------------------------------|
| LYNPARZA ORAL TABLET 150 MG                                | 5         | PA2; NMO; QL (120 EA per 30 days) |
| MESNEX ORAL TABLET 400 MG                                  | 5         | NMO                               |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG                    | 5         | PA2; NMO                          |
| ORGOVYX ORAL TABLET 120 MG                                 | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| SCEMBLIX ORAL TABLET 20 MG, 40 MG                          | 5         | PA2; NMO                          |
| SYNRIBO SUBCUTANEOUS SOLUTION RECONSTITUTED 3.5 MG         | 5         | PA2; NMO                          |
| XATMEP ORAL SOLUTION 2.5 MG/ML                             | 4         | BvD; MO                           |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG | 5         | PA2; NMO                          |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG  | 5         | PA2; NMO                          |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5         | PA2; NMO                          |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG  | 5         | PA2; NMO                          |
| XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5         | PA2; NMO                          |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG  | 5         | PA2; NMO                          |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5         | PA2; NMO                          |
| ZOLINZA ORAL CAPSULE 100 MG                                | 5         | PA2; NMO; QL (120 EA per 30 days) |
| <b>Aromatase Inhibitors, 3Rd Generation</b>                |           |                                   |
| <i>anastrozole oral tablet 1 mg</i>                        | 1         | MO                                |
| <i>exemestane oral tablet 25 mg</i>                        | 4         | MO                                |
| <i>letrozole oral tablet 2.5 mg</i>                        | 1         | MO                                |
| <b>Molecular Target Inhibitors</b>                         |           |                                   |
| ALECENSA ORAL CAPSULE 150 MG                               | 5         | PA2; NMO                          |
| ALUNBRIG ORAL TABLET 180 MG                                | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| ALUNBRIG ORAL TABLET 30 MG                                 | 5         | PA2; NMO; QL (180 EA per 30 days) |
| ALUNBRIG ORAL TABLET 90 MG                                 | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG              | 5         | PA2; NMO; QL (30 EA per 30 days)  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                 | Drug Tier | Requirements/Limits               |
|-----------------------------------------------------------|-----------|-----------------------------------|
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG  | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| BALVERSA ORAL TABLET 3 MG                                 | 5         | PA2; NMO; QL (90 EA per 30 days)  |
| BALVERSA ORAL TABLET 4 MG                                 | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| BALVERSA ORAL TABLET 5 MG                                 | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| BOSULIF ORAL TABLET 100 MG                                | 5         | PA2; NMO; QL (120 EA per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG                        | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| BRAFTOVI ORAL CAPSULE 75 MG                               | 5         | PA2; NMO; QL (180 EA per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG                               | 5         | PA2; NMO; QL (120 EA per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG                 | 5         | PA2; NMO                          |
| CALQUENCE ORAL CAPSULE 100 MG                             | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| CAPRELSA ORAL TABLET 100 MG                               | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| CAPRELSA ORAL TABLET 300 MG                               | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG          | 5         | PA2; NMO; QL (56 EA per 28 days)  |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG   | 5         | PA2; NMO; QL (112 EA per 28 days) |
| COMETRIQ (60 MG DAILY DOSE) ORAL KIT 20 MG                | 5         | PA2; NMO; QL (84 EA per 28 days)  |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG                        | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| COTELLIC ORAL TABLET 20 MG                                | 5         | PA2; NMO; QL (63 EA per 28 days)  |
| DAURISMO ORAL TABLET 100 MG, 25 MG                        | 5         | PA2; NMO                          |
| ERIVEDGE ORAL CAPSULE 150 MG                              | 5         | PA2; NMO                          |
| <i>erlotinib hcl oral tablet 100 mg, 150 mg</i>           | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| <i>erlotinib hcl oral tablet 25 mg</i>                    | 5         | PA2; NMO; QL (90 EA per 30 days)  |
| <i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| <i>everolimus oral tablet soluble 2 mg, 3 mg</i>          | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| <i>everolimus oral tablet soluble 5 mg</i>                | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| EXKIVITY ORAL CAPSULE 40 MG                               | 5         | PA2; NMO                          |
| FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG                  | 5         | PA2; NMO; QL (6 EA per 21 days)   |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG                     | 5         | PA2; NMO; QL (21 EA per 28 days)  |
| GAVRETO ORAL CAPSULE 100 MG                               | 5         | PA2; NMO; QL (120 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                      | Drug Tier | Requirements/Limits               |
|----------------------------------------------------------------|-----------|-----------------------------------|
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG                       | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG                     | 5         | PA2; NMO                          |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG                      | 5         | PA2; NMO                          |
| ICLUSIG ORAL TABLET 10 MG, 30 MG, 45 MG                        | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| ICLUSIG ORAL TABLET 15 MG                                      | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| <i>imatinib mesylate oral tablet 100 mg</i>                    | 5         | PA2; NMO; QL (180 EA per 30 days) |
| <i>imatinib mesylate oral tablet 400 mg</i>                    | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| IMBRUVICA ORAL CAPSULE 140 MG, 70 MG                           | 5         | PA2; NMO; QL (120 EA per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG                                   | 5         | PA2; NMO; QL (120 EA per 30 days) |
| IMBRUVICA ORAL TABLET 280 MG                                   | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| IMBRUVICA ORAL TABLET 420 MG, 560 MG                           | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| INLYTA ORAL TABLET 1 MG                                        | 5         | PA2; NMO; QL (180 EA per 30 days) |
| INLYTA ORAL TABLET 5 MG                                        | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| INREBIC ORAL CAPSULE 100 MG                                    | 5         | PA2; NMO; QL (120 EA per 30 days) |
| IRESSA ORAL TABLET 250 MG                                      | 5         | PA2; NMO                          |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG            | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK 200 MG          | 5         | PA2; NMO                          |
| KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK 200 MG          | 5         | PA2; NMO                          |
| KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK 200 MG          | 5         | PA2; NMO                          |
| KOSELUGO ORAL CAPSULE 10 MG                                    | 5         | PA2; NMO; QL (240 EA per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG                                    | 5         | PA2; NMO; QL (120 EA per 30 days) |
| <i>lapatinib ditosylate oral tablet 250 mg</i>                 | 5         | PA2; NMO; QL (180 EA per 30 days) |
| LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG     | 5         | PA2; NMO                          |
| LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4 MG  | 5         | PA2; NMO                          |
| LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4 MG | 5         | PA2; NMO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                             | Drug Tier | Requirements/Limits               |
|-----------------------------------------------------------------------|-----------|-----------------------------------|
| LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG & 2 X 4 MG | 5         | PA2; NMO                          |
| LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG        | 5         | PA2; NMO                          |
| LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG & 4 MG | 5         | PA2; NMO                          |
| LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4 MG              | 5         | PA2; NMO                          |
| LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4 MG          | 5         | PA2; NMO                          |
| LORBRENA ORAL TABLET 100 MG                                           | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| LORBRENA ORAL TABLET 25 MG                                            | 5         | PA2; NMO; QL (120 EA per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG                                           | 5         | PA2; NMO; QL (240 EA per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG                                           | 5         | PA2; NMO; QL (120 EA per 30 days) |
| MEKINIST ORAL TABLET 2 MG                                             | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| MEKTOVI ORAL TABLET 15 MG                                             | 5         | PA2; NMO; QL (180 EA per 30 days) |
| NERLYNX ORAL TABLET 40 MG                                             | 5         | PA2; NMO; QL (180 EA per 30 days) |
| NEXAVAR ORAL TABLET 200 MG                                            | 5         | PA2; NMO; QL (120 EA per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG                                            | 5         | PA2; NMO                          |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG                            | 5         | PA2; NMO; QL (14 EA per 21 days)  |
| PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 MG            | 5         | PA2; NMO                          |
| PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50 MG       | 5         | PA2; NMO                          |
| PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150 MG        | 5         | PA2; NMO                          |
| QINLOCK ORAL TABLET 50 MG                                             | 5         | PA2; NMO; QL (90 EA per 30 days)  |
| RETEVMO ORAL CAPSULE 40 MG                                            | 5         | PA2; NMO; QL (120 EA per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG                                            | 5         | PA2; NMO; QL (180 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 100 MG                                         | 5         | PA2; NMO; QL (150 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG                                         | 5         | PA2; NMO; QL (90 EA per 30 days)  |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG                            | 5         | PA2; NMO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                           | Drug Tier | Requirements/Limits               |
|---------------------------------------------------------------------|-----------|-----------------------------------|
| RYDAPT ORAL CAPSULE 25 MG                                           | 5         | PA2; NMO; QL (240 EA per 30 days) |
| SPRYCEL ORAL TABLET 100 MG, 50 MG, 70 MG, 80 MG                     | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| SPRYCEL ORAL TABLET 140 MG                                          | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| SPRYCEL ORAL TABLET 20 MG                                           | 5         | PA2; NMO; QL (90 EA per 30 days)  |
| STIVARGA ORAL TABLET 40 MG                                          | 5         | PA2; NMO; QL (84 EA per 28 days)  |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | 5         | PA2; NMO; QL (28 EA per 28 days)  |
| TABRECTA ORAL TABLET 150 MG, 200 MG                                 | 5         | PA2; NMO; QL (120 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 50 MG                                         | 5         | PA2; NMO; QL (180 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 75 MG                                         | 5         | PA2; NMO; QL (120 EA per 30 days) |
| TAGRISSE ORAL TABLET 40 MG, 80 MG                                   | 5         | PA2; NMO                          |
| TALZENNA ORAL CAPSULE 0.25 MG                                       | 5         | PA2; NMO; QL (120 EA per 30 days) |
| TALZENNA ORAL CAPSULE 0.5 MG                                        | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| TALZENNA ORAL CAPSULE 0.75 MG                                       | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| TALZENNA ORAL CAPSULE 1 MG                                          | 5         | PA2; NMO; QL (30 EA per 30 days)  |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG                          | 5         | PA2; NMO; QL (120 EA per 30 days) |
| TAZVERIK ORAL TABLET 200 MG                                         | 5         | PA2; NMO; QL (240 EA per 30 days) |
| TEPMETKO ORAL TABLET 225 MG                                         | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| TIBSOVO ORAL TABLET 250 MG                                          | 5         | PA2; NMO; QL (60 EA per 30 days)  |
| TRUSELTIQ (100MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100 MG       | 5         | PA2; NMO; QL (21 EA per 28 days)  |
| TRUSELTIQ (125MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100 & 25 MG  | 5         | PA2; NMO; QL (42 EA per 28 days)  |
| TRUSELTIQ (50MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25 MG         | 5         | PA2; NMO; QL (42 EA per 28 days)  |
| TRUSELTIQ (75MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25 MG         | 5         | PA2; NMO; QL (63 EA per 28 days)  |
| TUKYSA ORAL TABLET 150 MG, 50 MG                                    | 5         | PA2; NMO; QL (120 EA per 30 days) |
| TURALIO ORAL CAPSULE 200 MG                                         | 5         | PA2; NMO; QL (120 EA per 30 days) |
| UKONIQ ORAL TABLET 200 MG                                           | 5         | PA2; NMO; QL (120 EA per 30 days) |
| VENCLEXTA ORAL TABLET 10 MG, 50 MG                                  | 4         | PA2; MO                           |
| VENCLEXTA ORAL TABLET 100 MG                                        | 5         | PA2; NMO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                              | Drug Tier | Requirements/Limits                  |
|------------------------------------------------------------------------|-----------|--------------------------------------|
| VENCLEXTA STARTING PACK ORAL<br>TABLET THERAPY PACK 10 & 50 & 100 MG   | 3         | PA2; MO                              |
| VERZENIO ORAL TABLET 100 MG, 150 MG,<br>200 MG, 50 MG                  | 5         | PA2; NMO                             |
| VITRAKVI ORAL CAPSULE 100 MG                                           | 5         | PA2; NMO; QL (60 EA per 30 days)     |
| VITRAKVI ORAL CAPSULE 25 MG                                            | 5         | PA2; NMO; QL (180 EA per 30 days)    |
| VITRAKVI ORAL SOLUTION 20 MG/ML                                        | 5         | PA2; NMO; QL (310 ML per 30<br>days) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45<br>MG                            | 5         | PA2; NMO; QL (30 EA per 30 days)     |
| VOTRIENT ORAL TABLET 200 MG                                            | 5         | PA2; NMO; QL (120 EA per 30 days)    |
| WELIREG ORAL TABLET 40 MG                                              | 5         | PA2; NMO; QL (90 EA per 30 days)     |
| XALKORI ORAL CAPSULE 200 MG, 250 MG                                    | 5         | PA2; NMO; QL (120 EA per 30 days)    |
| XOSPATA ORAL TABLET 40 MG                                              | 5         | PA2; NMO; QL (90 EA per 30 days)     |
| ZEJULA ORAL CAPSULE 100 MG                                             | 5         | PA2; NMO; QL (90 EA per 30 days)     |
| ZELBORAF ORAL TABLET 240 MG                                            | 5         | PA2; NMO; QL (240 EA per 30 days)    |
| ZYDELIG ORAL TABLET 100 MG, 150 MG                                     | 5         | PA2; NMO; QL (60 EA per 30 days)     |
| ZYKADIA ORAL TABLET 150 MG                                             | 5         | PA2; NMO; QL (150 EA per 30 days)    |
| <b>Retinoids</b>                                                       |           |                                      |
| <i>bexarotene oral capsule 75 mg</i>                                   | 5         | PA2; NMO; QL (300 EA per 30 days)    |
| PANRETIN EXTERNAL GEL 0.1 %                                            | 5         | PA2; NMO                             |
| TARGRETIN EXTERNAL GEL 1 %                                             | 5         | PA2; NMO                             |
| <i>tretinoin oral capsule 10 mg</i>                                    | 5         | NMO                                  |
| <b>ANTIPARASITICS</b>                                                  |           |                                      |
| <b>Anthelmintics</b>                                                   |           |                                      |
| <i>albendazole oral tablet 200 mg</i>                                  | 4         | MO                                   |
| EMVERM ORAL TABLET CHEWABLE 100<br>MG                                  | 5         | NMO                                  |
| <i>ivermectin oral tablet 3 mg</i>                                     | 2         | PA2; MO                              |
| <b>Antiprotozoals</b>                                                  |           |                                      |
| <i>atovaquone oral suspension 750 mg/5ml</i>                           | 5         | NMO                                  |
| <i>atovaquone-proguanil hcl oral tablet 250-100 mg,<br/>62.5-25 mg</i> | 2         | MO                                   |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                                                                                                                         | Drug Tier | Requirements/Limits        |
|---------------------------------------------------------------------------------------------------------------------------------------------------|-----------|----------------------------|
| <i>benznidazole oral tablet 100 mg, 12.5 mg</i>                                                                                                   | 2         | MO                         |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i>                                                                                           | 2         | MO                         |
| COARTEM ORAL TABLET 20-120 MG                                                                                                                     | 4         | MO                         |
| <i>hydroxychloroquine sulfate oral tablet 100 mg, 200 mg, 300 mg, 400 mg</i>                                                                      | 2         | MO                         |
| LAMPIT ORAL TABLET 120 MG, 30 MG                                                                                                                  | 4         | MO                         |
| <i>mefloquine hcl oral tablet 250 mg</i>                                                                                                          | 2         | MO                         |
| <i>nitazoxanide oral tablet 500 mg</i>                                                                                                            | 4         | MO; QL (40 EA per 30 days) |
| <i>pentamidine isethionate inhalation solution reconstituted 300 mg</i>                                                                           | 4         | BvD; MO                    |
| <i>pentamidine isethionate injection solution reconstituted 300 mg</i>                                                                            | 4         | BvD; MO                    |
| <i>primaquine phosphate oral tablet 26.3 (15 base) mg</i>                                                                                         | 4         | MO                         |
| <i>quinine sulfate oral capsule 324 mg</i>                                                                                                        | 2         | PA; MO                     |
| <b>ANTIPARKINSON AGENTS</b>                                                                                                                       |           |                            |
| <b><i>Anticholinergics</i></b>                                                                                                                    |           |                            |
| <i>benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg</i>                                                                                        | 1         | MO                         |
| <i>trihexyphenidyl hcl oral solution 0.4 mg/ml</i>                                                                                                | 1         | MO                         |
| <i>trihexyphenidyl hcl oral tablet 2 mg, 5 mg</i>                                                                                                 | 1         | MO                         |
| <b><i>Antiparkinson Agents, Other</i></b>                                                                                                         |           |                            |
| <i>amantadine hcl oral capsule 100 mg</i>                                                                                                         | 2         | MO                         |
| <i>amantadine hcl oral solution 50 mg/5ml</i>                                                                                                     | 2         | MO                         |
| <i>amantadine hcl oral tablet 100 mg</i>                                                                                                          | 2         | MO                         |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 2         | MO                         |
| <i>entacapone oral tablet 200 mg</i>                                                                                                              | 2         | MO                         |
| <b><i>Dopamine Agonists</i></b>                                                                                                                   |           |                            |
| <i>bromocriptine mesylate oral capsule 5 mg</i>                                                                                                   | 2         | MO                         |
| <i>bromocriptine mesylate oral tablet 2.5 mg</i>                                                                                                  | 2         | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                         | Drug Tier | Requirements/Limits              |
|---------------------------------------------------------------------------------------------------|-----------|----------------------------------|
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG                                         | 5         | PA; NMO; QL (150 EA per 30 days) |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24HR, 2 MG/24HR, 3 MG/24HR, 4 MG/24HR, 6 MG/24HR, 8 MG/24HR | 4         | MO                               |
| <i>pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i>   | 1         | MO                               |
| <i>ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i>                   | 1         | MO                               |
| <b>Dopamine Precursors And/Or L-Amino Acid Decarboxylase Inhibitors</b>                           |           |                                  |
| <i>carbidopa oral tablet 25 mg</i>                                                                | 2         | MO                               |
| <i>carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg</i>                    | 2         | MO                               |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i>                             | 2         | MO                               |
| <i>carbidopa-levodopa oral tablet dispersible 10-100 mg, 25-100 mg, 25-250 mg</i>                 | 2         | MO                               |
| INBRIJA INHALATION CAPSULE 42 MG                                                                  | 5         | NMO                              |
| RYTARY ORAL CAPSULE EXTENDED RELEASE 23.75-95 MG, 36.25-145 MG, 48.75-195 MG, 61.25-245 MG        | 4         | ST2; MO                          |
| <b>Monoamine Oxidase B (Mao-B) Inhibitors</b>                                                     |           |                                  |
| <i>rasagiline mesylate oral tablet 0.5 mg, 1 mg</i>                                               | 4         | MO                               |
| <i>selegiline hcl oral capsule 5 mg</i>                                                           | 2         | MO                               |
| <i>selegiline hcl oral tablet 5 mg</i>                                                            | 2         | MO                               |
| <b>ANTIPSYCHOTICS</b>                                                                             |           |                                  |
| <b>1st Generation/Typical</b>                                                                     |           |                                  |
| <i>chlorpromazine hcl oral concentrate 100 mg/ml, 30 mg/ml</i>                                    | 4         | MO                               |
| <i>chlorpromazine hcl oral tablet 10 mg, 25 mg</i>                                                | 4         | BvD; MO                          |
| <i>chlorpromazine hcl oral tablet 100 mg, 200 mg, 50 mg</i>                                       | 4         | MO                               |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i>                                         | 4         | MO                               |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i>                                              | 4         | MO                               |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i>                                                  | 2         | MO                               |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                                       | <b>Drug Tier</b> | <b>Requirements/Limits</b>      |
|--------------------------------------------------------------------------------------------------------|------------------|---------------------------------|
| <i>fluphenazine hcl oral elixir 2.5 mg/5ml</i>                                                         | 2                | MO                              |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i>                                          | 2                | MO                              |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml 1 ml, 50 mg/ml, 50 mg/ml(1ml)</i> | 2                | MO                              |
| <i>haloperidol lactate injection solution 5 mg/ml</i>                                                  | 4                | MO                              |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i>                                                    | 1                | MO                              |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i>                                  | 1                | MO                              |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i>                                       | 2                | MO                              |
| <i>molindone hcl oral tablet 10 mg, 25 mg, 5 mg</i>                                                    | 2                | MO                              |
| <i>perphenazine oral tablet 16 mg, 2 mg</i>                                                            | 2                | MO                              |
| <i>perphenazine oral tablet 4 mg, 8 mg</i>                                                             | 2                | BvD; MO                         |
| <i>pimozide oral tablet 1 mg, 2 mg</i>                                                                 | 2                | MO                              |
| <i>thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i>                                        | 2                | MO                              |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i>                                                | 2                | MO                              |
| <i>trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i>                                         | 1                | MO                              |
| <b>2Nd Generation/Atypical</b>                                                                         |                  |                                 |
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG                                        | 5                | NMO                             |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG                              | 5                | NMO                             |
| <i>aripiprazole oral solution 1 mg/ml</i>                                                              | 4                | MO; QL (750 ML per 30 days)     |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i>                                 | 4                | MO; QL (30 EA per 30 days)      |
| <i>aripiprazole oral tablet dispersible 10 mg</i>                                                      | 5                | NMO; QL (90 EA per 30 days)     |
| <i>aripiprazole oral tablet dispersible 15 mg</i>                                                      | 5                | NMO; QL (60 EA per 30 days)     |
| <i>asenapine maleate sublingual tablet sublingual 10 mg, 2.5 mg, 5 mg</i>                              | 4                | MO; QL (60 EA per 30 days)      |
| CAPLYTA ORAL CAPSULE 42 MG                                                                             | 5                | NMO                             |
| FANAPT ORAL TABLET 1 MG, 2 MG, 4 MG                                                                    | 4                | ST2; MO; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                           | Drug Tier | Requirements/Limits              |
|---------------------------------------------------------------------------------------------------------------------|-----------|----------------------------------|
| FANAPT ORAL TABLET 10 MG, 12 MG, 6 MG, 8 MG                                                                         | 5         | ST2; NMO; QL (60 EA per 30 days) |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG                                                                  | 4         | ST2; MO; QL (60 EA per 30 days)  |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092 MG/3.5ML, 1560 MG/5ML                                | 5         | NMO                              |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML, 156 MG/ML, 234 MG/1.5ML, 78 MG/0.5ML      | 5         | NMO                              |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 39 MG/0.25ML                                             | 4         | MO                               |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML | 5         | NMO                              |
| LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG                                                               | 3         | MO                               |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG                                                           | 5         | ST2; NMO; QL (30 EA per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG                                                                                         | 5         | PA2; NMO                         |
| NUPLAZID ORAL TABLET 10 MG                                                                                          | 5         | PA2; NMO                         |
| <i>olanzapine intramuscular solution reconstituted 10 mg</i>                                                        | 4         | MO; QL (60 EA per 30 days)       |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 5 mg, 7.5 mg</i>                                                    | 1         | MO; QL (30 EA per 30 days)       |
| <i>olanzapine oral tablet 20 mg</i>                                                                                 | 1         | MO; QL (60 EA per 30 days)       |
| <i>olanzapine oral tablet dispersible 10 mg, 5 mg</i>                                                               | 4         | MO; QL (60 EA per 30 days)       |
| <i>olanzapine oral tablet dispersible 15 mg, 20 mg</i>                                                              | 4         | MO; QL (30 EA per 30 days)       |
| <i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 9 mg</i>                                      | 4         | MO; QL (30 EA per 30 days)       |
| <i>paliperidone er oral tablet extended release 24 hour 6 mg</i>                                                    | 4         | MO; QL (60 EA per 30 days)       |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg</i>                                           | 4         | MO; QL (90 EA per 30 days)       |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022. Last updated 04/18/2022.

| Drug Name                                                                                 | Drug Tier | Requirements/Limits              |
|-------------------------------------------------------------------------------------------|-----------|----------------------------------|
| <i>quetiapine fumarate er oral tablet extended release 24 hour 200 mg, 300 mg, 400 mg</i> | 4         | MO; QL (60 EA per 30 days)       |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 50 mg</i>                  | 4         | MO; QL (120 EA per 30 days)      |
| <i>quetiapine fumarate oral tablet 100 mg, 25 mg, 300 mg, 400 mg, 50 mg</i>               | 1         | MO; QL (60 EA per 30 days)       |
| <i>quetiapine fumarate oral tablet 200 mg</i>                                             | 1         | MO; QL (30 EA per 30 days)       |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG                               | 5         | NMO                              |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 12.5 MG                        | 4         | MO                               |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 25 MG, 37.5 MG, 50 MG          | 5         | NMO                              |
| <i>risperidone oral solution 1 mg/ml</i>                                                  | 2         | MO; QL (480 ML per 30 days)      |
| <i>risperidone oral tablet 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg</i>                            | 1         | MO; QL (60 EA per 30 days)       |
| <i>risperidone oral tablet 0.5 mg</i>                                                     | 1         | MO; QL (120 EA per 30 days)      |
| <i>risperidone oral tablet dispersible 0.25 mg, 1 mg, 2 mg</i>                            | 2         | MO; QL (60 EA per 30 days)       |
| <i>risperidone oral tablet dispersible 0.5 mg</i>                                         | 2         | MO; QL (120 EA per 30 days)      |
| <i>risperidone oral tablet dispersible 3 mg</i>                                           | 4         | MO; QL (60 EA per 30 days)       |
| <i>risperidone oral tablet dispersible 4 mg</i>                                           | 4         | MO; QL (120 EA per 30 days)      |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24HR, 5.7 MG/24HR, 7.6 MG/24HR                   | 5         | ST2; NMO; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG                                                               | 5         | ST2; NMO; QL (60 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 3 MG, 4.5 MG, 6 MG                                                   | 5         | ST2; NMO; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3 MG                                              | 4         | ST2; MO; QL (7 EA per 28 days)   |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i>                            | 2         | MO; QL (60 EA per 30 days)       |
| <i>ziprasidone mesylate intramuscular solution reconstituted 20 mg</i>                    | 4         | MO; QL (6 EA per 3 days)         |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210 MG                            | 4         | ST2; MO                          |

### **Treatment-Resistant**

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                               | Drug Tier | Requirements/Limits               |
|-------------------------------------------------------------------------|-----------|-----------------------------------|
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i>               | 2         | MO; QL (120 EA per 30 days)       |
| <i>clozapine oral tablet dispersible 100 mg, 12.5 mg, 150 mg, 25 mg</i> | 4         | MO; QL (120 EA per 30 days)       |
| <i>clozapine oral tablet dispersible 200 mg</i>                         | 5         | NMO; QL (120 EA per 30 days)      |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML                                      | 5         | ST2; NMO; QL (540 ML per 30 days) |

## ANTISPASTICITY AGENTS

### Antispasticity Agents

|                                                |   |    |
|------------------------------------------------|---|----|
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | MO |
| <i>tizanidine hcl oral tablet 2 mg, 4 mg</i>   | 2 | MO |

## ANTIVIRALS

### Anti-Cytomegalovirus (Cmv) Agents

|                                                                |   |                                 |
|----------------------------------------------------------------|---|---------------------------------|
| LIVTENCITY ORAL TABLET 200 MG                                  | 5 | PA; NMO                         |
| PREVYMIS ORAL TABLET 240 MG, 480 MG                            | 5 | PA; NMO; QL (28 EA per 28 days) |
| <i>valganciclovir hcl oral solution reconstituted 50 mg/ml</i> | 4 | MO                              |
| <i>valganciclovir hcl oral tablet 450 mg</i>                   | 3 | MO                              |
| ZIRGAN OPHTHALMIC GEL 0.15 %                                   | 3 | MO                              |

### Anti-Hepatitis B (Hbv) Agents

|                                             |   |                                  |
|---------------------------------------------|---|----------------------------------|
| <i>adefovir dipivoxil oral tablet 10 mg</i> | 5 | PA; NMO; QL (30 EA per 30 days)  |
| BARACLUDE ORAL SOLUTION 0.05 MG/ML          | 5 | PA; NMO; QL (600 ML per 30 days) |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i>   | 4 | PA; MO; QL (30 EA per 30 days)   |
| EPIVIR HBV ORAL SOLUTION 5 MG/ML            | 3 | MO                               |
| <i>lamivudine oral tablet 100 mg</i>        | 2 | MO; QL (90 EA per 30 days)       |
| VEMLIDY ORAL TABLET 25 MG                   | 5 | PA; NMO; QL (30 EA per 30 days)  |

### Anti-Hepatitis C (Hcv) Agents

|                                                      |   |         |
|------------------------------------------------------|---|---------|
| MAVYRET ORAL PACKET 50-20 MG                         | 5 | PA; NMO |
| MAVYRET ORAL TABLET 100-40 MG                        | 5 | PA; NMO |
| <i>ribavirin oral capsule 200 mg</i>                 | 4 | MO      |
| <i>ribavirin oral tablet 200 mg</i>                  | 2 | MO      |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | 5 | PA; NMO |
| VOSEVI ORAL TABLET 400-100-100 MG                    | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                       | Drug Tier | Requirements/Limits          |
|---------------------------------------------------------------------------------|-----------|------------------------------|
| <b>Antitherpetic Agents</b>                                                     |           |                              |
| <i>acyclovir oral capsule 200 mg</i>                                            | 1         | MO                           |
| <i>acyclovir oral suspension 200 mg/5ml</i>                                     | 2         | MO                           |
| <i>acyclovir oral tablet 400 mg, 800 mg</i>                                     | 1         | MO                           |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i>                           | 2         | BvD; MO                      |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i>                           | 2         | MO                           |
| <i>trifluridine ophthalmic solution 1 %</i>                                     | 2         | MO                           |
| <i>valacyclovir hcl oral tablet 1 gm, 500 mg</i>                                | 2         | MO                           |
| <b>Anti-Hiv Agents, Integrase Inhibitors (Insti)</b>                            |           |                              |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG                                 | 5         | NMO; QL (30 EA per 30 days)  |
| DOVATO ORAL TABLET 50-300 MG                                                    | 5         | NMO; QL (30 EA per 30 days)  |
| GENVOYA ORAL TABLET 150-150-200-10 MG                                           | 5         | NMO; QL (30 EA per 30 days)  |
| ISENTRESS HD ORAL TABLET 600 MG                                                 | 5         | NMO; QL (60 EA per 30 days)  |
| ISENTRESS ORAL PACKET 100 MG                                                    | 4         | MO; QL (60 EA per 30 days)   |
| ISENTRESS ORAL TABLET 400 MG                                                    | 5         | NMO; QL (120 EA per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 100 MG                                           | 4         | MO; QL (180 EA per 30 days)  |
| ISENTRESS ORAL TABLET CHEWABLE 25 MG                                            | 3         | MO; QL (180 EA per 30 days)  |
| STRIBILD ORAL TABLET 150-150-200-300 MG                                         | 5         | NMO; QL (30 EA per 30 days)  |
| SYMTUZA ORAL TABLET 800-150-200-10 MG                                           | 5         | NMO; QL (30 EA per 30 days)  |
| TIVICAY ORAL TABLET 10 MG                                                       | 4         | MO; QL (60 EA per 30 days)   |
| TIVICAY ORAL TABLET 25 MG, 50 MG                                                | 5         | NMO; QL (60 EA per 30 days)  |
| TIVICAY PD ORAL TABLET SOLUBLE 5 MG                                             | 4         | MO; QL (360 EA per 30 days)  |
| <b>Anti-Hiv Agents, Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrti)</b> |           |                              |
| COMPLERA ORAL TABLET 200-25-300 MG                                              | 5         | NMO; QL (30 EA per 30 days)  |
| EDURANT ORAL TABLET 25 MG                                                       | 5         | NMO; QL (30 EA per 30 days)  |
| <i>efavirenz oral capsule 200 mg</i>                                            | 4         | MO; QL (120 EA per 30 days)  |
| <i>efavirenz oral capsule 50 mg</i>                                             | 4         | MO; QL (360 EA per 30 days)  |
| <i>efavirenz oral tablet 600 mg</i>                                             | 4         | MO; QL (30 EA per 30 days)   |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                    | Drug Tier | Requirements/Limits          |
|----------------------------------------------------------------------------------------------|-----------|------------------------------|
| <i>etravirine oral tablet 100 mg</i>                                                         | 5         | NMO; QL (120 EA per 30 days) |
| <i>etravirine oral tablet 200 mg</i>                                                         | 5         | NMO; QL (60 EA per 30 days)  |
| INTELENCE ORAL TABLET 25 MG                                                                  | 4         | MO; QL (120 EA per 30 days)  |
| <i>nevirapine er oral tablet extended release 24 hour 100 mg</i>                             | 4         | MO; QL (120 EA per 30 days)  |
| <i>nevirapine er oral tablet extended release 24 hour 400 mg</i>                             | 4         | MO; QL (30 EA per 30 days)   |
| <i>nevirapine oral suspension 50 mg/5ml</i>                                                  | 4         | MO; QL (1200 ML per 30 days) |
| <i>nevirapine oral tablet 200 mg</i>                                                         | 2         | MO; QL (60 EA per 30 days)   |
| PIFELTRO ORAL TABLET 100 MG                                                                  | 5         | NMO; QL (30 EA per 30 days)  |
| <b>Anti-Hiv Agents, Nucleoside And Nucleotide Reverse Transcriptase Inhibitors (Nrti)</b>    |           |                              |
| <i>abacavir sulfate oral solution 20 mg/ml</i>                                               | 4         | MO; QL (960 ML per 30 days)  |
| <i>abacavir sulfate oral tablet 300 mg</i>                                                   | 4         | MO; QL (60 EA per 30 days)   |
| <i>abacavir sulfate-lamivudine oral tablet 600-300 mg</i>                                    | 4         | MO; QL (30 EA per 30 days)   |
| <i>abacavir-lamivudine-zidovudine oral tablet 300-150-300 mg</i>                             | 5         | NMO; QL (60 EA per 30 days)  |
| CIMDUO ORAL TABLET 300-300 MG                                                                | 5         | NMO; QL (30 EA per 30 days)  |
| DELSTRIGO ORAL TABLET 100-300-300 MG                                                         | 5         | NMO; QL (30 EA per 30 days)  |
| DESCOVY ORAL TABLET 200-25 MG                                                                | 5         | NMO; QL (30 EA per 30 days)  |
| <i>efavirenz-emtricitab-tenofovir oral tablet 600-200-300 mg</i>                             | 5         | NMO; QL (30 EA per 30 days)  |
| <i>efavirenz-lamivudine-tenofovir oral tablet 400-300-300 mg, 600-300-300 mg</i>             | 5         | NMO; QL (30 EA per 30 days)  |
| <i>emtricitabine oral capsule 200 mg</i>                                                     | 4         | MO; QL (30 EA per 30 days)   |
| <i>emtricitabine-tenofovir df oral tablet 100-150 mg, 133-200 mg, 167-250 mg, 200-300 mg</i> | 5         | NMO; QL (30 EA per 30 days)  |
| EMTRIVA ORAL SOLUTION 10 MG/ML                                                               | 4         | MO; QL (680 ML per 28 days)  |
| JULUCA ORAL TABLET 50-25 MG                                                                  | 5         | NMO; QL (30 EA per 30 days)  |
| <i>lamivudine oral solution 10 mg/ml</i>                                                     | 4         | MO; QL (900 ML per 30 days)  |
| <i>lamivudine oral tablet 150 mg</i>                                                         | 3         | MO; QL (60 EA per 30 days)   |
| <i>lamivudine oral tablet 300 mg</i>                                                         | 3         | MO; QL (30 EA per 30 days)   |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i>                                          | 4         | MO; QL (60 EA per 30 days)   |
| ODEFSEY ORAL TABLET 200-25-25 MG                                                             | 5         | NMO; QL (30 EA per 30 days)  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                               | Drug Tier | Requirements/Limits           |
|---------------------------------------------------------|-----------|-------------------------------|
| TEMIXYS ORAL TABLET 300-300 MG                          | 5         | NMO; QL (30 EA per 30 days)   |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | 4         | MO; QL (30 EA per 30 days)    |
| VIREAD ORAL POWDER 40 MG/GM                             | 5         | NMO; QL (240 GM per 30 days)  |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG               | 5         | NMO; QL (30 EA per 30 days)   |
| <i>zidovudine oral capsule 100 mg</i>                   | 2         | MO; QL (180 EA per 30 days)   |
| <i>zidovudine oral syrup 50 mg/5ml</i>                  | 2         | MO; QL (1680 ML per 28 days)  |
| <i>zidovudine oral tablet 300 mg</i>                    | 2         | MO; QL (60 EA per 30 days)    |
| <b>Anti-Hiv Agents, Other</b>                           |           |                               |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG        | 5         | NMO; QL (60 EA per 30 days)   |
| <i>maraviroc oral tablet 150 mg, 300 mg</i>             | 5         | NMO; QL (120 EA per 30 days)  |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HOUR 600 MG     | 5         | NMO; QL (60 EA per 30 days)   |
| SELZENTRY ORAL SOLUTION 20 MG/ML                        | 5         | NMO; QL (1800 ML per 30 days) |
| SELZENTRY ORAL TABLET 25 MG                             | 3         | MO; QL (120 EA per 30 days)   |
| SELZENTRY ORAL TABLET 75 MG                             | 5         | NMO; QL (120 EA per 30 days)  |
| TRIUMEQ ORAL TABLET 600-50-300 MG                       | 5         | NMO; QL (30 EA per 30 days)   |
| TYBOST ORAL TABLET 150 MG                               | 3         | MO; QL (30 EA per 30 days)    |
| <b>Anti-Hiv Agents, Protease Inhibitors (Pi)</b>        |           |                               |
| APTIVUS ORAL CAPSULE 250 MG                             | 5         | NMO; QL (120 EA per 30 days)  |
| <i>atazanavir sulfate oral capsule 150 mg, 200 mg</i>   | 4         | MO; QL (60 EA per 30 days)    |
| <i>atazanavir sulfate oral capsule 300 mg</i>           | 4         | MO; QL (30 EA per 30 days)    |
| EVOTAZ ORAL TABLET 300-150 MG                           | 5         | NMO; QL (30 EA per 30 days)   |
| <i>fosamprenavir calcium oral tablet 700 mg</i>         | 5         | NMO; QL (120 EA per 30 days)  |
| INVIRASE ORAL TABLET 500 MG                             | 5         | NMO; QL (120 EA per 30 days)  |
| LEXIVA ORAL SUSPENSION 50 MG/ML                         | 4         | MO; QL (1575 ML per 28 days)  |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5ml</i> | 4         | MO; QL (400 ML per 30 days)   |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i>        | 4         | MO; QL (300 EA per 30 days)   |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i>        | 4         | MO; QL (150 EA per 30 days)   |
| NORVIR ORAL PACKET 100 MG                               | 4         | MO; QL (360 EA per 30 days)   |
| NORVIR ORAL SOLUTION 80 MG/ML                           | 4         | MO; QL (480 ML per 30 days)   |
| PREZCOBIX ORAL TABLET 800-150 MG                        | 5         | NMO; QL (30 EA per 30 days)   |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                 | Drug Tier | Requirements/Limits          |
|---------------------------------------------------------------------------|-----------|------------------------------|
| PREZISTA ORAL SUSPENSION 100 MG/ML                                        | 5         | NMO; QL (360 ML per 30 days) |
| PREZISTA ORAL TABLET 150 MG                                               | 4         | MO; QL (240 EA per 30 days)  |
| PREZISTA ORAL TABLET 600 MG                                               | 5         | NMO; QL (60 EA per 30 days)  |
| PREZISTA ORAL TABLET 75 MG                                                | 4         | MO; QL (480 EA per 30 days)  |
| PREZISTA ORAL TABLET 800 MG                                               | 5         | NMO; QL (30 EA per 30 days)  |
| REYATAZ ORAL PACKET 50 MG                                                 | 4         | MO; QL (180 EA per 30 days)  |
| <i>ritonavir oral tablet 100 mg</i>                                       | 3         | MO; QL (360 EA per 30 days)  |
| VIRACEPT ORAL TABLET 250 MG                                               | 5         | NMO; QL (300 EA per 30 days) |
| VIRACEPT ORAL TABLET 625 MG                                               | 5         | NMO; QL (120 EA per 30 days) |
| <b>Anti-Influenza Agents</b>                                              |           |                              |
| <i>oseltamivir phosphate oral capsule 30 mg, 45 mg, 75 mg</i>             | 2         | MO                           |
| <i>oseltamivir phosphate oral suspension reconstituted 6 mg/ml</i>        | 2         | MO                           |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/BLISTER | 4         | MO                           |
| <i>rimantadine hcl oral tablet 100 mg</i>                                 | 2         | MO                           |
| XOFLUZA (40 MG DOSE) ORAL TABLET THERAPY PACK 1 X 40 MG                   | 3         | MO                           |
| XOFLUZA (80 MG DOSE) ORAL TABLET THERAPY PACK 1 X 80 MG                   | 3         | MO                           |
| <b>ANXIOLYTICS</b>                                                        |           |                              |
| <b>Anxiolytics, Other</b>                                                 |           |                              |
| <i>buspirone hcl oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i>        | 1         | MO                           |
| <i>hydroxyzine hcl oral syrup 10 mg/5ml</i>                               | 4         | MO                           |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg</i>                           | 1         | MO                           |
| <i>hydroxyzine hcl oral tablet 50 mg</i>                                  | 2         | MO                           |
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i>              | 2         | MO                           |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i>                          | 2         | MO; QL (120 EA per 30 days)  |
| <b>Benzodiazepines</b>                                                    |           |                              |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                       | Drug Tier | Requirements/Limits          |
|---------------------------------------------------------------------------------|-----------|------------------------------|
| ALPRAZOLAM INTENSOL ORAL CONCENTRATE 1 MG/ML                                    | 2         | MO; QL (300 ML per 30 days)  |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg</i>                                   | 2         | MO; QL (120 EA per 30 days)  |
| <i>alprazolam oral tablet 1 mg</i>                                              | 2         | MO; QL (240 EA per 30 days)  |
| <i>alprazolam oral tablet 2 mg</i>                                              | 2         | MO; QL (150 EA per 30 days)  |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i>                     | 2         | MO; QL (120 EA per 30 days)  |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i>                                      | 1         | MO; QL (90 EA per 30 days)   |
| <i>clonazepam oral tablet 2 mg</i>                                              | 1         | MO; QL (300 EA per 30 days)  |
| <i>clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i>       | 2         | MO; QL (90 EA per 30 days)   |
| <i>clonazepam oral tablet dispersible 2 mg</i>                                  | 2         | MO; QL (300 EA per 30 days)  |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i>               | 2         | MO; QL (180 EA per 30 days)  |
| <i>diazepam oral concentrate 5 mg/ml</i>                                        | 2         | MO; QL (240 ML per 30 days)  |
| <i>diazepam oral solution 5 mg/5ml</i>                                          | 2         | MO; QL (1200 ML per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg</i>                                         | 1         | MO; QL (120 EA per 30 days)  |
| <i>diazepam oral tablet 5 mg</i>                                                | 1         | MO; QL (240 EA per 30 days)  |
| LORAZEPAM INTENSOL ORAL CONCENTRATE 2 MG/ML                                     | 2         | MO; QL (240 ML per 30 days)  |
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i>                                 | 2         | MO; QL (150 EA per 30 days)  |
| <b>BIPOLAR AGENTS</b>                                                           |           |                              |
| <b>Mood Stabilizers</b>                                                         |           |                              |
| <i>divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg</i> | 2         | MO                           |
| <i>divalproex sodium oral capsule delayed release sprinkle 125 mg</i>           | 2         | MO                           |
| <i>divalproex sodium oral tablet delayed release 125 mg, 250 mg, 500 mg</i>     | 1         | MO                           |
| <i>lithium carbonate er oral tablet extended release 300 mg, 450 mg</i>         | 1         | MO                           |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i>                    | 1         | MO                           |
| <i>lithium carbonate oral tablet 300 mg</i>                                     | 1         | MO                           |
| <i>lithium oral solution 8 meq/5ml</i>                                          | 1         | MO                           |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022. Last updated 04/18/2022.

| Drug Name                                                                                        | Drug Tier | Requirements/Limits |
|--------------------------------------------------------------------------------------------------|-----------|---------------------|
| <b>BLOOD GLUCOSE REGULATORS</b>                                                                  |           |                     |
| <i>Antidiabetic Agents</i>                                                                       |           |                     |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i>                                                 | 2         | MO                  |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i>                                                  | 1         | MO                  |
| <i>glipizide er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i>                     | 1         | MO                  |
| <i>glipizide oral tablet 10 mg, 5 mg</i>                                                         | 1         | MO                  |
| <i>glipizide-metformin hcl oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg</i>                      | 2         | MO                  |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i>                         | 2         | MO                  |
| INVOKAMET ORAL TABLET 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG                             | 3         | MO                  |
| INVOKAMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG | 3         | MO                  |
| INVOKANA ORAL TABLET 100 MG, 300 MG                                                              | 3         | MO                  |
| JANUMET ORAL TABLET 50-1000 MG, 50-500 MG                                                        | 3         | MO                  |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG, 50-1000 MG, 50-500 MG               | 3         | MO                  |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG                                                         | 3         | MO                  |
| JARDIANCE ORAL TABLET 10 MG, 25 MG                                                               | 3         | MO                  |
| <i>metformin hcl er oral tablet extended release 24 hour 500 mg, 750 mg</i>                      | 1         | MO                  |
| <i>metformin hcl oral tablet 1000 mg, 500 mg, 850 mg</i>                                         | 1         | MO                  |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i>                                                 | 2         | MO                  |
| <i>nateglinide oral tablet 120 mg, 60 mg</i>                                                     | 2         | MO                  |
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML                      | 3         | MO                  |
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML, 4 MG/3ML                      | 3         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                          | Drug Tier | Requirements/Limits |
|----------------------------------------------------------------------------------------------------|-----------|---------------------|
| <i>pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg</i>                                            | 1         | MO                  |
| <i>pioglitazone hcl-glimepiride oral tablet 30-2 mg, 30-4 mg</i>                                   | 2         | MO                  |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg</i>                             | 2         | MO                  |
| <i>repaglinide oral tablet 0.5 mg, 1 mg, 2 mg</i>                                                  | 2         | MO                  |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG                                                             | 3         | MO                  |
| SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 2700 MCG/2.7ML                                    | 4         | PA; MO              |
| SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 1500 MCG/1.5ML                                     | 4         | PA; MO              |
| SYNJARDY ORAL TABLET 12.5-1000 MG, 12.5-500 MG, 5-1000 MG, 5-500 MG                                | 3         | MO                  |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 12.5-1000 MG, 25-1000 MG, 5-1000 MG   | 3         | MO                  |
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML, 3 MG/0.5ML, 4.5 MG/0.5ML | 3         | MO                  |
| VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR 18 MG/3ML                                               | 3         | MO                  |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML                                     | 3         | MO                  |
| <b><i>Glycemic Agents</i></b>                                                                      |           |                     |
| BAQSIMI ONE PACK NASAL POWDER 3 MG/DOSE                                                            | 3         | MO                  |
| <i>diazoxide oral suspension 50 mg/ml</i>                                                          | 5         | NMO                 |
| GLUCAGEN HYPOKIT INJECTION SOLUTION RECONSTITUTED 1 MG                                             | 3         | MO                  |
| <i>glucagon emergency injection kit 1 mg</i>                                                       | 3         | MO                  |
| KORLYM ORAL TABLET 300 MG                                                                          | 5         | PA; NMO             |
| <b><i>Insulins</i></b>                                                                             |           |                     |
| ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML                                                       | 3         | MO                  |
| COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML                                                     | 3         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                   | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|------------------------------------------------------------------------------------|------------------|----------------------------|
| <i>cvs gauze sterile pad 2"x2"</i>                                                 | 3                | MO                         |
| EXEL COMFORT POINT PEN NEEDLE 29G X 12MM                                           | 3                | MO                         |
| FIASP FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML                     | 3                | MO                         |
| FIASP PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML                          | 3                | MO                         |
| FIASP SUBCUTANEOUS SOLUTION 100 UNIT/ML                                            | 3                | MO                         |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML                     | 3                | MO                         |
| LANTUS SUBCUTANEOUS SOLUTION 100 UNIT/ML                                           | 3                | MO                         |
| LEVEMIR FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML                   | 3                | MO                         |
| LEVEMIR SUBCUTANEOUS SOLUTION 100 UNIT/ML                                          | 3                | MO                         |
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML     | 3                | MO                         |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML                          | 3                | MO                         |
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML                 | 3                | MO                         |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML                                      | 3                | MO                         |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML                      | 3                | MO                         |
| NOVOLIN R INJECTION SOLUTION 100 UNIT/ML                                           | 3                | MO                         |
| NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML                     | 3                | MO                         |
| NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 3                | MO                         |
| NOVOLOG MIX 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML                      | 3                | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                     | Drug Tier | Requirements/Limits |
|-------------------------------------------------------------------------------|-----------|---------------------|
| NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML                   | 3         | MO                  |
| NOVOLOG SUBCUTANEOUS SOLUTION 100 UNIT/ML                                     | 3         | MO                  |
| <i>preferred plus insulin syringe 28g x 1/2" 0.5 ml</i>                       | 3         | MO                  |
| RELI-ON INSULIN SYRINGE 29G 0.3 ML                                            | 3         | MO                  |
| SOLIQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML                  | 3         | MO                  |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML            | 3         | MO                  |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML                | 3         | MO                  |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML | 3         | MO                  |
| TRESIBA SUBCUTANEOUS SOLUTION 100 UNIT/ML                                     | 3         | MO                  |

## BLOOD PRODUCTS AND MODIFIERS

### Anticoagulants

|                                                                          |   |                               |
|--------------------------------------------------------------------------|---|-------------------------------|
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG                | 3 | MO                            |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG                                         | 3 | MO                            |
| <i>enoxaparin sodium subcutaneous solution 100 mg/ml, 150 mg/ml</i>      | 4 | MO; QL (60 ML per 30 days)    |
| <i>enoxaparin sodium subcutaneous solution 120 mg/0.8ml, 80 mg/0.8ml</i> | 4 | MO; QL (48 ML per 30 days)    |
| <i>enoxaparin sodium subcutaneous solution 30 mg/0.3ml, 60 mg/0.6ml</i>  | 4 | MO; QL (18 ML per 30 days)    |
| <i>enoxaparin sodium subcutaneous solution 40 mg/0.4ml</i>               | 4 | MO; QL (12 ML per 30 days)    |
| <i>fondaparinux sodium subcutaneous solution 10 mg/0.8ml</i>             | 5 | NMO; QL (11.2 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 2.5 mg/0.5ml</i>            | 4 | MO; QL (15 ML per 30 days)    |
| <i>fondaparinux sodium subcutaneous solution 5 mg/0.4ml</i>              | 5 | NMO; QL (5.6 ML per 30 days)  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                   | Drug Tier | Requirements/Limits              |
|-------------------------------------------------------------------------------------------------------------|-----------|----------------------------------|
| <i>fondaparinux sodium subcutaneous solution 7.5 mg/0.6ml</i>                                               | 5         | NMO; QL (8.4 ML per 30 days)     |
| <i>heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml</i> | 2         | BvD; MO                          |
| JANTOVEN ORAL TABLET 1 MG, 10 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG                              | 1         | MO                               |
| <i>warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i>                | 1         | MO                               |
| XARELTO ORAL SUSPENSION RECONSTITUTED 1 MG/ML                                                               | 3         | MO                               |
| XARELTO ORAL TABLET 10 MG, 15 MG, 2.5 MG, 20 MG                                                             | 3         | MO                               |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20 MG                                                    | 3         | MO                               |
| <b>Blood Products And Modifiers, Other</b>                                                                  |           |                                  |
| <i>anagrelide hcl oral capsule 0.5 mg, 1 mg</i>                                                             | 2         | MO                               |
| LEUKINE INJECTION SOLUTION RECONSTITUTED 250 MCG                                                            | 5         | PA; NMO                          |
| PROMACTA ORAL PACKET 12.5 MG                                                                                | 5         | PA; NMO; QL (360 EA per 30 days) |
| PROMACTA ORAL PACKET 25 MG                                                                                  | 5         | PA; NMO; QL (180 EA per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG                                                           | 5         | PA; NMO; QL (60 EA per 30 days)  |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 20000 UNIT/ML, 4000 UNIT/ML                  | 4         | PA; MO; QL (12 ML per 28 days)   |
| RETACRIT INJECTION SOLUTION 2000 UNIT/ML                                                                    | 4         | PA; MO; QL (23 ML per 30 days)   |
| RETACRIT INJECTION SOLUTION 3000 UNIT/ML                                                                    | 4         | PA; MO; QL (16 ML per 30 days)   |
| RETACRIT INJECTION SOLUTION 40000 UNIT/ML                                                                   | 5         | PA; NMO; QL (12 ML per 28 days)  |
| <i>tranexamic acid oral tablet 650 mg</i>                                                                   | 2         | MO                               |
| ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML                                    | 5         | PA; NMO                          |
| ZIEXTENZO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML                                                | 5         | PA; NMO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                                                       | Drug Tier | Requirements/Limits              |
|---------------------------------------------------------------------------------|-----------|----------------------------------|
| <b>Platelet Modifying Agents</b>                                                |           |                                  |
| <i>aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg</i>  | 2         | MO                               |
| BRILINTA ORAL TABLET 60 MG, 90 MG                                               | 3         | MO                               |
| CABLIVI INJECTION KIT 11 MG                                                     | 5         | PA; NMO                          |
| <i>cilostazol oral tablet 100 mg, 50 mg</i>                                     | 2         | MO                               |
| <i>clopidogrel bisulfate oral tablet 75 mg</i>                                  | 2         | MO                               |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i>                                    | 4         | MO                               |
| <b>CARDIOVASCULAR AGENTS</b>                                                    |           |                                  |
| <b>Alpha-Adrenergic Agonists</b>                                                |           |                                  |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i>                         | 1         | MO                               |
| <i>clonidine transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr</i> | 2         | MO; QL (4 EA per 28 days)        |
| <i>droxidopa oral capsule 100 mg, 200 mg, 300 mg</i>                            | 5         | PA; NMO; QL (180 EA per 30 days) |
| <i>guanfacine hcl oral tablet 1 mg, 2 mg</i>                                    | 1         | MO                               |
| <i>methyldopa oral tablet 250 mg, 500 mg</i>                                    | 2         | MO                               |
| <i>midodrine hcl oral tablet 10 mg, 2.5 mg, 5 mg</i>                            | 2         | MO                               |
| <b>Alpha-Adrenergic Blocking Agents</b>                                         |           |                                  |
| <i>doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i>                    | 1         | MO                               |
| <i>prazosin hcl oral capsule 1 mg, 2 mg</i>                                     | 1         | MO                               |
| <i>prazosin hcl oral capsule 5 mg</i>                                           | 2         | MO                               |
| <i>terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i>                       | 1         | MO                               |
| <b>Angiotensin II Receptor Antagonists</b>                                      |           |                                  |
| <i>candesartan cilexetil oral tablet 16 mg, 4 mg, 8 mg</i>                      | 2         | MO; QL (60 EA per 30 days)       |
| <i>candesartan cilexetil oral tablet 32 mg</i>                                  | 2         | MO; QL (30 EA per 30 days)       |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i>                             | 1         | MO; QL (30 EA per 30 days)       |
| <i>losartan potassium oral tablet 100 mg, 25 mg</i>                             | 1         | MO; QL (30 EA per 30 days)       |
| <i>losartan potassium oral tablet 50 mg</i>                                     | 1         | MO; QL (60 EA per 30 days)       |
| <i>olmesartan medoxomil oral tablet 20 mg, 40 mg</i>                            | 1         | MO; QL (30 EA per 30 days)       |
| <i>olmesartan medoxomil oral tablet 5 mg</i>                                    | 1         | MO; QL (60 EA per 30 days)       |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i>                              | 1         | MO; QL (30 EA per 30 days)       |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                       | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|------------------------------------------------------------------------|------------------|----------------------------|
| <i>valsartan oral tablet 160 mg</i>                                    | 2                | MO; QL (60 EA per 30 days) |
| <i>valsartan oral tablet 320 mg</i>                                    | 2                | MO; QL (30 EA per 30 days) |
| <i>valsartan oral tablet 40 mg, 80 mg</i>                              | 2                | MO; QL (90 EA per 30 days) |
| <b>Angiotensin-Converting Enzyme (Ace) Inhibitors</b>                  |                  |                            |
| <i>benazepril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i>            | 1                | MO                         |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i>             | 2                | MO                         |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i>        | 1                | MO                         |
| <i>fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg</i>               | 1                | MO                         |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 1                | MO                         |
| <i>moexipril hcl oral tablet 15 mg, 7.5 mg</i>                         | 2                | MO                         |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i>               | 2                | MO                         |
| <i>quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i>             | 1                | MO                         |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i>              | 1                | MO                         |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i>                       | 2                | MO                         |
| <b>Antiarrhythmics</b>                                                 |                  |                            |
| <i>amiodarone hcl oral tablet 100 mg, 200 mg, 400 mg</i>               | 2                | MO                         |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i>              | 2                | MO                         |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i>               | 4                | MO                         |
| <i>flecainide acetate oral tablet 100 mg, 150 mg, 50 mg</i>            | 1                | MO                         |
| <i>mexiletine hcl oral capsule 150 mg, 200 mg, 250 mg</i>              | 2                | MO                         |
| MULTAQ ORAL TABLET 400 MG                                              | 3                | MO                         |
| <i>propafenone hcl oral tablet 150 mg, 225 mg, 300 mg</i>              | 2                | MO                         |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i>                    | 1                | MO                         |
| <i>sotalol hcl (af) oral tablet 120 mg, 160 mg</i>                     | 2                | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                         | Drug Tier | Requirements/Limits        |
|-----------------------------------------------------------------------------------|-----------|----------------------------|
| sotalol hcl (af) oral tablet 80 mg                                                | 1         | MO                         |
| sotalol hcl oral tablet 120 mg, 160 mg, 240 mg, 80 mg                             | 1         | MO                         |
| <b>Beta-Adrenergic Blocking Agents</b>                                            |           |                            |
| acebutolol hcl oral capsule 200 mg, 400 mg                                        | 1         | MO                         |
| atenolol oral tablet 100 mg, 25 mg, 50 mg                                         | 1         | MO                         |
| betaxolol hcl oral tablet 10 mg, 20 mg                                            | 2         | MO                         |
| bisoprolol fumarate oral tablet 10 mg, 5 mg                                       | 1         | MO                         |
| carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg                          | 1         | MO                         |
| labetalol hcl oral tablet 100 mg, 200 mg, 300 mg                                  | 2         | MO                         |
| metoprolol succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg | 1         | MO                         |
| metoprolol succinate er oral tablet extended release 24 hour 200 mg               | 2         | MO                         |
| metoprolol tartrate oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg              | 1         | MO                         |
| nadolol oral tablet 20 mg, 40 mg, 80 mg                                           | 2         | MO                         |
| nebivolol hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg                              | 4         | MO                         |
| pindolol oral tablet 10 mg, 5 mg                                                  | 2         | MO                         |
| propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg    | 2         | MO                         |
| propranolol hcl oral solution 20 mg/5ml, 40 mg/5ml                                | 2         | MO                         |
| propranolol hcl oral tablet 10 mg, 20 mg, 40 mg                                   | 1         | MO                         |
| propranolol hcl oral tablet 60 mg                                                 | 2         | MO                         |
| timolol maleate oral tablet 10 mg, 20 mg, 5 mg                                    | 2         | MO                         |
| <b>Calcium Channel Blocking Agents, Dihydropyridines</b>                          |           |                            |
| amlodipine besylate oral tablet 10 mg, 2.5 mg, 5 mg                               | 1         | MO                         |
| felodipine er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg            | 1         | MO; QL (30 EA per 30 days) |
| isradipine oral capsule 2.5 mg, 5 mg                                              | 2         | MO                         |
| KATERZIA ORAL SUSPENSION 1 MG/ML                                                  | 4         | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                                                  | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|---------------------------------------------------------------------------------------------------|------------------|----------------------------|
| <i>nicardipine hcl oral capsule 20 mg, 30 mg</i>                                                  | 2                | MO                         |
| <i>nifedipine er oral tablet extended release 24 hour 30 mg, 60 mg</i>                            | 1                | MO; QL (60 EA per 30 days) |
| <i>nifedipine er oral tablet extended release 24 hour 90 mg</i>                                   | 1                | MO; QL (30 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 60 mg</i>            | 1                | MO; QL (60 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 90 mg</i>                   | 1                | MO; QL (30 EA per 30 days) |
| <i>nifedipine oral capsule 10 mg, 20 mg</i>                                                       | 2                | MO                         |
| <b>Calcium Channel Blocking Agents, Nondihydropyridines</b>                                       |                  |                            |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG                            | 2                | MO; QL (60 EA per 30 days) |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG                                            | 2                | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er beads oral capsule extended release 24 hour 360 mg, 420 mg</i>                | 2                | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 2                | MO; QL (60 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 300 mg</i>                 | 2                | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er oral capsule extended release 12 hour 120 mg, 60 mg, 90 mg</i>                | 2                | MO                         |
| <i>diltiazem hcl oral tablet 120 mg, 90 mg</i>                                                    | 2                | MO                         |
| <i>diltiazem hcl oral tablet 30 mg, 60 mg</i>                                                     | 1                | MO                         |
| <i>dilt-xr oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i>                       | 2                | MO; QL (60 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG                            | 2                | MO; QL (60 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG, 360 MG                                    | 2                | MO; QL (30 EA per 30 days) |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG                           | 2                | MO; QL (60 EA per 30 days) |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG, 360 MG, 420 MG                           | 2                | MO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                                                              | Drug Tier | Requirements/Limits         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------------|
| <i>verapamil hcl er oral capsule extended release 24 hour 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg</i>                                   | 2         | MO                          |
| <i>verapamil hcl er oral tablet extended release 120 mg, 180 mg, 240 mg</i>                                                                            | 2         | MO                          |
| <i>verapamil hcl oral tablet 120 mg, 40 mg, 80 mg</i>                                                                                                  | 1         | MO                          |
| <b>Cardiovascular Agents, Other</b>                                                                                                                    |           |                             |
| <i>aliskiren fumarate oral tablet 150 mg, 300 mg</i>                                                                                                   | 3         | MO; QL (30 EA per 30 days)  |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i>                                                                                               | 1         | MO                          |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i>                                            | 1         | MO                          |
| <i>amlodipine besylate-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i>                                                              | 2         | MO; QL (30 EA per 30 days)  |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 2         | MO; QL (30 EA per 30 days)  |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i>                                                                          | 2         | MO; QL (30 EA per 30 days)  |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i>                                                                                         | 1         | MO                          |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i>                                                          | 2         | MO                          |
| BIDIL ORAL TABLET 20-37.5 MG                                                                                                                           | 4         | MO                          |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i>                                                                   | 1         | MO                          |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i>                                                                         | 2         | MO; QL (30 EA per 30 days)  |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG                                                                                                                      | 4         | PA; MO                      |
| DIGITEK ORAL TABLET 125 MCG, 250 MCG                                                                                                                   | 1         | MO; QL (30 EA per 30 days)  |
| DIGOX ORAL TABLET 125 MCG, 250 MCG                                                                                                                     | 1         | MO; QL (30 EA per 30 days)  |
| <i>digoxin oral solution 0.05 mg/ml</i>                                                                                                                | 2         | MO; QL (255 ML per 30 days) |
| <i>digoxin oral tablet 125 mcg, 250 mcg</i>                                                                                                            | 1         | MO; QL (30 EA per 30 days)  |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i>                                                                                   | 1         | MO                          |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG                                                                                                     | 3         | PA; MO                      |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                        | Drug Tier | Requirements/Limits        |
|------------------------------------------------------------------------------------------------------------------|-----------|----------------------------|
| <i>fosinopril sodium-hctz oral tablet 10-12.5 mg, 20-12.5 mg</i>                                                 | 2         | MO                         |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i>                                       | 1         | MO; QL (30 EA per 30 days) |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i>                               | 1         | MO                         |
| <i>losartan potassium-hctz oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i>                                    | 1         | MO; QL (30 EA per 30 days) |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i>                                 | 2         | MO                         |
| <i>metyrosine oral capsule 250 mg</i>                                                                            | 5         | NMO                        |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i>                                    | 1         | MO; QL (30 EA per 30 days) |
| <i>olmesartan-amlodipine-hctz oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 2         | MO; QL (30 EA per 30 days) |
| <i>pentoxifylline er oral tablet extended release 400 mg</i>                                                     | 1         | MO                         |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i>                                | 2         | MO                         |
| <i>ranolazine er oral tablet extended release 12 hour 1000 mg, 500 mg</i>                                        | 3         | MO                         |
| <i>spironolactone-hctz oral tablet 25-25 mg</i>                                                                  | 1         | MO                         |
| TEKTURNA HCT ORAL TABLET 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG                                          | 3         | MO; QL (30 EA per 30 days) |
| <i>telmisartan-hctz oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i>                                             | 2         | MO; QL (30 EA per 30 days) |
| <i>triamterene-hctz oral capsule 37.5-25 mg</i>                                                                  | 1         | MO                         |
| <i>triamterene-hctz oral tablet 37.5-25 mg, 75-50 mg</i>                                                         | 1         | MO                         |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i>      | 1         | MO; QL (30 EA per 30 days) |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG                                                                          | 4         | PA; MO                     |
| <b>Diuretics, Loop</b>                                                                                           |           |                            |
| <i>bumetanide injection solution 0.25 mg/ml</i>                                                                  | 2         | MO                         |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i>                                                                 | 2         | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                         | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|--------------------------------------------------------------------------|------------------|----------------------------|
| <i>furosemide injection solution 10 mg/ml, 10 mg/ml (4ml syringe)</i>    | 2                | BvD; MO                    |
| <i>furosemide oral solution 10 mg/ml, 8 mg/ml</i>                        | 2                | MO                         |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i>                        | 1                | MO                         |
| <i>torseamide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i>                 | 1                | MO                         |
| <b>Diuretics, Potassium-Sparing</b>                                      |                  |                            |
| <i>amiloride hcl oral tablet 5 mg</i>                                    | 2                | MO                         |
| <i>eplerenone oral tablet 25 mg, 50 mg</i>                               | 2                | MO                         |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i>                   | 1                | MO                         |
| <b>Diuretics, Thiazide</b>                                               |                  |                            |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i>                           | 2                | MO                         |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i>                          | 1                | MO                         |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i>             | 1                | MO                         |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i>                            | 1                | MO                         |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i>                        | 2                | MO                         |
| <b>Dyslipidemics, Fibric Acid Derivatives</b>                            |                  |                            |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 67 mg</i> | 2                | MO; QL (30 EA per 30 days) |
| <i>fenofibrate micronized oral capsule 43 mg</i>                         | 2                | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral capsule 150 mg</i>                                   | 2                | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral capsule 50 mg</i>                                    | 2                | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral tablet 145 mg, 160 mg</i>                            | 1                | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral tablet 48 mg, 54 mg</i>                              | 1                | MO; QL (60 EA per 30 days) |
| <i>fenofibric acid oral capsule delayed release 135 mg, 45 mg</i>        | 2                | MO; QL (30 EA per 30 days) |
| <i>gemfibrozil oral tablet 600 mg</i>                                    | 1                | MO; QL (60 EA per 30 days) |
| <b>Dyslipidemics, Hmg Coa Reductase Inhibitors</b>                       |                  |                            |
| <i>atorvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i>       | 1                | MO; QL (30 EA per 30 days) |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG                                      | 3                | MO; QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 10 mg</i>                                      | 1                | MO; QL (45 EA per 30 days) |
| <i>lovastatin oral tablet 20 mg</i>                                      | 1                | MO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                           | Drug Tier | Requirements/Limits        |
|-------------------------------------------------------------------------------------|-----------|----------------------------|
| lovastatin oral tablet 40 mg                                                        | 1         | MO; QL (60 EA per 30 days) |
| pravastatin sodium oral tablet 10 mg, 20 mg, 40 mg, 80 mg                           | 1         | MO; QL (30 EA per 30 days) |
| rosuvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 5 mg                          | 1         | MO; QL (30 EA per 30 days) |
| simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg                            | 1         | MO; QL (30 EA per 30 days) |
| ZYPITAMAG ORAL TABLET 2 MG, 4 MG                                                    | 3         | MO; QL (30 EA per 30 days) |
| <b>Dyslipidemics, Other</b>                                                         |           |                            |
| cholestyramine light oral packet 4 gm                                               | 2         | MO                         |
| cholestyramine oral packet 4 gm                                                     | 2         | MO                         |
| colestipol hcl oral packet 5 gm                                                     | 2         | MO                         |
| colestipol hcl oral tablet 1 gm                                                     | 2         | MO                         |
| ezetimibe oral tablet 10 mg                                                         | 1         | MO; QL (30 EA per 30 days) |
| JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG                                     | 5         | PA; NMO                    |
| niacin er (antihyperlipidemic) oral tablet extended release 1000 mg, 500 mg, 750 mg | 2         | MO                         |
| omega-3-acid ethyl esters oral capsule 1 gm                                         | 2         | MO                         |
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420 MG/3.5ML              | 3         | PA; MO                     |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML                           | 3         | PA; MO                     |
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML                     | 3         | PA; MO                     |
| VASCEPA ORAL CAPSULE 0.5 GM, 1 GM                                                   | 3         | MO                         |
| <b>Vasodilators, Direct-Acting Arterial/ Venous</b>                                 |           |                            |
| hydralazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg                             | 1         | MO                         |
| isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg                          | 2         | MO                         |
| isosorbide mononitrate er oral tablet extended release 24 hour 120 mg               | 2         | MO                         |
| isosorbide mononitrate er oral tablet extended release 24 hour 30 mg, 60 mg         | 1         | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| <b>Drug Name</b>                                                                          | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|-------------------------------------------------------------------------------------------|------------------|----------------------------|
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i>                                    | 1                | MO                         |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i>                                                | 1                | MO                         |
| NITRO-BID TRANSDERMAL OINTMENT 2 %                                                        | 3                | MO                         |
| <i>nitroglycerin sublingual tablet sublingual 0.3 mg, 0.4 mg, 0.6 mg</i>                  | 2                | MO                         |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 2                | MO                         |
| <i>nitroglycerin translingual solution 0.4 mg/spray</i>                                   | 2                | MO                         |
| RECTIV RECTAL OINTMENT 0.4 %                                                              | 4                | MO                         |

## CENTRAL NERVOUS SYSTEM AGENTS

### Attention Deficit Hyperactivity Disorder Agents, Amphetamines

|                                                                                             |   |                              |
|---------------------------------------------------------------------------------------------|---|------------------------------|
| <i>amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg</i> | 2 | MO; QL (90 EA per 30 days)   |
| <i>amphetamine-dextroamphetamine oral tablet 30 mg</i>                                      | 2 | MO; QL (60 EA per 30 days)   |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg</i>             | 4 | MO; QL (180 EA per 30 days)  |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 15 mg</i>             | 4 | MO; QL (120 EA per 30 days)  |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 5 mg</i>              | 4 | MO; QL (360 EA per 30 days)  |
| <i>dextroamphetamine sulfate oral solution 5 mg/5ml</i>                                     | 4 | MO; QL (1800 ML per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i>                                          | 4 | MO; QL (180 EA per 30 days)  |
| <i>dextroamphetamine sulfate oral tablet 15 mg</i>                                          | 4 | MO; QL (120 EA per 30 days)  |
| <i>dextroamphetamine sulfate oral tablet 20 mg</i>                                          | 4 | MO; QL (90 EA per 30 days)   |
| <i>dextroamphetamine sulfate oral tablet 30 mg</i>                                          | 4 | MO; QL (60 EA per 30 days)   |
| <i>dextroamphetamine sulfate oral tablet 5 mg</i>                                           | 4 | MO; QL (150 EA per 30 days)  |

### Attention Deficit Hyperactivity Disorder Agents, Non-Amphetamines

|                                                                                      |   |                             |
|--------------------------------------------------------------------------------------|---|-----------------------------|
| <i>atomoxetine hcl oral capsule 10 mg, 100 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg</i> | 4 | MO; QL (30 EA per 30 days)  |
| <i>dexmethylphenidate hcl oral tablet 10 mg</i>                                      | 1 | MO; QL (60 EA per 30 days)  |
| <i>dexmethylphenidate hcl oral tablet 2.5 mg</i>                                     | 1 | MO; QL (240 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 5 mg</i>                                       | 1 | MO; QL (120 EA per 30 days) |
| <i>guanfacine hcl er oral tablet extended release 24 hour 1 mg, 2 mg, 3 mg, 4 mg</i> | 4 | MO; QL (30 EA per 30 days)  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                            | Drug Tier | Requirements/Limits              |
|----------------------------------------------------------------------|-----------|----------------------------------|
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i>            | 2         | MO; QL (90 EA per 30 days)       |
| <b>Central Nervous System, Other</b>                                 |           |                                  |
| AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG                                | 5         | PA; NMO; QL (120 EA per 30 days) |
| EVRYSDI ORAL SOLUTION RECONSTITUTED 0.75 MG/ML                       | 5         | PA; NMO                          |
| NUDEXTA ORAL CAPSULE 20-10 MG                                        | 3         | PA; MO                           |
| <i>riluzole oral tablet 50 mg</i>                                    | 4         | PA; MO                           |
| <i>tetrabenazine oral tablet 12.5 mg</i>                             | 5         | PA; NMO; QL (240 EA per 30 days) |
| <i>tetrabenazine oral tablet 25 mg</i>                               | 5         | PA; NMO; QL (120 EA per 30 days) |
| <b>Fibromyalgia Agents</b>                                           |           |                                  |
| <i>pregabalin oral capsule 100 mg, 150 mg, 25 mg, 50 mg</i>          | 2         | MO; QL (90 EA per 30 days)       |
| <i>pregabalin oral capsule 200 mg, 225 mg, 300 mg</i>                | 2         | MO; QL (60 EA per 30 days)       |
| <i>pregabalin oral capsule 75 mg</i>                                 | 2         | MO; QL (120 EA per 30 days)      |
| <i>pregabalin oral solution 20 mg/ml</i>                             | 2         | MO; QL (900 ML per 30 days)      |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG                    | 3         | MO; QL (60 EA per 30 days)       |
| SAVELLA TITRATION PACK ORAL 12.5 & 25 & 50 MG                        | 3         | MO; QL (55 EA per 28 days)       |
| <b>Multiple Sclerosis Agents</b>                                     |           |                                  |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML              | 5         | PA; NMO                          |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML    | 5         | PA; NMO                          |
| BETASERON SUBCUTANEOUS KIT 0.3 MG                                    | 5         | PA; NMO                          |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML            | 5         | PA; NMO                          |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/ML            | 5         | PA; NMO                          |
| <i>dalfampridine er oral tablet extended release 12 hour 10 mg</i>   | 5         | PA; NMO; QL (60 EA per 30 days)  |
| <i>dimethyl fumarate oral capsule delayed release 120 mg, 240 mg</i> | 5         | PA; NMO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                     | Drug Tier | Requirements/Limits |
|---------------------------------------------------------------|-----------|---------------------|
| <i>dimethyl fumarate starter pack oral 120 &amp; 240 mg</i>   | 5         | PA; NMO             |
| GILENYA ORAL CAPSULE 0.5 MG                                   | 5         | PA; NMO             |
| KESIMPTA SUBCUTANEOUS SOLUTION<br>AUTO-INJECTOR 20 MG/0.4ML   | 5         | PA; NMO             |
| MAYZENT ORAL TABLET 0.25 MG, 2 MG                             | 5         | PA; NMO             |
| MAYZENT STARTER PACK ORAL TABLET<br>THERAPY PACK 12 X 0.25 MG | 5         | PA; NMO             |

## DENTAL AND ORAL AGENTS

### Dental And Oral Agents

|                                                                 |   |    |
|-----------------------------------------------------------------|---|----|
| <i>chlorhexidine gluconate mouth/throat solution<br/>0.12 %</i> | 1 | MO |
| PERIOGARD MOUTH/THROAT SOLUTION<br>0.12 %                       | 1 | MO |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i>                 | 2 | MO |
| <i>triamcinolone acetonide mouth/throat paste 0.1 %</i>         | 2 | MO |

## DERMATOLOGICAL AGENTS

### Acne And Rosacea Agents

|                                                                 |   |        |
|-----------------------------------------------------------------|---|--------|
| ACCUTANE ORAL CAPSULE 10 MG, 20 MG,<br>30 MG, 40 MG             | 3 | MO     |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i>             | 4 | PA; MO |
| AMNESTEEM ORAL CAPSULE 10 MG, 20<br>MG, 40 MG                   | 4 | MO     |
| <i>benzoyl peroxide-erythromycin external gel 5-3 %</i>         | 2 | MO     |
| CLARAVIS ORAL CAPSULE 10 MG, 20 MG,<br>30 MG, 40 MG             | 4 | MO     |
| <i>clindamycin phos-benzoyl perox external gel 1.2-5<br/>%</i>  | 2 | MO     |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40<br/>mg</i> | 4 | MO     |
| <i>tazarotene external cream 0.1 %</i>                          | 2 | PA; MO |
| TAZORAC EXTERNAL CREAM 0.05 %                                   | 4 | PA; MO |
| TAZORAC EXTERNAL GEL 0.05 %, 0.1 %                              | 4 | PA; MO |
| <i>tretinoin external cream 0.025 %, 0.05 %, 0.1 %</i>          | 2 | PA; MO |
| <i>tretinoin external gel 0.01 %, 0.025 %, 0.05 %</i>           | 2 | PA; MO |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                      | Drug Tier | Requirements/Limits |
|----------------------------------------------------------------|-----------|---------------------|
| <b><i>Dermatitis And Pruitus Agents</i></b>                    |           |                     |
| <i>alclometasone dipropionate external cream 0.05 %</i>        | 2         | MO                  |
| <i>alclometasone dipropionate external ointment 0.05 %</i>     | 2         | MO                  |
| <i>amcinonide external cream 0.1 %</i>                         | 4         | MO                  |
| <i>amcinonide external ointment 0.1 %</i>                      | 4         | MO                  |
| <i>ammonium lactate external cream 12 %</i>                    | 1         | MO                  |
| <i>ammonium lactate external lotion 12 %</i>                   | 1         | MO                  |
| <i>betamethasone dipropionate aug external cream 0.05 %</i>    | 2         | MO                  |
| <i>betamethasone dipropionate aug external lotion 0.05 %</i>   | 2         | MO                  |
| <i>betamethasone dipropionate aug external ointment 0.05 %</i> | 2         | MO                  |
| <i>betamethasone dipropionate external cream 0.05 %</i>        | 2         | MO                  |
| <i>betamethasone dipropionate external lotion 0.05 %</i>       | 2         | MO                  |
| <i>betamethasone dipropionate external ointment 0.05 %</i>     | 2         | MO                  |
| <i>betamethasone valerate external cream 0.1 %</i>             | 2         | MO                  |
| <i>betamethasone valerate external lotion 0.1 %</i>            | 2         | MO                  |
| <i>betamethasone valerate external ointment 0.1 %</i>          | 2         | MO                  |
| <i>clobetasol propionate e external cream 0.05 %</i>           | 4         | MO                  |
| <i>clobetasol propionate external cream 0.05 %</i>             | 4         | MO                  |
| <i>clobetasol propionate external gel 0.05 %</i>               | 4         | MO                  |
| <i>clobetasol propionate external ointment 0.05 %</i>          | 4         | MO                  |
| <i>clobetasol propionate external solution 0.05 %</i>          | 2         | MO                  |
| <i>desonide external cream 0.05 %</i>                          | 4         | MO                  |
| <i>desonide external lotion 0.05 %</i>                         | 4         | MO                  |
| <i>desonide external ointment 0.05 %</i>                       | 2         | MO                  |
| <i>desoximetasone external cream 0.05 %, 0.25 %</i>            | 4         | MO                  |
| <i>desoximetasone external gel 0.05 %</i>                      | 4         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                             | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|--------------------------------------------------------------|------------------|----------------------------|
| <i>desoximetasone external ointment 0.25 %</i>               | 4                | MO                         |
| EUCRISA EXTERNAL OINTMENT 2 %                                | 4                | MO                         |
| <i>fluocinolone acetonide external cream 0.01 %, 0.025 %</i> | 2                | MO                         |
| <i>fluocinolone acetonide external ointment 0.025 %</i>      | 2                | MO                         |
| <i>fluocinolone acetonide external solution 0.01 %</i>       | 4                | MO                         |
| <i>fluocinonide emulsified base external cream 0.05 %</i>    | 2                | MO                         |
| <i>fluocinonide external gel 0.05 %</i>                      | 4                | MO                         |
| <i>fluocinonide external ointment 0.05 %</i>                 | 2                | MO                         |
| <i>fluocinonide external solution 0.05 %</i>                 | 2                | MO                         |
| <i>fluticasone propionate external cream 0.05 %</i>          | 1                | MO                         |
| <i>fluticasone propionate external ointment 0.005 %</i>      | 1                | MO                         |
| <i>halobetasol propionate external cream 0.05 %</i>          | 4                | MO                         |
| <i>halobetasol propionate external ointment 0.05 %</i>       | 2                | MO                         |
| <i>hydrocortisone (perianal) external cream 2.5 %</i>        | 1                | MO                         |
| <i>hydrocortisone external cream 1 %</i>                     | 1                | MO                         |
| <i>hydrocortisone external lotion 2.5 %</i>                  | 1                | MO                         |
| <i>hydrocortisone external ointment 1 %</i>                  | 2                | MO                         |
| <i>hydrocortisone external ointment 2.5 %</i>                | 1                | MO                         |
| <i>hydrocortisone valerate external cream 0.2 %</i>          | 2                | MO                         |
| <i>hydrocortisone valerate external ointment 0.2 %</i>       | 2                | MO                         |
| <i>mometasone furoate external cream 0.1 %</i>               | 2                | MO                         |
| <i>mometasone furoate external ointment 0.1 %</i>            | 2                | MO                         |
| <i>mometasone furoate external solution 0.1 %</i>            | 2                | MO                         |
| <i>pimecrolimus external cream 1 %</i>                       | 4                | MO                         |
| <i>prednicarbate external ointment 0.1 %</i>                 | 4                | MO                         |
| PROCTO-MED HC EXTERNAL CREAM 2.5 %                           | 4                | MO                         |
| PROCTO-PAK EXTERNAL CREAM 1 %                                | 4                | MO                         |
| PROCTOSOL HC EXTERNAL CREAM 2.5 %                            | 4                | MO                         |
| PROCTOZONE-HC EXTERNAL CREAM 2.5 %                           | 3                | MO                         |
| <i>selenium sulfide external lotion 2.5 %</i>                | 1                | MO                         |
| <i>tacrolimus external ointment 0.03 %, 0.1 %</i>            | 4                | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                              | Drug Tier | Requirements/Limits |
|------------------------------------------------------------------------|-----------|---------------------|
| <i>triamcinolone acetonide external cream 0.025 %, 0.1 %, 0.5 %</i>    | 1         | MO                  |
| <i>triamcinolone acetonide external lotion 0.025 %, 0.1 %</i>          | 2         | MO                  |
| <i>triamcinolone acetonide external ointment 0.025 %, 0.1 %, 0.5 %</i> | 1         | MO                  |
| <b><i>Dermatological Agents, Other</i></b>                             |           |                     |
| <i>calcipotriene external solution 0.005 %</i>                         | 4         | MO                  |
| <i>clotrimazole-betamethasone external cream 1-0.05 %</i>              | 2         | MO                  |
| <i>clotrimazole-betamethasone external lotion 1-0.05 %</i>             | 2         | MO                  |
| <i>diclofenac sodium external gel 3 %</i>                              | 4         | PA; MO              |
| FLUOROPLEX EXTERNAL CREAM 1 %                                          | 4         | MO                  |
| <i>fluorouracil external cream 5 %</i>                                 | 2         | MO                  |
| <i>fluorouracil external solution 2 %, 5 %</i>                         | 2         | MO                  |
| <i>global alcohol prep ease pad 70 %</i>                               | 2         | MO                  |
| <i>hydrocortisone ace-pramoxine external cream 1-1 %</i>               | 2         | MO                  |
| <i>imiquimod external cream 5 %</i>                                    | 2         | MO                  |
| <i>nystatin-triamcinolone external cream 100000-0.1 unit/gm-%</i>      | 2         | MO                  |
| <i>nystatin-triamcinolone external ointment 100000-0.1 unit/gm-%</i>   | 2         | MO                  |
| <i>podofilox external solution 0.5 %</i>                               | 2         | MO                  |
| REGRANEX EXTERNAL GEL 0.01 %                                           | 5         | PA; NMO             |
| SANTYL EXTERNAL OINTMENT 250 UNIT/GM                                   | 4         | MO                  |
| <i>silver sulfadiazine external cream 1 %</i>                          | 2         | MO                  |
| SSD EXTERNAL CREAM 1 %                                                 | 3         | MO                  |
| <b><i>Pediculicides/Scabicides</i></b>                                 |           |                     |
| <i>malathion external lotion 0.5 %</i>                                 | 4         | MO                  |
| <i>permethrin external cream 5 %</i>                                   | 2         | MO                  |
| <b><i>Topical Anti-Infectives</i></b>                                  |           |                     |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                                                                                                       | Drug Tier | Requirements/Limits |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------|
| <i>ciclopirox external gel 0.77 %</i>                                                                                                                                                           | 2         | MO                  |
| <i>ciclopirox external shampoo 1 %</i>                                                                                                                                                          | 2         | MO                  |
| <i>ciclopirox external solution 8 %</i>                                                                                                                                                         | 2         | MO                  |
| <i>clindamycin phosphate external gel 1 %</i>                                                                                                                                                   | 2         | MO                  |
| <i>clindamycin phosphate external lotion 1 %</i>                                                                                                                                                | 2         | MO                  |
| <i>clindamycin phosphate external solution 1 %</i>                                                                                                                                              | 2         | MO                  |
| <i>ery external pad 2 %</i>                                                                                                                                                                     | 3         | MO                  |
| <i>erythromycin external gel 2 %</i>                                                                                                                                                            | 2         | MO                  |
| <i>erythromycin external solution 2 %</i>                                                                                                                                                       | 2         | MO                  |
| <i>mupirocin calcium external cream 2 %</i>                                                                                                                                                     | 4         | MO                  |
| <i>mupirocin external ointment 2 %</i>                                                                                                                                                          | 1         | MO                  |
| <b>ELECTROLYTES/MINERALS/METALS/VITAMINS</b>                                                                                                                                                    |           |                     |
| <b><i>Electrolyte/ Mineral Replacement</i></b>                                                                                                                                                  |           |                     |
| <i>carglumic acid oral tablet 200 mg</i>                                                                                                                                                        | 5         | PA; NMO             |
| ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION                                                                                                                                                           | 4         | BvD; MO             |
| <i>kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40-5-0.45 meq/l-%-%, 40-5-0.9 meq/l-%-%</i> | 2         | BvD; MO             |
| <i>kcl-lactated ringers-d5w intravenous solution 20 meq/l</i>                                                                                                                                   | 2         | BvD; MO             |
| KLOR-CON 10 ORAL TABLET EXTENDED RELEASE 10 MEQ                                                                                                                                                 | 1         | MO                  |
| KLOR-CON M10 ORAL TABLET EXTENDED RELEASE 10 MEQ                                                                                                                                                | 1         | MO                  |
| KLOR-CON M15 ORAL TABLET EXTENDED RELEASE 15 MEQ                                                                                                                                                | 2         | MO                  |
| KLOR-CON M20 ORAL TABLET EXTENDED RELEASE 20 MEQ                                                                                                                                                | 1         | MO                  |
| KLOR-CON ORAL PACKET 20 MEQ                                                                                                                                                                     | 2         | MO                  |
| KLOR-CON ORAL TABLET EXTENDED RELEASE 8 MEQ                                                                                                                                                     | 2         | MO                  |
| <i>magnesium sulfate injection solution 50 %, 50 % (10ml syringe)</i>                                                                                                                           | 2         | BvD; MO             |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                   | Drug Tier | Requirements/Limits |
|-------------------------------------------------------------------------------------------------------------|-----------|---------------------|
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION                                                                        | 3         | BvD; MO             |
| PLASMA-LYTE A INTRAVENOUS SOLUTION                                                                          | 3         | BvD; MO             |
| <i>potassium chloride crys er oral tablet extended release 10 meq, 15 meq, 20 meq</i>                       | 1         | MO                  |
| <i>potassium chloride er oral capsule extended release 10 meq, 8 meq</i>                                    | 2         | MO                  |
| <i>potassium chloride er oral tablet extended release 10 meq, 20 meq, 8 meq</i>                             | 1         | MO                  |
| <i>potassium chloride in dextrose intravenous solution 20-5 meq/l-%</i>                                     | 2         | BvD; MO             |
| <i>potassium chloride in nacl intravenous solution 20-0.45 meq/l-%, 20-0.9 meq/l-%, 40-0.9 meq/l-%</i>      | 3         | BvD; MO             |
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml), 20 meq/100ml</i>                     | 2         | BvD; MO             |
| <i>potassium chloride oral packet 20 meq</i>                                                                | 2         | MO                  |
| <i>potassium chloride oral solution 20 meq/15ml (10%), 40 meq/15ml (20%)</i>                                | 2         | MO                  |
| <i>potassium citrate er oral tablet extended release 10 meq (1080 mg), 15 meq (1620 mg), 5 meq (540 mg)</i> | 2         | MO                  |
| <i>sodium chloride intravenous solution 0.45 %</i>                                                          | 2         | MO                  |
| <i>sodium chloride intravenous solution 0.9 %, 3 %, 5 %</i>                                                 | 2         | BvD; MO             |
| <i>sodium chloride irrigation solution 0.9 %</i>                                                            | 1         | MO                  |
| <i>sodium fluoride oral tablet 2.2 (1 f) mg</i>                                                             | 2         | MO                  |
| <b>Electrolyte/Mineral/Metal Modifiers</b>                                                                  |           |                     |
| <i>deferasirox granules oral packet 180 mg, 360 mg, 90 mg</i>                                               | 5         | PA; NMO             |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i>                                                        | 5         | PA; NMO             |
| <i>deferasirox oral tablet soluble 125 mg, 250 mg, 500 mg</i>                                               | 5         | PA; NMO             |
| <i>deferiprone oral tablet 500 mg</i>                                                                       | 5         | PA; NMO             |
| FERRIPROX ORAL SOLUTION 100 MG/ML                                                                           | 5         | PA; NMO             |
| FERRIPROX ORAL TABLET 1000 MG                                                                               | 5         | PA; NMO             |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                                                      | Drug Tier | Requirements/Limits              |
|--------------------------------------------------------------------------------|-----------|----------------------------------|
| LOKELMA ORAL PACKET 10 GM, 5 GM                                                | 4         | MO                               |
| <i>sodium polystyrene sulfonate oral powder</i>                                | 2         | MO                               |
| SPS ORAL SUSPENSION 15 GM/60ML                                                 | 3         | MO                               |
| <i>tolvaptan oral tablet 15 mg</i>                                             | 5         | PA; NMO; QL (120 EA per 30 days) |
| <i>tolvaptan oral tablet 30 mg</i>                                             | 5         | PA; NMO; QL (60 EA per 30 days)  |
| <i>trientine hcl oral capsule 250 mg</i>                                       | 5         | PA; NMO                          |
| <b>Electrolytes/Minerals/Metals/Vitamins</b>                                   |           |                                  |
| CLINIMIX E/DEXTROSE (2.75/5)<br>INTRAVENOUS SOLUTION 2.75 %                    | 3         | BvD; MO                          |
| CLINIMIX E/DEXTROSE (4.25/10)<br>INTRAVENOUS SOLUTION 4.25 %                   | 3         | BvD; MO                          |
| CLINIMIX E/DEXTROSE (4.25/5)<br>INTRAVENOUS SOLUTION 4.25 %                    | 3         | BvD; MO                          |
| CLINIMIX E/DEXTROSE (5/15)<br>INTRAVENOUS SOLUTION 5 %                         | 3         | BvD; MO                          |
| CLINIMIX E/DEXTROSE (5/20)<br>INTRAVENOUS SOLUTION 5 %                         | 3         | BvD; MO                          |
| CLINIMIX/DEXTROSE (4.25/10)<br>INTRAVENOUS SOLUTION 4.25 %                     | 4         | BvD; MO                          |
| CLINIMIX/DEXTROSE (4.25/5)<br>INTRAVENOUS SOLUTION 4.25 %                      | 4         | BvD; MO                          |
| CLINIMIX/DEXTROSE (5/15) INTRAVENOUS<br>SOLUTION 5 %                           | 4         | BvD; MO                          |
| CLINIMIX/DEXTROSE (5/20) INTRAVENOUS<br>SOLUTION 5 %                           | 4         | BvD; MO                          |
| <i>dextrose intravenous solution 10 %, 5 %</i>                                 | 2         | BvD; MO                          |
| <i>dextrose-nacl intravenous solution 10-0.2 %, 10-<br/>0.45 %, 2.5-0.45 %</i> | 3         | BvD; MO                          |
| <i>dextrose-nacl intravenous solution 5-0.2 %, 5-0.45<br/>%, 5-0.9 %</i>       | 3         | MO                               |
| DOJOLVI ORAL LIQUID 100 %                                                      | 5         | PA; NMO                          |
| INTRALIPID INTRAVENOUS EMULSION 20<br>%, 30 %                                  | 4         | BvD; MO                          |
| ISOLYTE-P IN D5W INTRAVENOUS<br>SOLUTION                                       | 4         | BvD; MO                          |
| <i>levocarnitine oral solution 1 gm/10ml</i>                                   | 2         | BvD; MO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                | Drug Tier | Requirements/Limits          |
|----------------------------------------------------------|-----------|------------------------------|
| <i>levocarnitine oral tablet 330 mg</i>                  | 2         | BvD; MO                      |
| NUTRILIPID INTRAVENOUS EMULSION 20 %                     | 4         | BvD; MO                      |
| PREMASOL INTRAVENOUS SOLUTION 10 %                       | 4         | BvD; MO                      |
| <i>prenatal oral tablet 27-1 mg</i>                      | 2         | MO                           |
| PROCALAMINE INTRAVENOUS SOLUTION 3 %                     | 4         | BvD; MO                      |
| PROSOL INTRAVENOUS SOLUTION 20 %                         | 4         | BvD; MO                      |
| TPN ELECTROLYTES INTRAVENOUS CONCENTRATE                 | 2         | BvD; MO                      |
| TRAVASOL INTRAVENOUS SOLUTION 10 %                       | 4         | BvD; MO                      |
| TROPHAMINE INTRAVENOUS SOLUTION 10 %                     | 4         | BvD; MO                      |
| <b>Phosphate Binders</b>                                 |           |                              |
| AURYXIA ORAL TABLET 1 GM 210 MG(FE)                      | 4         | PA; MO                       |
| <i>calcium acetate (phos binder) oral capsule 667 mg</i> | 2         | MO                           |
| <i>calcium acetate oral tablet 667 mg</i>                | 2         | MO                           |
| <i>sevelamer carbonate oral packet 0.8 gm</i>            | 5         | NMO; QL (540 EA per 30 days) |
| <i>sevelamer carbonate oral packet 2.4 gm</i>            | 5         | NMO; QL (180 EA per 30 days) |
| <i>sevelamer carbonate oral tablet 800 mg</i>            | 4         | MO; QL (540 EA per 30 days)  |
| VELPHORO ORAL TABLET CHEWABLE 500 MG                     | 4         | MO                           |
| <b>GASTROINTESTINAL AGENTS</b>                           |           |                              |
| <b>Anti-Constipation Agents</b>                          |           |                              |
| <i>constulose oral solution 10 gm/15ml</i>               | 1         | MO                           |
| <i>enulose oral solution 10 gm/15ml</i>                  | 1         | MO                           |
| <i>generlac oral solution 10 gm/15ml</i>                 | 1         | MO                           |
| <i>lactulose oral solution 10 gm/15ml</i>                | 1         | MO                           |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG            | 3         | MO; QL (30 EA per 30 days)   |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i>           | 3         | MO; QL (60 EA per 30 days)   |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG                      | 3         | MO; QL (30 EA per 30 days)   |
| <b>Anti-Diarrheal Agents</b>                             |           |                              |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022. Last updated 04/18/2022.

| Drug Name                                                             | Drug Tier | Requirements/Limits         |
|-----------------------------------------------------------------------|-----------|-----------------------------|
| <i>alosetron hcl oral tablet 0.5 mg, 1 mg</i>                         | 5         | NMO; QL (60 EA per 30 days) |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5ml</i>            | 4         | MO                          |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i>                | 2         | MO                          |
| <i>loperamide hcl oral capsule 2 mg</i>                               | 1         | MO                          |
| <b>Antispasmodics, Gastrointestinal</b>                               |           |                             |
| <i>dicyclomine hcl oral capsule 10 mg</i>                             | 1         | MO                          |
| <i>dicyclomine hcl oral solution 10 mg/5ml</i>                        | 2         | MO                          |
| <i>dicyclomine hcl oral tablet 20 mg</i>                              | 1         | MO                          |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i>                          | 2         | MO                          |
| <b>Gastrointestinal Agents, Other</b>                                 |           |                             |
| BYLVAY (PELLETS) ORAL CAPSULE SPRINKLE 200 MCG                        | 5         | PA; NMO                     |
| BYLVAY ORAL CAPSULE 1200 MCG, 400 MCG                                 | 5         | PA; NMO                     |
| CLENPIQ ORAL SOLUTION 10-3.5-12 MG-GM -GM/160ML                       | 4         | MO                          |
| GATTEX SUBCUTANEOUS KIT 5 MG                                          | 5         | PA; NMO                     |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240 GM                         | 1         | MO                          |
| GAVILYTE-G ORAL SOLUTION RECONSTITUTED 236 GM                         | 1         | MO                          |
| GAVILYTE-N WITH FLAVOR PACK ORAL SOLUTION RECONSTITUTED 420 GM        | 2         | MO                          |
| LIVMARLI ORAL SOLUTION 9.5 MG/ML                                      | 5         | PA; NMO                     |
| <i>metoclopramide hcl oral solution 5 mg/5ml</i>                      | 1         | MO                          |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i>                     | 1         | MO                          |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420 gm</i> | 2         | MO                          |
| <i>peg-3350/electrolytes oral solution reconstituted 236 gm</i>       | 2         | MO                          |
| SUPREP BOWEL PREP KIT ORAL SOLUTION 17.5-3.13-1.6 GM/177ML            | 4         | MO                          |
| SUTAB ORAL TABLET 1479-225-188 MG                                     | 4         | MO                          |
| <i>ursodiol oral capsule 300 mg</i>                                   | 2         | MO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022. Last updated 04/18/2022.

| Drug Name                                                                                                                           | Drug Tier | Requirements/Limits |
|-------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------|
| ursodiol oral tablet 250 mg, 500 mg                                                                                                 | 2         | MO                  |
| <b>Histamine2 (H2) Receptor Antagonists</b>                                                                                         |           |                     |
| famotidine oral suspension reconstituted 40 mg/5ml                                                                                  | 2         | MO                  |
| famotidine oral tablet 20 mg, 40 mg                                                                                                 | 1         | MO                  |
| nizatidine oral capsule 150 mg, 300 mg                                                                                              | 2         | MO                  |
| nizatidine oral solution 15 mg/ml                                                                                                   | 2         | MO                  |
| <b>Protectants</b>                                                                                                                  |           |                     |
| misoprostol oral tablet 100 mcg, 200 mcg                                                                                            | 2         | MO                  |
| sucralfate oral suspension 1 gm/10ml                                                                                                | 4         | MO                  |
| sucralfate oral tablet 1 gm                                                                                                         | 1         | MO                  |
| <b>Proton Pump Inhibitors</b>                                                                                                       |           |                     |
| DEXILANT ORAL CAPSULE DELAYED RELEASE 30 MG, 60 MG                                                                                  | 3         | MO                  |
| esomeprazole magnesium oral capsule delayed release 20 mg, 40 mg                                                                    | 2         | MO                  |
| lansoprazole oral capsule delayed release 15 mg, 30 mg                                                                              | 2         | MO                  |
| omeprazole oral capsule delayed release 10 mg, 20 mg, 40 mg                                                                         | 1         | MO                  |
| pantoprazole sodium oral tablet delayed release 20 mg, 40 mg                                                                        | 1         | MO                  |
| <b>GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT</b>                                                     |           |                     |
| <b>Genetic Or Enzyme Or Protein Disorder: Replacement, Modifiers, Treatment</b>                                                     |           |                     |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000-38000 UNIT, 24000-76000 UNIT, 3000-9500 UNIT, 36000-114000 UNIT, 6000-19000 UNIT | 3         | MO                  |
| cromolyn sodium oral concentrate 100 mg/5ml                                                                                         | 4         | MO                  |
| CYSTADANE ORAL POWDER                                                                                                               | 5         | NMO                 |
| CYSTAGON ORAL CAPSULE 150 MG, 50 MG                                                                                                 | 4         | PA; MO              |
| ENDARI ORAL PACKET 5 GM                                                                                                             | 4         | PA; MO              |
| GALAFOLD ORAL CAPSULE 123 MG                                                                                                        | 5         | PA; NMO             |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                                                                                              | Drug Tier | Requirements/Limits             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------|
| <i>miglustat oral capsule 100 mg</i>                                                                                                                                                   | 5         | PA; NMO                         |
| <i>nitisinone oral capsule 10 mg, 2 mg, 5 mg</i>                                                                                                                                       | 5         | PA; NMO                         |
| ORFADIN ORAL CAPSULE 20 MG                                                                                                                                                             | 5         | PA; NMO                         |
| PROLASTIN-C INTRAVENOUS SOLUTION<br>RECONSTITUTED 1000 MG                                                                                                                              | 5         | PA; NMO                         |
| RAVICTI ORAL LIQUID 1.1 GM/ML                                                                                                                                                          | 5         | PA; NMO                         |
| <i>sapropterin dihydrochloride oral packet 100 mg,<br/>500 mg</i>                                                                                                                      | 5         | PA; NMO                         |
| <i>sapropterin dihydrochloride oral tablet 100 mg</i>                                                                                                                                  | 5         | PA; NMO                         |
| TEGSEDI SUBCUTANEOUS SOLUTION<br>PREFILLED SYRINGE 284 MG/1.5ML                                                                                                                        | 5         | PA; NMO                         |
| VYNDAMAX ORAL CAPSULE 61 MG                                                                                                                                                            | 5         | PA; NMO; QL (30 EA per 30 days) |
| XURIDEN ORAL PACKET 2 GM                                                                                                                                                               | 5         | PA; NMO                         |
| ZENPEP ORAL CAPSULE DELAYED<br>RELEASE PARTICLES 10000-32000 UNIT,<br>15000-47000 UNIT, 20000-63000 UNIT, 25000-<br>79000 UNIT, 3000-10000 UNIT, 40000-126000<br>UNIT, 5000-24000 UNIT | 3         | MO                              |
| <b>GENITOURINARY AGENTS</b>                                                                                                                                                            |           |                                 |
| <b><i>Antispasmodics, Urinary</i></b>                                                                                                                                                  |           |                                 |
| <i>darifenacin hydrobromide er oral tablet extended<br/>release 24 hour 15 mg, 7.5 mg</i>                                                                                              | 4         | MO                              |
| MYRBETRIQ ORAL SUSPENSION<br>RECONSTITUTED ER 8 MG/ML                                                                                                                                  | 3         | MO; QL (300 ML per 30 days)     |
| MYRBETRIQ ORAL TABLET EXTENDED<br>RELEASE 24 HOUR 25 MG, 50 MG                                                                                                                         | 3         | MO; QL (30 EA per 30 days)      |
| <i>oxybutynin chloride er oral tablet extended release<br/>24 hour 10 mg, 15 mg, 5 mg</i>                                                                                              | 2         | MO; QL (60 EA per 30 days)      |
| <i>oxybutynin chloride oral syrup 5 mg/5ml</i>                                                                                                                                         | 2         | MO; QL (600 ML per 30 days)     |
| <i>oxybutynin chloride oral tablet 5 mg</i>                                                                                                                                            | 1         | MO; QL (120 EA per 30 days)     |
| <i>solifenacin succinate oral tablet 10 mg, 5 mg</i>                                                                                                                                   | 2         | MO; QL (30 EA per 30 days)      |
| <i>tolterodine tartrate er oral capsule extended<br/>release 24 hour 2 mg, 4 mg</i>                                                                                                    | 2         | MO; QL (30 EA per 30 days)      |
| <i>tolterodine tartrate oral tablet 1 mg, 2 mg</i>                                                                                                                                     | 2         | MO; QL (60 EA per 30 days)      |
| <i>tropium chloride er oral capsule extended release<br/>24 hour 60 mg</i>                                                                                                             | 2         | MO; QL (30 EA per 30 days)      |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                               | Drug Tier | Requirements/Limits              |
|---------------------------------------------------------------------------------------------------------|-----------|----------------------------------|
| <i>tropium chloride oral tablet 20 mg</i>                                                               | 2         | MO; QL (60 EA per 30 days)       |
| <b>Benign Prostatic Hypertrophy Agents</b>                                                              |           |                                  |
| <i>alfuzosin hcl er oral tablet extended release 24 hour 10 mg</i>                                      | 1         | MO; QL (30 EA per 30 days)       |
| <i>dutasteride oral capsule 0.5 mg</i>                                                                  | 1         | MO; QL (30 EA per 30 days)       |
| <i>dutasteride-tamsulosin hcl oral capsule 0.5-0.4 mg</i>                                               | 2         | MO; QL (30 EA per 30 days)       |
| <i>finasteride oral tablet 5 mg</i>                                                                     | 1         | MO; QL (30 EA per 30 days)       |
| <i>silodosin oral capsule 4 mg, 8 mg</i>                                                                | 4         | MO; QL (30 EA per 30 days)       |
| <i>tamsulosin hcl oral capsule 0.4 mg</i>                                                               | 1         | MO; QL (60 EA per 30 days)       |
| <b>Genitourinary Agents, Other</b>                                                                      |           |                                  |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i>                                       | 2         | MO                               |
| ELMIRON ORAL CAPSULE 100 MG                                                                             | 4         | MO                               |
| <i>penicillamine oral tablet 250 mg</i>                                                                 | 5         | NMO                              |
| <b>HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL)</b>                                     |           |                                  |
| <b>Hormonal Agents, Stimulant/ Replacement/ Modifying (Adrenal)</b>                                     |           |                                  |
| <i>dexamethasone oral elixir 0.5 mg/5ml</i>                                                             | 2         | MO                               |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i>                        | 1         | MO                               |
| <i>fludrocortisone acetate oral tablet 0.1 mg</i>                                                       | 1         | MO                               |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i>                                                    | 1         | MO                               |
| ISTURISA ORAL TABLET 1 MG                                                                               | 5         | PA; NMO; QL (240 EA per 30 days) |
| ISTURISA ORAL TABLET 10 MG                                                                              | 5         | PA; NMO; QL (180 EA per 30 days) |
| ISTURISA ORAL TABLET 5 MG                                                                               | 5         | PA; NMO; QL (120 EA per 30 days) |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i>                                          | 2         | BvD; MO                          |
| <i>methylprednisolone oral tablet therapy pack 4 mg</i>                                                 | 2         | MO                               |
| <i>prednisolone oral solution 15 mg/5ml</i>                                                             | 2         | BvD; MO                          |
| <i>prednisolone sodium phosphate oral solution 10 mg/5ml, 20 mg/5ml, 25 mg/5ml, 6.7 (5 base) mg/5ml</i> | 4         | BvD; MO                          |
| <i>prednisolone sodium phosphate oral tablet dispersible 10 mg, 15 mg, 30 mg</i>                        | 2         | BvD; MO                          |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                   | Drug Tier | Requirements/Limits |
|---------------------------------------------------------------------------------------------|-----------|---------------------|
| PREDNISONE INTENSOL ORAL CONCENTRATE 5 MG/ML                                                | 2         | BvD; MO             |
| <i>prednisone oral solution 5 mg/5ml</i>                                                    | 2         | BvD; MO             |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i>                       | 1         | BvD; MO             |
| <i>prednisone oral tablet therapy pack 10 mg (21), 10 mg (48), 5 mg (21), 5 mg (48)</i>     | 1         | MO                  |
| <b>HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (PITUITARY)</b>                       |           |                     |
| <b><i>Hormonal Agents, Stimulant/ Replacement/ Modifying (Pituitary)</i></b>                |           |                     |
| <i>desmopressin acetate oral tablet 0.1 mg, 0.2 mg</i>                                      | 2         | MO                  |
| <i>desmopressin acetate spray nasal solution 0.01 %</i>                                     | 2         | MO                  |
| INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4ML                                                    | 5         | PA; NMO             |
| NOC DURNA SUBLINGUAL TABLET SUBLINGUAL 27.7 MCG, 55.3 MCG                                   | 4         | MO                  |
| OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 10 MG/1.5ML, 5 MG/1.5ML                           | 5         | PA; NMO             |
| OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED 5.8 MG                                        | 5         | PA; NMO             |
| <b>HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS)</b>         |           |                     |
| <b><i>Androgens</i></b>                                                                     |           |                     |
| ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 MG/24HR, 4 MG/24HR                                    | 3         | MO                  |
| <i>danazol oral capsule 100 mg, 50 mg</i>                                                   | 2         | MO                  |
| <i>danazol oral capsule 200 mg</i>                                                          | 4         | MO                  |
| <i>oxandrolone oral tablet 10 mg</i>                                                        | 4         | PA; MO              |
| <i>oxandrolone oral tablet 2.5 mg</i>                                                       | 3         | PA; MO              |
| <i>testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 2         | MO                  |
| <i>testosterone enanthate intramuscular solution 200 mg/ml</i>                              | 2         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                                                             | Drug Tier | Requirements/Limits |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------|
| testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%) | 3         | MO                  |
| testosterone transdermal gel 50 mg/5gm (1%)                                                                                                           | 4         | MO                  |
| testosterone transdermal solution 30 mg/act                                                                                                           | 3         | MO                  |
| <b>Estrogens</b>                                                                                                                                      |           |                     |
| DUAVEE ORAL TABLET 0.45-20 MG                                                                                                                         | 3         | MO                  |
| estradiol oral tablet 0.5 mg, 1 mg, 2 mg                                                                                                              | 1         | MO                  |
| estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr                                      | 2         | MO                  |
| estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr                              | 2         | MO                  |
| estradiol vaginal cream 0.1 mg/gm                                                                                                                     | 4         | MO                  |
| estradiol vaginal tablet 10 mcg                                                                                                                       | 4         | MO                  |
| IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10 MCG, 4 MCG                                                                                                 | 4         | MO                  |
| IMVEXXY STARTER PACK VAGINAL INSERT 10 MCG, 4 MCG                                                                                                     | 4         | MO                  |
| MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG                                                                                                          | 4         | MO                  |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG                                                                                       | 3         | MO                  |
| PREMARIN VAGINAL CREAM 0.625 MG/GM                                                                                                                    | 3         | MO                  |
| <b>Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)</b>                                                                   |           |                     |
| ALTAVERA ORAL TABLET 0.15-30 MG-MCG                                                                                                                   | 1         | MO                  |
| alyacen 1/35 oral tablet 1-35 mg-mcg                                                                                                                  | 1         | MO                  |
| APRI ORAL TABLET 0.15-30 MG-MCG                                                                                                                       | 1         | MO                  |
| ARANELLE ORAL TABLET 0.5/1/0.5-35 MG-MCG                                                                                                              | 2         | MO                  |
| AUBRA EQ ORAL TABLET 0.1-20 MG-MCG                                                                                                                    | 1         | MO                  |
| AVIANE ORAL TABLET 0.1-20 MG-MCG                                                                                                                      | 1         | MO                  |
| BALZIVA ORAL TABLET 0.4-35 MG-MCG                                                                                                                     | 2         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                                                 | Drug Tier | Requirements/Limits |
|---------------------------------------------------------------------------|-----------|---------------------|
| BLISOVI FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG                               | 1         | MO                  |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i>                                 | 2         | MO                  |
| CAZIAN ORAL TABLET 0.1/0.125/0.15 -0.025 MG                               | 2         | MO                  |
| CRYSSELLE-28 ORAL TABLET 0.3-30 MG-MCG                                    | 2         | MO                  |
| CYRED EQ ORAL TABLET 0.15-30 MG-MCG                                       | 1         | MO                  |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2         | MO                  |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-30 mg-mcg</i>           | 1         | MO                  |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i>    | 2         | MO                  |
| ELURYNG VAGINAL RING 0.12-0.015 MG/24HR                                   | 4         | MO                  |
| EMOQUETTE ORAL TABLET 0.15-30 MG-MCG                                      | 1         | MO                  |
| ENPRESSE-28 ORAL TABLET 50-30/75-40/125-30 MCG                            | 1         | MO                  |
| ENSKYCE ORAL TABLET 0.15-30 MG-MCG                                        | 1         | MO                  |
| ESTARYLLA ORAL TABLET 0.25-35 MG-MCG                                      | 1         | MO                  |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | 2         | MO                  |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24hr</i>     | 4         | MO                  |
| FALMINA ORAL TABLET 0.1-20 MG-MCG                                         | 1         | MO                  |
| FEMYNOR ORAL TABLET 0.25-35 MG-MCG                                        | 1         | MO                  |
| ICLEVIA ORAL TABLET 0.15-0.03 MG                                          | 2         | MO                  |
| INTRAROSA VAGINAL INSERT 6.5 MG                                           | 3         | PA; MO              |
| INTROVALE ORAL TABLET 0.15-0.03 MG                                        | 2         | MO                  |
| ISIBLOOM ORAL TABLET 0.15-30 MG-MCG                                       | 1         | MO                  |
| JASMIEL ORAL TABLET 3-0.02 MG                                             | 2         | MO                  |
| JULEBER ORAL TABLET 0.15-30 MG-MCG                                        | 1         | MO                  |
| JUNEL 1.5/30 ORAL TABLET 1.5-30 MG-MCG                                    | 2         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                      | Drug Tier | Requirements/Limits |
|--------------------------------------------------------------------------------|-----------|---------------------|
| JUNEL 1/20 ORAL TABLET 1-20 MG-MCG                                             | 1         | MO                  |
| JUNEL FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG                                      | 1         | MO                  |
| JUNEL FE 1/20 ORAL TABLET 1-20 MG-MCG                                          | 1         | MO                  |
| KARIVA ORAL TABLET 0.15-0.02/0.01 MG (21/5)                                    | 2         | MO                  |
| KELNOR 1/35 ORAL TABLET 1-35 MG-MCG                                            | 1         | MO                  |
| KELNOR 1/50 ORAL TABLET 1-50 MG-MCG                                            | 1         | MO                  |
| KURVELO ORAL TABLET 0.15-30 MG-MCG                                             | 1         | MO                  |
| LARIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG                                         | 2         | MO                  |
| LARIN 1/20 ORAL TABLET 1-20 MG-MCG                                             | 1         | MO                  |
| LARIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG                                      | 1         | MO                  |
| LARIN FE 1/20 ORAL TABLET 1-20 MG-MCG                                          | 1         | MO                  |
| LARISSIA ORAL TABLET 0.1-20 MG-MCG                                             | 1         | MO                  |
| LEENA ORAL TABLET 0.5/1/0.5-35 MG-MCG                                          | 2         | MO                  |
| LESSINA ORAL TABLET 0.1-20 MG-MCG                                              | 1         | MO                  |
| LEVONEST ORAL TABLET 50-30/75-40/ 125-30 MCG                                   | 1         | MO                  |
| <i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03 mg</i>                  | 2         | MO                  |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-30 mg-mcg</i> | 1         | MO                  |
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30 mcg</i>       | 1         | MO                  |
| LEVORA 0.15/30 (28) ORAL TABLET 0.15-30 MG-MCG                                 | 1         | MO                  |
| LORYNA ORAL TABLET 3-0.02 MG                                                   | 2         | MO                  |
| LOW-OGESTREL ORAL TABLET 0.3-30 MG-MCG                                         | 2         | MO                  |
| LUTERA ORAL TABLET 0.1-20 MG-MCG                                               | 1         | MO                  |
| <i>marlissa oral tablet 0.15-30 mg-mcg</i>                                     | 1         | MO                  |
| MICROGESTIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG                                   | 2         | MO                  |
| MICROGESTIN 1/20 ORAL TABLET 1-20 MG-MCG                                       | 1         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022. Last updated 04/18/2022.

| Drug Name                                                                   | Drug Tier | Requirements/Limits |
|-----------------------------------------------------------------------------|-----------|---------------------|
| MICROGESTIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG                             | 2         | MO                  |
| MICROGESTIN FE 1/20 ORAL TABLET 1-20 MG-MCG                                 | 1         | MO                  |
| MILI ORAL TABLET 0.25-35 MG-MCG                                             | 1         | MO                  |
| NECON 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG                                 | 2         | MO                  |
| NIKKI ORAL TABLET 3-0.02 MG                                                 | 2         | MO                  |
| <i>norethin ace-eth estrad-fe oral tablet 1-20 mg-mcg</i>                   | 1         | MO                  |
| <i>norethindrone acet-ethinyl est oral tablet 1-20 mg-mcg</i>               | 2         | MO                  |
| <i>norethindrone-eth estradiol oral tablet 1-5 mg-mcg</i>                   | 2         | MO                  |
| <i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i>                | 1         | MO                  |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 1         | MO                  |
| NORTREL 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG                               | 2         | MO                  |
| NORTREL 1/35 (21) ORAL TABLET 1-35 MG-MCG                                   | 1         | MO                  |
| NORTREL 1/35 (28) ORAL TABLET 1-35 MG-MCG                                   | 1         | MO                  |
| NORTREL 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG                              | 1         | MO                  |
| NYLIA 1/35 ORAL TABLET 1-35 MG-MCG                                          | 1         | MO                  |
| NYLIA 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG                                | 1         | MO                  |
| NYMYO ORAL TABLET 0.25-35 MG-MCG                                            | 1         | MO                  |
| OCELLA ORAL TABLET 3-0.03 MG                                                | 2         | MO                  |
| ORSYTHIA ORAL TABLET 0.1-20 MG-MCG                                          | 1         | MO                  |
| OSPHENA ORAL TABLET 60 MG                                                   | 3         | PA; MO              |
| PIMTREA ORAL TABLET 0.15-0.02/0.01 MG (21/5)                                | 2         | MO                  |
| PIRMELLA 1/35 ORAL TABLET 1-35 MG-MCG                                       | 1         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                             | Drug Tier | Requirements/Limits |
|-----------------------------------------------------------------------|-----------|---------------------|
| PORTIA-28 ORAL TABLET 0.15-30 MG-MCG                                  | 1         | MO                  |
| PREMPHASE ORAL TABLET 0.625-5 MG                                      | 3         | MO                  |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3         | MO                  |
| PREVIFEM ORAL TABLET 0.25-35 MG-MCG                                   | 1         | MO                  |
| RECLIPSEN ORAL TABLET 0.15-30 MG-MCG                                  | 1         | MO                  |
| SETLAKIN ORAL TABLET 0.15-0.03 MG                                     | 2         | MO                  |
| SPRINTEC 28 ORAL TABLET 0.25-35 MG-MCG                                | 1         | MO                  |
| SRONYX ORAL TABLET 0.1-20 MG-MCG                                      | 1         | MO                  |
| SYEDA ORAL TABLET 3-0.03 MG                                           | 2         | MO                  |
| TARINA FE 1/20 EQ ORAL TABLET 1-20 MG-MCG                             | 1         | MO                  |
| TRI-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG                   | 1         | MO                  |
| TRI-MILI ORAL TABLET 0.18/0.215/0.25 MG-35 MCG                        | 1         | MO                  |
| TRI-NYMYO ORAL TABLET 0.18/0.215/0.25 MG-35 MCG                       | 1         | MO                  |
| TRI-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG-35 MCG                    | 1         | MO                  |
| TRIVORA (28) ORAL TABLET 50-30/75-40/125-30 MCG                       | 1         | MO                  |
| TRI-VYLIBRA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG                     | 1         | MO                  |
| VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025 MG                          | 2         | MO                  |
| VESTURA ORAL TABLET 3-0.02 MG                                         | 2         | MO                  |
| VIENVA ORAL TABLET 0.1-20 MG-MCG                                      | 1         | MO                  |
| VYFEMLA ORAL TABLET 0.4-35 MG-MCG                                     | 2         | MO                  |
| VYLIBRA ORAL TABLET 0.25-35 MG-MCG                                    | 1         | MO                  |
| ZOVIA 1/35 (28) ORAL TABLET 1-35 MG-MCG                               | 1         | MO                  |
| <b>Progestins</b>                                                     |           |                     |
| CAMILA ORAL TABLET 0.35 MG                                            | 1         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                               | Drug Tier | Requirements/Limits |
|-----------------------------------------------------------------------------------------|-----------|---------------------|
| DEBLITANE ORAL TABLET 0.35 MG                                                           | 1         | MO                  |
| ERRIN ORAL TABLET 0.35 MG                                                               | 1         | MO                  |
| INCASSIA ORAL TABLET 0.35 MG                                                            | 1         | MO                  |
| LYLEQ ORAL TABLET 0.35 MG                                                               | 1         | MO                  |
| LYZA ORAL TABLET 0.35 MG                                                                | 1         | MO                  |
| <i>medroxyprogesterone acetate intramuscular suspension 150 mg/ml</i>                   | 2         | MO                  |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150 mg/ml</i> | 2         | MO                  |
| <i>medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg</i>                      | 1         | MO                  |
| <i>megestrol acetate oral suspension 40 mg/ml</i>                                       | 2         | MO                  |
| <i>megestrol acetate oral suspension 625 mg/5ml</i>                                     | 4         | MO                  |
| <i>megestrol acetate oral tablet 20 mg, 40 mg</i>                                       | 1         | MO                  |
| NORA-BE ORAL TABLET 0.35 MG                                                             | 1         | MO                  |
| <i>norethindrone acetate oral tablet 5 mg</i>                                           | 2         | MO                  |
| <i>norethindrone oral tablet 0.35 mg</i>                                                | 1         | MO                  |
| <i>progesterone oral capsule 100 mg, 200 mg</i>                                         | 2         | MO                  |
| SHAROBEL ORAL TABLET 0.35 MG                                                            | 1         | MO                  |

## **HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (THYROID)**

### ***Hormonal Agents, Stimulant/ Replacement/ Modifying (Thyroid)***

|                                                                                                                                                |   |    |
|------------------------------------------------------------------------------------------------------------------------------------------------|---|----|
| EUTHYROX ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG                             | 1 | MO |
| LEVO-T ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG                      | 1 | MO |
| <i>levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | MO |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG                              | 1 | MO |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                                    | Drug Tier | Requirements/Limits             |
|------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------|
| <i>liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg</i>                                                                 | 1         | MO                              |
| SYNTHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 3         | MO                              |
| UNITHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 3         | MO                              |
| <b>HORMONAL AGENTS, SUPPRESSANT (PITUITARY)</b>                                                                              |           |                                 |
| <b><i>Hormonal Agents, Suppressant (Pituitary)</i></b>                                                                       |           |                                 |
| <i>cabergoline oral tablet 0.5 mg</i>                                                                                        | 2         | MO                              |
| ELIGARD SUBCUTANEOUS KIT 22.5 MG, 30 MG, 45 MG, 7.5 MG                                                                       | 4         | PA2; MO                         |
| <i>leuprolide acetate injection kit 1 mg/0.2ml</i>                                                                           | 2         | PA2; MO                         |
| LUPRON DEPOT (1-MONTH)<br>INTRAMUSCULAR KIT 3.75 MG, 7.5 MG                                                                  | 5         | PA2; NMO                        |
| LUPRON DEPOT (3-MONTH)<br>INTRAMUSCULAR KIT 11.25 MG, 22.5 MG                                                                | 5         | PA2; NMO                        |
| LUPRON DEPOT (4-MONTH)<br>INTRAMUSCULAR KIT 30 MG                                                                            | 5         | PA2; NMO                        |
| LUPRON DEPOT (6-MONTH)<br>INTRAMUSCULAR KIT 45 MG                                                                            | 5         | PA2; NMO                        |
| <i>octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml</i>                                                           | 2         | PA; MO                          |
| <i>octreotide acetate injection solution 1000 mcg/ml, 500 mcg/ml</i>                                                         | 5         | PA; NMO                         |
| <i>octreotide acetate injection solution 200 mcg/ml</i>                                                                      | 4         | PA; MO                          |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML, 0.6 MG/ML, 0.9 MG/ML                                                               | 5         | PA; NMO; QL (60 ML per 30 days) |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 15 MG, 20 MG, 25 MG, 30 MG                                               | 5         | PA; NMO; QL (60 EA per 30 days) |
| SYNAREL NASAL SOLUTION 2 MG/ML                                                                                               | 5         | PA; NMO                         |
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG                                           | 5         | PA2; NMO                        |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                             | Drug Tier | Requirements/Limits |
|-------------------------------------------------------------------------------------------------------|-----------|---------------------|
| <b>HORMONAL AGENTS, SUPPRESSANT (THYROID)</b>                                                         |           |                     |
| <b><i>Antithyroid Agents</i></b>                                                                      |           |                     |
| <i>methimazole oral tablet 10 mg, 5 mg</i>                                                            | 1         | MO                  |
| <i>propylthiouracil oral tablet 50 mg</i>                                                             | 1         | MO                  |
| <b>IMMUNOLOGICAL AGENTS</b>                                                                           |           |                     |
| <b><i>Angioedema Agents</i></b>                                                                       |           |                     |
| CINRYZE INTRAVENOUS SOLUTION RECONSTITUTED 500 UNIT                                                   | 5         | PA; NMO             |
| FIRAZYR SUBCUTANEOUS SOLUTION 30 MG/3ML                                                               | 5         | PA; NMO             |
| <i>icatibant acetate subcutaneous solution 30 mg/3ml</i>                                              | 5         | PA; NMO             |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2ML                                                             | 5         | PA; NMO             |
| <b><i>Immunoglobulins</i></b>                                                                         |           |                     |
| PANZYGA INTRAVENOUS SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML | 5         | BvD; NMO            |
| PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML                                                             | 5         | BvD; NMO            |
| <b><i>Immunological Agents, Other</i></b>                                                             |           |                     |
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED 220 MG                                                   | 5         | PA; NMO             |
| COSENTYX (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML                              | 5         | PA; NMO             |
| COSENTYX SENSOREADY (300 MG) SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML                            | 5         | PA; NMO             |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML                                          | 5         | PA; NMO             |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200 MG/1.14ML, 300 MG/2ML                                 | 5         | PA; NMO             |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML, 200 MG/1.14ML, 300 MG/2ML             | 5         | PA; NMO             |
| <i>leflunomide oral tablet 10 mg, 20 mg</i>                                                           | 2         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                             | Drug Tier | Requirements/Limits |
|---------------------------------------------------------------------------------------|-----------|---------------------|
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG                                     | 5         | PA; NMO             |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 30 MG                                     | 5         | PA; NMO             |
| SKYRIZI (150 MG DOSE) SUBCUTANEOUS PREFILLED SYRINGE KIT 75 MG/0.83ML                 | 5         | PA; NMO             |
| SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML                             | 5         | PA; NMO             |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML                             | 5         | PA; NMO             |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML                                             | 5         | PA; NMO             |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML                 | 5         | PA; NMO             |
| TAVNEOS ORAL CAPSULE 10 MG                                                            | 5         | PA; NMO             |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 75 MG/0.5ML                 | 5         | PA; NMO             |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150 MG                                     | 5         | PA; NMO             |
| <b>Immunostimulants</b>                                                               |           |                     |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 2000000 UNIT/0.5ML                                    | 5         | PA2; NMO            |
| BESREMI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 500 MCG/ML                            | 5         | PA2; NMO            |
| INTRON A INJECTION SOLUTION RECONSTITUTED 10000000 UNIT, 18000000 UNIT, 50000000 UNIT | 5         | PA2; NMO            |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML                                              | 5         | PA; NMO             |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 180 MCG/0.5ML                         | 5         | PA; NMO             |
| <b>Immunosuppressants</b>                                                             |           |                     |
| AZASAN ORAL TABLET 100 MG, 75 MG                                                      | 3         | BvD; MO             |
| azathioprine oral tablet 100 mg, 75 mg                                                | 3         | BvD; MO             |
| azathioprine oral tablet 50 mg                                                        | 2         | BvD; MO             |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                                                                              | Drug Tier | Requirements/Limits               |
|--------------------------------------------------------------------------------------------------------|-----------|-----------------------------------|
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML                                                 | 5         | PA; NMO                           |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML                                             | 5         | PA; NMO                           |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i>                                         | 2         | BvD; MO                           |
| <i>cyclosporine modified oral solution 100 mg/ml</i>                                                   | 2         | BvD; MO                           |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i>                                                         | 2         | BvD; MO                           |
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML                                                   | 5         | PA; NMO                           |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML                                                               | 5         | PA; NMO                           |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50 MG/ML                                   | 5         | PA; NMO                           |
| ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED 25 MG                                                       | 5         | PA; NMO                           |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML                                          | 5         | PA; NMO                           |
| ENSPRYNG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML                                             | 5         | PA2; NMO                          |
| ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG                                   | 4         | BvD; MO                           |
| <i>everolimus oral tablet 0.25 mg</i>                                                                  | 4         | BvD; MO; QL (60 EA per 30 days)   |
| <i>everolimus oral tablet 0.5 mg</i>                                                                   | 5         | BvD; NMO; QL (120 EA per 30 days) |
| <i>everolimus oral tablet 0.75 mg, 1 mg</i>                                                            | 5         | BvD; NMO; QL (60 EA per 30 days)  |
| GENGRAF ORAL CAPSULE 100 MG, 25 MG                                                                     | 2         | BvD; MO                           |
| GENGRAF ORAL SOLUTION 100 MG/ML                                                                        | 2         | BvD; MO                           |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML | 5         | PA; NMO                           |
| HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML, 80 MG/0.8ML                         | 5         | PA; NMO                           |
| HUMIRA PEN-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML, 80 MG/0.8ML                     | 5         | PA; NMO                           |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                          | Drug Tier | Requirements/Limits              |
|----------------------------------------------------------------------------------------------------|-----------|----------------------------------|
| HUMIRA PEN-PEDIATRIC UC START<br>SUBCUTANEOUS PEN-INJECTOR KIT 80<br>MG/0.8ML                      | 5         | PA; NMO                          |
| HUMIRA PEN-PS/UV/ADOL HS START<br>SUBCUTANEOUS PEN-INJECTOR KIT 40<br>MG/0.8ML                     | 5         | PA; NMO                          |
| HUMIRA PEN-PSOR/UEIT STARTER<br>SUBCUTANEOUS PEN-INJECTOR KIT 80<br>MG/0.8ML & 40MG/0.4ML          | 5         | PA; NMO                          |
| HUMIRA SUBCUTANEOUS PREFILLED<br>SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40<br>MG/0.4ML, 40 MG/0.8ML | 5         | PA; NMO                          |
| LUPKYNIS ORAL CAPSULE 7.9 MG                                                                       | 5         | PA; NMO; QL (180 EA per 30 days) |
| <i>methotrexate oral tablet 2.5 mg</i>                                                             | 2         | BvD; MO                          |
| <i>methotrexate sodium (pf) injection solution 50<br/>mg/2ml</i>                                   | 1         | BvD; MO                          |
| <i>methotrexate sodium injection solution 50 mg/2ml</i>                                            | 1         | BvD; MO                          |
| <i>mycophenolate mofetil oral capsule 250 mg</i>                                                   | 4         | BvD; MO                          |
| <i>mycophenolate mofetil oral suspension<br/>reconstituted 200 mg/ml</i>                           | 5         | BvD; NMO                         |
| <i>mycophenolate mofetil oral tablet 500 mg</i>                                                    | 2         | BvD; MO                          |
| <i>mycophenolate sodium oral tablet delayed release<br/>180 mg, 360 mg</i>                         | 2         | BvD; MO                          |
| PROGRAF ORAL PACKET 0.2 MG, 1 MG                                                                   | 4         | BvD; MO                          |
| REZUROCK ORAL TABLET 200 MG                                                                        | 5         | PA; NMO                          |
| <i>sirolimus oral solution 1 mg/ml</i>                                                             | 5         | BvD; NMO                         |
| <i>sirolimus oral tablet 0.5 mg, 1 mg</i>                                                          | 4         | BvD; MO                          |
| <i>sirolimus oral tablet 2 mg</i>                                                                  | 5         | BvD; NMO                         |
| <i>tacrolimus oral capsule 0.5 mg</i>                                                              | 2         | BvD; MO                          |
| <i>tacrolimus oral capsule 1 mg, 5 mg</i>                                                          | 4         | BvD; MO                          |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5<br>MG, 7.5 MG                                                  | 4         | BvD; MO                          |
| <b>Vaccines</b>                                                                                    |           |                                  |
| ACTHIB INTRAMUSCULAR SOLUTION<br>RECONSTITUTED                                                     | 3         | MO                               |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                         | Drug Tier | Requirements/Limits |
|-----------------------------------------------------------------------------------|-----------|---------------------|
| ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 (PREFILLED SYRINGE), 5-2-15.5 LF-MCG/0.5 | 4         | MO                  |
| <i>bcg vaccine injection injectable</i>                                           | 4         | MO                  |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE                                | 3         | MO                  |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 LF-MCG/0.5                           | 3         | MO                  |
| BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 5-2.5-18.5 LF-MCG/0.5         | 3         | MO                  |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5                                         | 4         | MO                  |
| <i>diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml</i>      | 4         | BvD; MO             |
| ENGRIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML                             | 3         | BvD; MO             |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION                                               | 3         | MO                  |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE                             | 3         | MO                  |
| HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML, 720 EL U/0.5ML                      | 3         | MO                  |
| HIBERIX INJECTION SOLUTION RECONSTITUTED 10 MCG                                   | 3         | MO                  |
| IMOVAX RABIES INTRAMUSCULAR INJECTABLE 2.5 UNIT/ML                                | 3         | BvD; MO             |
| INFANRIX INTRAMUSCULAR SUSPENSION 25-58-10                                        | 4         | MO                  |
| IPOL INJECTION INJECTABLE                                                         | 3         | MO                  |
| IXIARO INTRAMUSCULAR SUSPENSION                                                   | 3         | MO                  |
| KINRIX INTRAMUSCULAR SUSPENSION                                                   | 4         | MO                  |
| KINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML                          | 4         | MO                  |
| MENACTRA INTRAMUSCULAR SOLUTION                                                   | 3         | MO                  |
| MENQUADFI INTRAMUSCULAR SOLUTION                                                  | 3         | MO                  |
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED                                       | 3         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                       | Drug Tier | Requirements/Limits |
|-------------------------------------------------------------------------------------------------|-----------|---------------------|
| M-M-R II INJECTION SOLUTION RECONSTITUTED                                                       | 3         | MO                  |
| PEDIARIX INTRAMUSCULAR SUSPENSION                                                               | 4         | MO                  |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION 7.5 MCG/0.5ML                                               | 3         | MO                  |
| PENTACEL INTRAMUSCULAR SUSPENSION RECONSTITUTED                                                 | 4         | MO                  |
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED                                                   | 3         | MO                  |
| QUADRACEL INTRAMUSCULAR SUSPENSION                                                              | 4         | MO                  |
| RABAERT INTRAMUSCULAR SUSPENSION RECONSTITUTED                                                  | 3         | BvD; MO             |
| RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 10 MCG/ML (1ML SYRINGE), 40 MCG/ML, 5 MCG/0.5ML   | 3         | BvD; MO             |
| ROTARIX ORAL SUSPENSION RECONSTITUTED                                                           | 3         | MO                  |
| ROTATEQ ORAL SOLUTION                                                                           | 3         | MO                  |
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50 MCG/0.5ML                                    | 3         | MO                  |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML                                                     | 3         | BvD; MO             |
| TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU                                                        | 3         | BvD; MO             |
| TICOVAC INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 2.4 MCG/0.5ML                                | 3         | MO                  |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE                                             | 3         | MO                  |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML                            | 3         | MO                  |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5ML, 25 MCG/0.5ML (0.5ML SYRINGE)                     | 3         | MO                  |
| VAQTA INTRAMUSCULAR SUSPENSION 25 UNIT/0.5ML, 25 UNIT/0.5ML 0.5 ML, 50 UNIT/ML, 50 UNIT/ML 1 ML | 3         | MO                  |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                               | Drug Tier | Requirements/Limits               |
|-------------------------------------------------------------------------|-----------|-----------------------------------|
| VARIVAX SUBCUTANEOUS INJECTABLE<br>1350 PFU/0.5ML                       | 3         | MO                                |
| YF-VAX SUBCUTANEOUS INJECTABLE                                          | 3         | MO                                |
| <b>INFLAMMATORY BOWEL DISEASE AGENTS</b>                                |           |                                   |
| <b>Aminosalicylates</b>                                                 |           |                                   |
| <i>balsalazide disodium oral capsule 750 mg</i>                         | 2         | MO                                |
| LIALDA ORAL TABLET DELAYED RELEASE<br>1.2 GM                            | 3         | MO                                |
| <i>mesalamine er oral capsule extended release 24<br/>hour 0.375 gm</i> | 4         | MO                                |
| <i>mesalamine oral capsule delayed release 400 mg</i>                   | 4         | MO                                |
| <i>mesalamine oral tablet delayed release 800 mg</i>                    | 4         | MO                                |
| <i>mesalamine rectal enema 4 gm</i>                                     | 4         | MO                                |
| <i>sulfasalazine oral tablet 500 mg</i>                                 | 1         | MO                                |
| <i>sulfasalazine oral tablet delayed release 500 mg</i>                 | 1         | MO                                |
| <b>Glucocorticoids</b>                                                  |           |                                   |
| <i>budesonide er oral tablet extended release 24 hour<br/>9 mg</i>      | 4         | MO                                |
| <i>budesonide oral capsule delayed release particles<br/>3 mg</i>       | 4         | MO                                |
| <i>hydrocortisone rectal enema 100 mg/60ml</i>                          | 4         | MO                                |
| <b>METABOLIC BONE DISEASE AGENTS</b>                                    |           |                                   |
| <b>Metabolic Bone Disease Agents</b>                                    |           |                                   |
| <i>alendronate sodium oral tablet 10 mg</i>                             | 1         | MO; QL (30 EA per 30 days)        |
| <i>alendronate sodium oral tablet 35 mg, 70 mg</i>                      | 1         | MO; QL (4 EA per 28 days)         |
| <i>calcitonin (salmon) nasal solution 200 unit/act</i>                  | 2         | BvD; MO; QL (4 ML per 28 days)    |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i>                        | 1         | BvD; MO                           |
| <i>calcitriol oral solution 1 mcg/ml</i>                                | 4         | BvD; MO                           |
| <i>cinacalcet hcl oral tablet 30 mg</i>                                 | 4         | BvD; MO; QL (120 EA per 30 days)  |
| <i>cinacalcet hcl oral tablet 60 mg</i>                                 | 5         | BvD; NMO; QL (60 EA per 30 days)  |
| <i>cinacalcet hcl oral tablet 90 mg</i>                                 | 5         | BvD; NMO; QL (120 EA per 30 days) |
| <i>ibandronate sodium oral tablet 150 mg</i>                            | 1         | MO; QL (1 EA per 30 days)         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                           | Drug Tier | Requirements/Limits               |
|-------------------------------------------------------------------------------------|-----------|-----------------------------------|
| NATPARA SUBCUTANEOUS CARTRIDGE<br>100 MCG, 25 MCG, 50 MCG, 75 MCG                   | 5         | PA; NMO                           |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i>                                | 4         | BvD; MO                           |
| PROLIA SUBCUTANEOUS SOLUTION<br>PREFILLED SYRINGE 60 MG/ML                          | 4         | MO; QL (1 ML per 180 days)        |
| <i>raloxifene hcl oral tablet 60 mg</i>                                             | 2         | MO                                |
| <i>risedronate sodium oral tablet 150 mg</i>                                        | 2         | MO; QL (1 EA per 28 days)         |
| <i>risedronate sodium oral tablet 30 mg, 5 mg</i>                                   | 2         | MO; QL (30 EA per 30 days)        |
| <i>risedronate sodium oral tablet 35 mg, 35 mg (12 pack), 35 mg (4 pack)</i>        | 2         | MO; QL (4 EA per 28 days)         |
| <i>teriparatide (recombinant) subcutaneous solution pen-injector 620 mcg/2.48ml</i> | 5         | PA; NMO; QL (2.48 ML per 28 days) |
| TYMLOS SUBCUTANEOUS SOLUTION PEN-INJECTOR 3120 MCG/1.56ML                           | 5         | PA; NMO; QL (1.56 ML per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7ML                                            | 5         | PA; NMO; QL (2 ML per 28 days)    |
| <b>OPHTHALMIC AGENTS</b>                                                            |           |                                   |
| <b><i>Ophthalmic Agents, Other</i></b>                                              |           |                                   |
| <i>atropine sulfate ophthalmic solution 1 %</i>                                     | 2         | MO                                |
| <i>bacitra-neomycin-polymyxin-hc ophthalmic ointment 1 %</i>                        | 2         | MO                                |
| CYSTADROPS OPHTHALMIC SOLUTION 0.37 %                                               | 5         | PA; NMO                           |
| CYSTARAN OPHTHALMIC SOLUTION 0.44 %                                                 | 5         | PA; NMO                           |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i>                | 2         | MO                                |
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i>              | 1         | MO                                |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i>            | 2         | MO                                |
| <i>neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1</i>                      | 2         | MO                                |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1 unit/ml-%</i>             | 1         | MO                                |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                             | Drug Tier | Requirements/Limits        |
|-----------------------------------------------------------------------|-----------|----------------------------|
| RESTASIS MULTIDOSE OPHTHALMIC EMULSION 0.05 %                         | 3         | MO; QL (60 ML per 30 days) |
| RESTASIS OPHTHALMIC EMULSION 0.05 %                                   | 3         | MO; QL (60 EA per 30 days) |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23 %</i>       | 2         | MO                         |
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1 %</i>       | 2         | MO                         |
| <b>Ophthalmic Anti-Allergy Agents</b>                                 |           |                            |
| <i>azelastine hcl ophthalmic solution 0.05 %</i>                      | 2         | MO                         |
| <i>cromolyn sodium ophthalmic solution 4 %</i>                        | 1         | MO                         |
| <i>olopatadine hcl ophthalmic solution 0.1 %, 0.2 %</i>               | 2         | MO                         |
| <b>Ophthalmic Anti-Infectives</b>                                     |           |                            |
| AZASITE OPHTHALMIC SOLUTION 1 %                                       | 4         | MO                         |
| <i>bacitracin ophthalmic ointment 500 unit/gm</i>                     | 2         | MO                         |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm</i>   | 2         | MO                         |
| <i>erythromycin ophthalmic ointment 5 mg/gm</i>                       | 1         | MO                         |
| <i>gatifloxacin ophthalmic solution 0.5 %</i>                         | 2         | MO                         |
| GENTAK OPHTHALMIC OINTMENT 0.3 %                                      | 2         | MO                         |
| <i>gentamicin sulfate ophthalmic solution 0.3 %</i>                   | 1         | MO                         |
| <i>moxifloxacin hcl ophthalmic solution 0.5 %</i>                     | 2         | MO                         |
| NATACYN OPHTHALMIC SUSPENSION 5 %                                     | 4         | MO                         |
| <i>neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000</i> | 2         | MO                         |
| <i>ofloxacin ophthalmic solution 0.3 %</i>                            | 2         | MO                         |
| <i>sulfacetamide sodium ophthalmic solution 10 %</i>                  | 2         | MO                         |
| <i>tobramycin ophthalmic solution 0.3 %</i>                           | 1         | MO                         |
| <b>Ophthalmic Anti-Inflammatories</b>                                 |           |                            |
| <i>bromfenac sodium (once-daily) ophthalmic solution 0.09 %</i>       | 2         | MO                         |
| BROMSITE OPHTHALMIC SOLUTION 0.075 %                                  | 4         | MO                         |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1 %</i>       | 2         | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| <b>Drug Name</b>                                                           | <b>Drug Tier</b> | <b>Requirements/Limits</b> |
|----------------------------------------------------------------------------|------------------|----------------------------|
| <i>diclofenac sodium ophthalmic solution 0.1 %</i>                         | 2                | MO                         |
| DUREZOL OPHTHALMIC EMULSION 0.05 %                                         | 3                | MO                         |
| <i>fluorometholone ophthalmic suspension 0.1 %</i>                         | 2                | MO                         |
| <i>flurbiprofen sodium ophthalmic solution 0.03 %</i>                      | 1                | MO                         |
| ILEVRO OPHTHALMIC SUSPENSION 0.3 %                                         | 3                | MO                         |
| <i>ketorolac tromethamine ophthalmic solution 0.4 %<br/>%, 0.5 %</i>       | 2                | MO                         |
| <i>loteprednol etabonate ophthalmic suspension 0.5 %</i>                   | 2                | MO                         |
| <i>prednisolone acetate ophthalmic suspension 1 %</i>                      | 2                | MO                         |
| <i>prednisolone sodium phosphate ophthalmic solution 1 %</i>               | 2                | MO                         |
| <b>Ophthalmic Beta-Adrenergic Blocking Agents</b>                          |                  |                            |
| <i>betaxolol hcl ophthalmic solution 0.5 %</i>                             | 2                | MO                         |
| <i>carteolol hcl ophthalmic solution 1 %</i>                               | 1                | MO                         |
| <i>levobunolol hcl ophthalmic solution 0.5 %</i>                           | 1                | MO                         |
| <i>timolol maleate (once-daily) ophthalmic solution 0.5 %</i>              | 2                | MO                         |
| <i>timolol maleate ophthalmic gel forming solution 0.25 %<br/>%, 0.5 %</i> | 2                | MO                         |
| <i>timolol maleate ophthalmic solution 0.25 %<br/>%, 0.5 %</i>             | 1                | MO                         |
| <b>Ophthalmic Intraocular Pressure Lowering Agents, Other</b>              |                  |                            |
| <i>acetazolamide er oral capsule extended release 12 hour 500 mg</i>       | 2                | MO                         |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i>                            | 2                | MO                         |
| ALPHAGAN P OPHTHALMIC SOLUTION 0.1 %                                       | 3                | MO                         |
| <i>apraclonidine hcl ophthalmic solution 0.5 %</i>                         | 2                | MO                         |
| AZOPT OPHTHALMIC SUSPENSION 1 %                                            | 3                | MO                         |
| <i>brimonidine tartrate ophthalmic solution 0.15 %<br/>%, 0.2 %</i>        | 2                | MO                         |
| <i>brimonidine tartrate-timolol ophthalmic solution 0.2-0.5 %</i>          | 3                | MO                         |
| COMBIGAN OPHTHALMIC SOLUTION 0.2-0.5 %                                     | 4                | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.



| Drug Name                                                             | Drug Tier | Requirements/Limits        |
|-----------------------------------------------------------------------|-----------|----------------------------|
| <i>dorzolamide hcl ophthalmic solution 2 %</i>                        | 1         | MO                         |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 22.3-6.8 mg/ml</i> | 2         | MO                         |
| <i>dorzolamide hcl-timolol mal pf ophthalmic solution 2-0.5 %</i>     | 2         | MO                         |
| <i>methazolamide oral tablet 25 mg, 50 mg</i>                         | 4         | MO                         |
| <i>pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %</i>              | 2         | MO                         |
| ROCKLATAN OPHTHALMIC SOLUTION 0.02-0.005 %                            | 4         | MO                         |
| SIMBRINZA OPHTHALMIC SUSPENSION 1-0.2 %                               | 4         | MO                         |
| <b>Ophthalmic Prostaglandin And Prostamide Analogs</b>                |           |                            |
| <i>latanoprost ophthalmic solution 0.005 %</i>                        | 2         | MO                         |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 %                                    | 3         | MO                         |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02 %                                  | 4         | MO                         |
| <i>travoprost (bak free) ophthalmic solution 0.004 %</i>              | 3         | MO                         |
| <b>OTIC AGENTS</b>                                                    |           |                            |
| <b>Otic Agents</b>                                                    |           |                            |
| <i>acetic acid otic solution 2 %</i>                                  | 1         | MO                         |
| CIPRODEX OTIC SUSPENSION 0.3-0.1 %                                    | 4         | MO                         |
| <i>ciprofloxacin hcl otic solution 0.2 %</i>                          | 4         | MO                         |
| <i>ciprofloxacin-fluocinolone pf otic solution 0.3-0.025 %</i>        | 4         | MO                         |
| <i>fluocinolone acetonide otic oil 0.01 %</i>                         | 2         | MO                         |
| <i>neomycin-polymyxin-hc otic solution 1 %</i>                        | 2         | MO                         |
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i>              | 2         | MO                         |
| <i>ofloxacin otic solution 0.3 %</i>                                  | 4         | MO                         |
| <b>RESPIRATORY TRACT/ PULMONARY AGENTS</b>                            |           |                            |
| <b>Antihistamines</b>                                                 |           |                            |
| <i>azelastine hcl nasal solution 0.1 %, 0.15 %</i>                    | 2         | MO; QL (30 ML per 25 days) |
| <i>cetirizine hcl oral solution 1 mg/ml</i>                           | 1         | MO                         |
| <i>cyproheptadine hcl oral syrup 2 mg/5ml</i>                         | 4         | MO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                            | Drug Tier | Requirements/Limits          |
|------------------------------------------------------------------------------------------------------|-----------|------------------------------|
| <i>ciproheptadine hcl oral tablet 4 mg</i>                                                           | 4         | MO                           |
| <i>levocetirizine dihydrochloride oral solution 2.5 mg/5ml</i>                                       | 2         | MO                           |
| <i>levocetirizine dihydrochloride oral tablet 5 mg</i>                                               | 1         | MO                           |
| <b>Anti-Inflammatories, Inhaled Corticosteroids</b>                                                  |           |                              |
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT      | 3         | MO; QL (30 EA per 30 days)   |
| ASMANEX (120 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/INH                   | 3         | MO; QL (2 EA per 30 days)    |
| ASMANEX (30 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 110 MCG/INH, 220 MCG/INH       | 3         | MO; QL (2 EA per 30 days)    |
| ASMANEX (60 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/INH                    | 3         | MO; QL (2 EA per 30 days)    |
| ASMANEX HFA INHALATION AEROSOL 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT                                  | 3         | MO; QL (26 GM per 30 days)   |
| <i>budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml</i>                            | 4         | BvD; MO                      |
| FLOVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/BLIST, 250 MCG/BLIST, 50 MCG/BLIST | 3         | MO; QL (60 EA per 30 days)   |
| FLOVENT HFA INHALATION AEROSOL 110 MCG/ACT, 220 MCG/ACT                                              | 3         | MO; QL (24 GM per 30 days)   |
| FLOVENT HFA INHALATION AEROSOL 44 MCG/ACT                                                            | 3         | MO; QL (21.2 GM per 30 days) |
| <i>flunisolide nasal solution 25 mcg/act (0.025%)</i>                                                | 2         | MO; QL (50 ML per 30 days)   |
| <i>fluticasone propionate nasal suspension 50 mcg/act</i>                                            | 1         | MO; QL (16 GM per 30 days)   |
| <i>mometasone furoate nasal suspension 50 mcg/act</i>                                                | 2         | MO; QL (34 GM per 30 days)   |
| <b>Antileukotrienes</b>                                                                              |           |                              |
| <i>montelukast sodium oral packet 4 mg</i>                                                           | 2         | MO; QL (30 EA per 30 days)   |
| <i>montelukast sodium oral tablet 10 mg</i>                                                          | 1         | MO; QL (30 EA per 30 days)   |
| <i>montelukast sodium oral tablet chewable 4 mg, 5 mg</i>                                            | 1         | MO; QL (30 EA per 30 days)   |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                      | Drug Tier | Requirements/Limits          |
|----------------------------------------------------------------------------------------------------------------|-----------|------------------------------|
| zafirlukast oral tablet 10 mg, 20 mg                                                                           | 2         | MO; QL (60 EA per 30 days)   |
| <b>Bronchodilators, Anticholinergic</b>                                                                        |           |                              |
| ATROVENT HFA INHALATION AEROSOL SOLUTION 17 MCG/ACT                                                            | 4         | MO; QL (26 GM per 30 days)   |
| ipratropium bromide inhalation solution 0.02 %                                                                 | 2         | BvD; MO                      |
| ipratropium bromide nasal solution 0.03 %                                                                      | 2         | MO; QL (60 ML per 30 days)   |
| ipratropium bromide nasal solution 0.06 %                                                                      | 2         | MO; QL (30 ML per 30 days)   |
| SPIRIVA HANDIHALER INHALATION CAPSULE 18 MCG                                                                   | 3         | MO; QL (30 EA per 30 days)   |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT                                         | 3         | MO; QL (4 GM per 30 days)    |
| <b>Bronchodilators, Sympathomimetic</b>                                                                        |           |                              |
| albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act                                        | 2         | MO; QL (17 GM per 30 days)   |
| albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020503)                            | 2         | MO; QL (13.4 GM per 30 days) |
| albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020983)                            | 2         | MO; QL (36 GM per 30 days)   |
| albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml | 2         | BvD; MO                      |
| albuterol sulfate oral syrup 2 mg/5ml                                                                          | 2         | MO                           |
| albuterol sulfate oral tablet 2 mg, 4 mg                                                                       | 2         | MO                           |
| epinephrine injection solution 0.3 mg/0.3ml                                                                    | 2         | MO                           |
| epinephrine injection solution auto-injector 0.15 mg/0.15ml, 0.15 mg/0.3ml, 0.3 mg/0.3ml                       | 2         | MO                           |
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/DOSE                                         | 3         | MO; QL (60 EA per 30 days)   |
| terbutaline sulfate oral tablet 2.5 mg, 5 mg                                                                   | 4         | MO                           |
| VENTOLIN HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT                                                 | 3         | MO; QL (36 GM per 30 days)   |
| <b>Cystic Fibrosis Agents</b>                                                                                  |           |                              |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75 MG                                                                | 5         | PA; NMO                      |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                  | Drug Tier | Requirements/Limits             |
|----------------------------------------------------------------------------|-----------|---------------------------------|
| KALYDECO ORAL PACKET 25 MG, 50 MG, 75 MG                                   | 5         | PA; NMO                         |
| KALYDECO ORAL TABLET 150 MG                                                | 5         | PA; NMO                         |
| ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG                                 | 5         | PA; NMO                         |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG                                 | 5         | PA; NMO                         |
| PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML                                 | 5         | BvD; NMO                        |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150 MG, 50-75 & 75 MG           | 5         | PA; NMO                         |
| TOBI PODHALER INHALATION CAPSULE 28 MG                                     | 5         | PA; NMO                         |
| <i>tobramycin inhalation nebulization solution 300 mg/5ml</i>              | 5         | BvD; NMO                        |
| TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150 MG, 50-25-37.5 & 75 MG   | 5         | PA; NMO                         |
| <b>Phosphodiesterase Inhibitors, Airways Disease</b>                       |           |                                 |
| DALIRESP ORAL TABLET 250 MCG, 500 MCG                                      | 3         | MO; QL (30 EA per 30 days)      |
| <i>theophylline er oral tablet extended release 12 hour 300 mg, 450 mg</i> | 2         | MO                              |
| <i>theophylline er oral tablet extended release 24 hour 400 mg, 600 mg</i> | 2         | MO                              |
| <b>Pulmonary Antihypertensives</b>                                         |           |                                 |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG                     | 5         | PA; NMO; QL (90 EA per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i>                                 | 5         | PA; NMO; QL (30 EA per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i>                                | 5         | PA; NMO; QL (60 EA per 30 days) |
| OPSUMIT ORAL TABLET 10 MG                                                  | 5         | PA; NMO; QL (90 EA per 30 days) |
| <i>sildenafil citrate oral tablet 20 mg</i>                                | 2         | PA; MO; QL (90 EA per 30 days)  |
| <b>Pulmonary Fibrosis Agents</b>                                           |           |                                 |
| ESBRIET ORAL CAPSULE 267 MG                                                | 5         | PA; NMO                         |
| ESBRIET ORAL TABLET 267 MG, 801 MG                                         | 5         | PA; NMO                         |
| OFEV ORAL CAPSULE 100 MG, 150 MG                                           | 5         | PA; NMO                         |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                                                                  | Drug Tier | Requirements/Limits          |
|----------------------------------------------------------------------------------------------------------------------------|-----------|------------------------------|
| <b>Respiratory Tract Agents, Other</b>                                                                                     |           |                              |
| <i>acetylcysteine inhalation solution 10 %, 20 %</i>                                                                       | 2         | BvD; MO                      |
| ADVAIR DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE                 | 3         | MO; QL (60 EA per 30 days)   |
| ADVAIR HFA INHALATION AEROSOL 115-21 MCG/ACT, 230-21 MCG/ACT, 45-21 MCG/ACT                                                | 3         | MO; QL (12 GM per 30 days)   |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/INH                                                   | 3         | MO; QL (60 EA per 30 days)   |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/INH, 200-25 MCG/INH                                     | 3         | MO; QL (60 EA per 30 days)   |
| BREZTRI AEROSPHERE INHALATION AEROSOL 160-9-4.8 MCG/ACT                                                                    | 3         | MO; QL (10.7 GM per 30 days) |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100 MCG/ACT                                                              | 4         | MO; QL (4 GM per 20 days)    |
| <i>cromolyn sodium inhalation nebulization solution 20 mg/2ml</i>                                                          | 2         | BvD; MO                      |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 3         | MO; QL (60 EA per 30 days)   |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 113-14 mcg/act, 232-14 mcg/act, 55-14 mcg/act</i>     | 3         | MO; QL (1 EA per 30 days)    |
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i>                                                        | 2         | BvD; MO                      |
| NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML                                                                       | 5         | PA; NMO                      |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML                                                                   | 5         | PA; NMO                      |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 100 MG                                                                          | 5         | PA; NMO                      |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/INH, 200-62.5-25 MCG/INH                        | 3         | MO; QL (60 EA per 30 days)   |

## SKELETAL MUSCLE RELAXANTS

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

| Drug Name                                                                  | Drug Tier | Requirements/Limits              |
|----------------------------------------------------------------------------|-----------|----------------------------------|
| <b>Skeletal Muscle Relaxants</b>                                           |           |                                  |
| <i>chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg</i>                    | 2         | MO                               |
| <i>cyclobenzaprine hcl oral tablet 10 mg, 5 mg</i>                         | 1         | MO                               |
| <i>cyclobenzaprine hcl oral tablet 7.5 mg</i>                              | 4         | MO                               |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i>                            | 2         | MO                               |
| <i>orphenadrine citrate er oral tablet extended release 12 hour 100 mg</i> | 2         | MO                               |
| <b>SLEEP DISORDER AGENTS</b>                                               |           |                                  |
| <b>Sleep Promoting Agents</b>                                              |           |                                  |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG                             | 4         | MO; QL (30 EA per 30 days)       |
| <i>temazepam oral capsule 15 mg, 30 mg</i>                                 | 1         | MO; QL (30 EA per 30 days)       |
| <i>temazepam oral capsule 22.5 mg</i>                                      | 4         | MO; QL (30 EA per 30 days)       |
| <i>temazepam oral capsule 7.5 mg</i>                                       | 2         | MO; QL (120 EA per 30 days)      |
| <i>zaleplon oral capsule 10 mg, 5 mg</i>                                   | 2         | MO; QL (30 EA per 30 days)       |
| <i>zolpidem tartrate oral tablet 10 mg</i>                                 | 2         | MO; QL (30 EA per 30 days)       |
| <i>zolpidem tartrate oral tablet 5 mg</i>                                  | 2         | MO; QL (60 EA per 30 days)       |
| <b>Wakefulness Promoting Agents</b>                                        |           |                                  |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i>               | 3         | PA; MO; QL (30 EA per 30 days)   |
| <i>modafinil oral tablet 100 mg, 200 mg</i>                                | 4         | PA; MO; QL (60 EA per 30 days)   |
| SUNOSI ORAL TABLET 150 MG, 75 MG                                           | 4         | PA; MO; QL (30 EA per 30 days)   |
| XYREM ORAL SOLUTION 500 MG/ML                                              | 5         | PA; NMO; QL (540 ML per 30 days) |
| XYWAV ORAL SOLUTION 500 MG/ML                                              | 5         | PA; NMO; QL (540 ML per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 8 of the introduction. 2022 Alterwood Advantage Choice, Formulary ID 22473, Version 11, effective 05/01/2022.  
Last updated 04/18/2022.

## Index of Drugs/Alphabetical Listing

|                                          |        |  |
|------------------------------------------|--------|--|
| <b>A</b>                                 |        |  |
| abacavir sulfate.....                    | 47     |  |
| abacavir sulfate-lamivudine .            | 47     |  |
| abacavir-lamivudine-<br>zidovudine ..... | 47     |  |
| ABELCET.....                             | 28     |  |
| ABILIFY MAINTENA.....                    | 42     |  |
| abiraterone acetate.....                 | 32     |  |
| acamprosate calcium .....                | 13     |  |
| acarbose.....                            | 51     |  |
| ACCUTANE .....                           | 66     |  |
| acebutolol hcl .....                     | 58     |  |
| acetaminophen-codeine.....               | 12     |  |
| acetaminophen-codeine #3...              | 12     |  |
| acetazolamide .....                      | 95     |  |
| acetazolamide er.....                    | 95     |  |
| acetic acid.....                         | 96     |  |
| acetylcysteine .....                     | 100    |  |
| acitretin.....                           | 66     |  |
| ACTHIB.....                              | 89     |  |
| ACTIMMUNE .....                          | 87     |  |
| acyclovir .....                          | 46     |  |
| acyclovir sodium .....                   | 46     |  |
| ADACEL.....                              | 90     |  |
| adefovir dipivoxil .....                 | 45     |  |
| ADEMPAS.....                             | 99     |  |
| ADVAIR DISKUS.....                       | 100    |  |
| ADVAIR HFA .....                         | 100    |  |
| albendazole.....                         | 39     |  |
| albuterol sulfate .....                  | 98     |  |
| albuterol sulfate hfa.....               | 98     |  |
| alclometasone dipropionate..             | 67     |  |
| ALECENSA .....                           | 34     |  |
| alendronate sodium .....                 | 92     |  |
| alfuzosin hcl er .....                   | 77     |  |
| aliskiren fumarate.....                  | 60     |  |
| allopurinol .....                        | 30     |  |
| alosetron hcl .....                      | 74     |  |
| ALPHAGAN P.....                          | 95     |  |
| alprazolam .....                         | 50     |  |
| ALPRAZOLAM INTENSOL<br>.....             | 50     |  |
| ALTAVERA .....                           | 79     |  |
| ALUNBRIG .....                           | 34     |  |
| alyacen 1/35.....                        | 79     |  |
| amantadine hcl.....                      | 40     |  |
| AMBISOME .....                           | 28     |  |
| ambrisentan .....                        | 99     |  |
| amcinonide .....                         | 67     |  |
| amikacin sulfate.....                    | 14     |  |
| amiloride hcl.....                       | 62     |  |
| amiloride-hydrochlorothiazide<br>.....   | 60     |  |
| amiodarone hcl .....                     | 57     |  |
| amitriptyline hcl .....                  | 27     |  |
| amlodipine besy-benazepril hcl<br>.....  | 60     |  |
| amlodipine besylate.....                 | 58     |  |
| amlodipine besylate-valsartan<br>.....   | 60     |  |
| amlodipine-atorvastatin .....            | 60     |  |
| amlodipine-olmesartan .....              | 60     |  |
| ammonium lactate .....                   | 67     |  |
| AMNESTEEM.....                           | 66     |  |
| amoxapine .....                          | 27     |  |
| amoxicillin.....                         | 17     |  |
| amoxicillin-pot clavulanate .17,<br>18   |        |  |
| amoxicillin-pot clavulanate er<br>.....  | 17     |  |
| amphetamine-<br>dextroamphetamine .....  | 64     |  |
| amphotericin b.....                      | 28     |  |
| ampicillin.....                          | 18     |  |
| ampicillin sodium .....                  | 18     |  |
| ampicillin-sulbactam sodium              | 18     |  |
| anagrelide hcl .....                     | 55     |  |
| anastrozole.....                         | 34     |  |
| ANDRODERM .....                          | 78     |  |
| ANORO ELLIPTA.....                       | 100    |  |
| apraclonidine hcl .....                  | 95     |  |
| aprepitant.....                          | 28     |  |
| APRI.....                                | 79     |  |
| APTIOM.....                              | 23     |  |
| APTIVUS .....                            | 48     |  |
| ARANELLE.....                            | 79     |  |
| ARCALYST.....                            | 86     |  |
| ARIKAYCE .....                           | 14     |  |
| aripiprazole.....                        | 42     |  |
| armodafinil .....                        | 101    |  |
| ARNUITY ELLIPTA.....                     | 97     |  |
| asenapine maleate.....                   | 42     |  |
| ASMANEX (120 METERED<br>DOSES).....      | 97     |  |
| ASMANEX (30 METERED<br>DOSES).....       | 97     |  |
| ASMANEX (60 METERED<br>DOSES).....       | 97     |  |
| ASMANEX HFA .....                        | 97     |  |
| aspirin-dipyridamole er .....            | 56     |  |
| ASSURE ID INSULIN<br>SAFETY SYR .....    | 52     |  |
| atazanavir sulfate .....                 | 48     |  |
| atenolol .....                           | 58     |  |
| atenolol-chlorthalidone.....             | 60     |  |
| atomoxetine hcl .....                    | 64     |  |
| atorvastatin calcium.....                | 62     |  |
| atovaquone.....                          | 39     |  |
| atovaquone-proguanil hcl .....           | 39     |  |
| atropine sulfate .....                   | 93     |  |
| ATROVENT HFA.....                        | 98     |  |
| AUBRA EQ.....                            | 79     |  |
| AURYXIA.....                             | 73     |  |
| AUSTEDO .....                            | 65     |  |
| AVIANE.....                              | 79     |  |
| AVONEX PEN.....                          | 65     |  |
| AVONEX PREFILLED .....                   | 65     |  |
| AYVAKIT .....                            | 35     |  |
| AZACTAM .....                            | 15     |  |
| AZASAN.....                              | 87     |  |
| AZASITE .....                            | 94     |  |
| azathioprine .....                       | 87     |  |
| azelastine hcl .....                     | 94, 96 |  |
| azithromycin .....                       | 19     |  |
| AZOPT .....                              | 95     |  |
| aztreonam .....                          | 15     |  |
| <b>B</b>                                 |        |  |
| bacitracin .....                         | 94     |  |
| bacitracin-polymyxin b.....              | 94     |  |
| bacitra-neomycin-polymyxin-<br>hc .....  | 93     |  |
| baclofen .....                           | 45     |  |
| balsalazide disodium .....               | 92     |  |
| BALVERSA .....                           | 35     |  |
| BALZIVA.....                             | 79     |  |
| BAQSIMI ONE PACK .....                   | 52     |  |
| BARACLUDE.....                           | 45     |  |
| bcg vaccine .....                        | 90     |  |
| BELSOMRA .....                           | 101    |  |
| benazepril hcl.....                      | 57     |  |

|                                      |        |                                 |    |                                 |        |
|--------------------------------------|--------|---------------------------------|----|---------------------------------|--------|
| benazepril-hydrochlorothiazide ..... | 60     | bupropion hcl er (sr) .....     | 25 | ceftazidime .....               | 17     |
| BENLYSTA .....                       | 88     | bupropion hcl er (xl) .....     | 25 | ceftriaxone sodium .....        | 17     |
| benznidazole .....                   | 40     | buspirone hcl .....             | 49 | cefuroxime axetil .....         | 17     |
| benzoyl peroxide-erythromycin .....  | 66     | butalbital-apap-caffeine .....  | 11 | cefuroxime sodium .....         | 17     |
| benztropine mesylate .....           | 40     | butalbital-asa-caff-codeine ... | 11 | celecoxib .....                 | 11     |
| BESREMI .....                        | 87     | butalbital-aspirin-caffeine ... | 11 | CELONTIN .....                  | 22     |
| betamethasone dipropionate .         | 67     | BYLVAY .....                    | 74 | cephalexin .....                | 17     |
| betamethasone dipropionate           |        | BYLVAY (PELLETS) .....          | 74 | cetirizine hcl .....            | 96     |
| aug .....                            | 67     | <b>C</b>                        |    | CHANTIX CONTINUING              |        |
| betamethasone valerate .....         | 67     | cabergoline .....               | 85 | MONTH PAK .....                 | 14     |
| BETASERON .....                      | 65     | CABLIVI .....                   | 56 | CHANTIX STARTING                |        |
| betaxolol hcl .....                  | 58, 95 | CABOMETYX .....                 | 35 | MONTH PAK .....                 | 14     |
| bethanechol chloride .....           | 77     | calcipotriene .....             | 69 | chlordiazepoxide hcl .....      | 50     |
| bexarotene .....                     | 39     | calcitonin (salmon) .....       | 92 | chlorhexidine gluconate .....   | 66     |
| BEXSERO .....                        | 90     | calcitriol .....                | 92 | chloroquine phosphate .....     | 40     |
| bicalutamide .....                   | 32     | calcium acetate .....           | 73 | chlorpromazine hcl .....        | 41     |
| BICILLIN L-A .....                   | 18     | calcium acetate (phos binder)   |    | chlorthalidone .....            | 62     |
| BIDIL .....                          | 60     | .....                           | 73 | chlorzoxazone .....             | 101    |
| BIKTARVY .....                       | 46     | CALQUENCE .....                 | 35 | cholestyramine .....            | 63     |
| bisoprolol fumarate .....            | 58     | CAMILA .....                    | 83 | cholestyramine light .....      | 63     |
| bisoprolol-hydrochlorothiazide       |        | candesartan cilexetil .....     | 56 | ciclopirox .....                | 70     |
| .....                                | 60     | candesartan cilexetil-hctz .... | 60 | ciclopirox olamine .....        | 29     |
| BLISOVI FE 1.5/30 .....              | 80     | CAPLYTA .....                   | 42 | cilostazol .....                | 56     |
| BOOSTRIX .....                       | 90     | CAPRELSA .....                  | 35 | CIMDUO .....                    | 47     |
| bosentan .....                       | 99     | captopril .....                 | 57 | cinacalcet hcl .....            | 92     |
| BOSULIF .....                        | 35     | carbamazepine .....             | 23 | CINRYZE .....                   | 86     |
| BRAFTOVI .....                       | 35     | carbamazepine er .....          | 23 | CIPRODEX .....                  | 96     |
| BREO ELLIPTA .....                   | 100    | carbidopa .....                 | 41 | ciprofloxacin hcl .....         | 20, 96 |
| BREZTRI AEROSPHERE                   | 100    | carbidopa-levodopa .....        | 41 | ciprofloxacin in d5w .....      | 20     |
| briellyn .....                       | 80     | carbidopa-levodopa er .....     | 41 | ciprofloxacin-fluocinolone pf   |        |
| BRILINTA .....                       | 56     | carbidopa-levodopa-             |    | .....                           | 96     |
| brimonidine tartrate .....           | 95     | entacapone .....                | 40 | citalopram hydrobromide         | 25, 26 |
| brimonidine tartrate-timolol .       | 95     | carglumic acid .....            | 70 | CLARAVIS .....                  | 66     |
| BRIVIACT .....                       | 21     | carteolol hcl .....             | 95 | clarithromycin .....            | 19     |
| bromfenac sodium (once-daily)        |        | CARTIA XT .....                 | 59 | clarithromycin er .....         | 19     |
| .....                                | 94     | carvedilol .....                | 58 | CLENPIQ .....                   | 74     |
| bromocriptine mesylate .....         | 40     | caspofungin acetate .....       | 28 | clindamycin hcl .....           | 15     |
| BROMSITE .....                       | 94     | CAYSTON .....                   | 98 | clindamycin palmitate hcl ..... | 15     |
| BRUKINSA .....                       | 35     | CAZIENT .....                   | 80 | clindamycin phos-benzoyl        |        |
| budesonide .....                     | 92, 97 | cefaclor .....                  | 16 | perox .....                     | 66     |
| budesonide er .....                  | 92     | cefaclor er .....               | 16 | clindamycin phosphate ...       | 15, 70 |
| bumetanide .....                     | 61     | cefadroxil .....                | 16 | clindamycin phosphate in d5w    |        |
| buprenorphine hcl .....              | 13     | cefazolin sodium .....          | 16 | .....                           | 15     |
| buprenorphine hcl-naloxone           |        | cefdinir .....                  | 16 | CLINIMIX E/DEXTROSE             |        |
| hcl .....                            | 13     | cefepime hcl .....              | 16 | (2.75/5) .....                  | 72     |
| bupropion hcl .....                  | 25     | cefixime .....                  | 16 | CLINIMIX E/DEXTROSE             |        |
| bupropion hcl er (smoking det)       |        | cefotetan disodium .....        | 16 | (4.25/10) .....                 | 72     |
| .....                                | 14     | cefoxitin sodium .....          | 16 | CLINIMIX E/DEXTROSE             |        |
|                                      |        | cefpodoxime proxetil .....      | 17 | (4.25/5) .....                  | 72     |
|                                      |        | cefprozil .....                 | 17 |                                 |        |



|                                      |    |                                |             |                                |            |
|--------------------------------------|----|--------------------------------|-------------|--------------------------------|------------|
| CLINIMIX E/DEXTROSE<br>(5/15) .....  | 72 | COTELLIC.....                  | 35          | diazoxide.....                 | 52         |
| CLINIMIX E/DEXTROSE<br>(5/20) .....  | 72 | CREON .....                    | 75          | diclofenac potassium .....     | 11         |
| CLINIMIX/DEXTROSE<br>(4.25/10) ..... | 72 | cromolyn sodium....            | 75, 94, 100 | diclofenac sodium....          | 11, 69, 95 |
| CLINIMIX/DEXTROSE<br>(4.25/5) .....  | 72 | CRYSSELLE-28 .....             | 80          | diclofenac sodium er.....      | 11         |
| CLINIMIX/DEXTROSE<br>(5/15) .....    | 72 | cvs gauze sterile.....         | 53          | dicloxacillin sodium .....     | 18         |
| CLINIMIX/DEXTROSE<br>(5/20) .....    | 72 | cyclobenzaprine hcl.....       | 101         | dicyclomine hcl .....          | 74         |
| clobazam.....                        | 22 | cyclophosphamide .....         | 32          | diflunisal .....               | 11         |
| clobetasol propionate.....           | 67 | cyclosporine.....              | 88          | DIGITEK .....                  | 60         |
| clobetasol propionate e.....         | 67 | cyclosporine modified .....    | 88          | DIGOX .....                    | 60         |
| clomipramine hcl.....                | 27 | cyproheptadine hcl .....       | 96, 97      | digoxin .....                  | 60         |
| clonazepam.....                      | 50 | CYRED EQ.....                  | 80          | dihydroergotamine mesylate     | 30         |
| clonidine .....                      | 56 | CYSTADANE.....                 | 75          | DILANTIN .....                 | 23         |
| clonidine hcl .....                  | 56 | CYSTADROPS .....               | 93          | diltiazem hcl .....            | 59         |
| clopidogrel bisulfate .....          | 56 | CYSTAGON .....                 | 75          | diltiazem hcl er .....         | 59         |
| clorazepate dipotassium .....        | 50 | CYSTARAN .....                 | 93          | diltiazem hcl er beads .....   | 59         |
| clotrimazole .....                   | 29 | <b>D</b>                       |             | diltiazem hcl er coated beads  | 59         |
| clotrimazole-betamethasone.          | 69 | dalfampridine er .....         | 65          | dilt-xr .....                  | 59         |
| clozapine.....                       | 45 | DALIRESP .....                 | 99          | dimethyl fumarate.....         | 65         |
| COARTEM .....                        | 40 | danazol.....                   | 78          | dimethyl fumarate starter pack |            |
| codeine sulfate.....                 | 12 | dapsone .....                  | 31          | .....                          | 66         |
| colchicine .....                     | 30 | DAPTACEL .....                 | 90          | diphenoxylate-atropine .....   | 74         |
| colchicine-probenecid .....          | 30 | daptomycin .....               | 15          | diphtheria-tetanus toxoids dt  | 90         |
| colestipol hcl .....                 | 63 | darifenacin hydrobromide er    | 76          | disopyramide phosphate .....   | 57         |
| colistimethate sodium (cba) .        | 15 | DAURISMO.....                  | 35          | disulfiram.....                | 13         |
| COMBIGAN .....                       | 95 | DEBLITANE.....                 | 84          | divalproex sodium .....        | 50         |
| COMBIVENT RESPIMAT100                |    | deferasirox .....              | 71          | divalproex sodium er .....     | 50         |
| COMETRIQ (100 MG DAILY               |    | deferasirox granules .....     | 71          | dofetilide.....                | 57         |
| DOSE) .....                          | 35 | deferiprone.....               | 71          | DOJOLVI .....                  | 72         |
| COMETRIQ (140 MG DAILY               |    | DELSTRIGO.....                 | 47          | donepezil hcl.....             | 24         |
| DOSE) .....                          | 35 | DESCOVY .....                  | 47          | dorzolamide hcl .....          | 96         |
| COMETRIQ (60 MG DAILY                |    | desipramine hcl.....           | 27          | dorzolamide hcl-timolol mal    | 96         |
| DOSE) .....                          | 35 | desmopressin acetate .....     | 78          | dorzolamide hcl-timolol mal pf |            |
| COMFORT ASSIST INSULIN               |    | desmopressin acetate spray ..  | 78          | .....                          | 96         |
| SYRINGE.....                         | 52 | desogestrel-ethinyl estradiol. | 80          | DOVATO .....                   | 46         |
| COMPLERA .....                       | 46 | desonide.....                  | 67          | doxazosin mesylate.....        | 56         |
| constulose .....                     | 73 | desoximetasone .....           | 67, 68      | doxepin hcl .....              | 27         |
| COPAXONE .....                       | 65 | desvenlafaxine er.....         | 26          | DOXY 100.....                  | 20         |
| COPIKTRA.....                        | 35 | desvenlafaxine succinate er..  | 26          | doxycycline hyclate .....      | 20         |
| CORLANOR.....                        | 60 | dexamethasone .....            | 77          | doxycycline monohydrate ....   | 20         |
| COSENTYX.....                        | 86 | dexamethasone sodium           |             | DRIZALMA SPRINKLE .....        | 26         |
| COSENTYX (300 MG DOSE)               |    | phosphate.....                 | 94          | dronabinol.....                | 28         |
| .....                                | 86 | DEXILANT.....                  | 75          | drospirenone-ethinyl estradiol |            |
| COSENTYX SENSOREADY                  |    | dexmethylphenidate hcl.....    | 64          | .....                          | 80         |
| (300 MG).....                        | 86 | dextroamphetamine sulfate..    | 64          | DROXIA.....                    | 33         |
|                                      |    | dextroamphetamine sulfate er   |             | droxidopa .....                | 56         |
|                                      |    | .....                          | 64          | DUAVEE.....                    | 79         |
|                                      |    | dextrose .....                 | 72          | duloxetine hcl .....           | 26         |
|                                      |    | dextrose-nacl .....            | 72          | DUPIXENT .....                 | 86         |
|                                      |    | DIACOMIT .....                 | 21          | DUREZOL .....                  | 95         |
|                                      |    | diazepam.....                  | 22, 50      | dutasteride.....               | 77         |

|                                 |    |                                     |            |                                 |        |
|---------------------------------|----|-------------------------------------|------------|---------------------------------|--------|
| dutasteride-tamsulosin hcl....  | 77 | erlotinib hcl.....                  | 35         | FIASP .....                     | 53     |
| <b>E</b>                        |    | ERRIN .....                         | 84         | FIASP FLEXTOUCH .....           | 53     |
| econazole nitrate.....          | 29 | ertapenem sodium.....               | 19         | FIASP PENFILL .....             | 53     |
| EDURANT.....                    | 46 | ery .....                           | 70         | finasteride .....               | 77     |
| efavirenz .....                 | 46 | ERYTHROCIN                          |            | FINTEPLA .....                  | 21     |
| efavirenz-emtricitab-tenofovir  |    | LACTOBIONATE .....                  | 19         | FIRAZYR.....                    | 86     |
| .....                           | 47 | erythromycin .....                  | 19, 70, 94 | FIRVANQ .....                   | 15     |
| efavirenz-lamivudine-tenofovir  |    | erythromycin base .....             | 19         | flecainide acetate .....        | 57     |
| .....                           | 47 | erythromycin ethylsuccinate.....    | 19         | FLOVENT DISKUS .....            | 97     |
| ELIGARD .....                   | 85 | ESBRIET.....                        | 99         | FLOVENT HFA.....                | 97     |
| ELIQUIS .....                   | 54 | escitalopram oxalate .....          | 26         | fluconazole .....               | 29     |
| ELIQUIS DVT/PE STARTER          |    | esomeprazole magnesium.....         | 75         | fluconazole in sodium chloride  |        |
| PACK .....                      | 54 | ESTARYLLA.....                      | 80         | .....                           | 29     |
| ELMIRON.....                    | 77 | estradiol .....                     | 79         | flucytosine .....               | 29     |
| ELURYNG.....                    | 80 | ethambutol hcl .....                | 32         | fludrocortisone acetate.....    | 77     |
| EMCYT .....                     | 33 | ethosuximide .....                  | 22         | flunisolide .....               | 97     |
| EMGALITY .....                  | 30 | ethynodiol diac-eth estradiol ..    | 80         | fluocinolone acetonide....      | 68, 96 |
| EMOQUETTE .....                 | 80 | etodolac .....                      | 11         | fluocinonide .....              | 68     |
| EMSAM .....                     | 25 | etonogestrel-ethinyl estradiol..... | 80         | fluocinonide emulsified base .. | 68     |
| emtricitabine.....              | 47 | etravirine.....                     | 47         | fluorometholone .....           | 95     |
| emtricitabine-tenofovir df .... | 47 | EUCRISA.....                        | 68         | FLUOROPLEX .....                | 69     |
| EMTRIVA.....                    | 47 | EUTHYROX .....                      | 84         | fluorouracil .....              | 69     |
| EMVERM .....                    | 39 | everolimus .....                    | 35, 88     | fluoxetine hcl .....            | 26     |
| enalapril maleate .....         | 57 | EVOTAZ.....                         | 48         | fluphenazine decanoate .....    | 41     |
| enalapril-hydrochlorothiazide   |    | EVRYSDI.....                        | 65         | fluphenazine hcl.....           | 41, 42 |
| .....                           | 60 | EXEL COMFORT POINT                  |            | flurbiprofen.....               | 11     |
| ENBREL .....                    | 88 | PEN NEEDLE.....                     | 53         | flurbiprofen sodium .....       | 95     |
| ENBREL MINI .....               | 88 | exemestane .....                    | 34         | flutamide.....                  | 32     |
| ENBREL SURECLICK .....          | 88 | EXKIVITY .....                      | 35         | fluticasone propionate ....     | 68, 97 |
| ENDARI.....                     | 75 | ezetimibe .....                     | 63         | fluticasone-salmeterol.....     | 100    |
| ENGERIX-B .....                 | 90 | <b>F</b>                            |            | fluvoxamine maleate .....       | 26     |
| enoxaparin sodium .....         | 54 | FALMINA.....                        | 80         | fondaparinux sodium .....       | 54, 55 |
| ENPRESSE-28.....                | 80 | famciclovir.....                    | 46         | fosamprenavir calcium .....     | 48     |
| ENSKYCE .....                   | 80 | famotidine.....                     | 75         | fosinopril sodium.....          | 57     |
| ENSPRYNG.....                   | 88 | FANAPT .....                        | 42, 43     | fosinopril sodium-hctz.....     | 61     |
| entacapone.....                 | 40 | FANAPT TITRATION PACK               |            | FOTIVDA.....                    | 35     |
| entecavir .....                 | 45 | .....                               | 43         | furosemide .....                | 62     |
| ENTRESTO .....                  | 60 | FARYDAK.....                        | 35         | FUZEON .....                    | 48     |
| enulose.....                    | 73 | febuxostat .....                    | 30         | FYCOMPA.....                    | 21     |
| ENVARUSUS XR .....              | 88 | felbamate .....                     | 21         | <b>G</b>                        |        |
| EPIDIOLEX.....                  | 21 | felodipine er.....                  | 58         | gabapentin.....                 | 22, 23 |
| epinephrine .....               | 98 | FEMYNOR .....                       | 80         | GALAFOLD.....                   | 75     |
| EPITOL .....                    | 23 | fenofibrate .....                   | 62         | galantamine hydrobromide....    | 24     |
| EPIVIR HBV.....                 | 45 | fenofibrate micronized .....        | 62         | galantamine hydrobromide er     |        |
| eplerenone .....                | 62 | fenofibric acid.....                | 62         | .....                           | 24     |
| EPRONTIA .....                  | 30 | fentanyl.....                       | 12         | GARDASIL 9.....                 | 90     |
| ERAXIS .....                    | 29 | fentanyl citrate.....               | 12         | gatifloxacin .....              | 94     |
| ergotamine-caffeine.....        | 30 | FERRIPROX .....                     | 71         | GATTEX .....                    | 74     |
| ERIVEDGE .....                  | 35 | FETZIMA.....                        | 26         | GAVILYTE-C .....                | 74     |
| ERLEADA .....                   | 32 | FETZIMA TITRATION .....             | 26         | GAVILYTE-G.....                 | 74     |

|                                         |        |                                       |            |                                         |     |
|-----------------------------------------|--------|---------------------------------------|------------|-----------------------------------------|-----|
| GAVILYTE-N WITH<br>FLAVOR PACK .....    | 74     | hydrocortisone .....                  | 68, 77, 92 | INVOKAMET XR .....                      | 51  |
| GAVRETO .....                           | 35     | hydrocortisone (perianal) .....       | 68         | INVOKANA .....                          | 51  |
| gemfibrozil .....                       | 62     | hydrocortisone ace-pramoxine<br>..... | 69         | I POL .....                             | 90  |
| generlac .....                          | 73     | hydrocortisone valerate .....         | 68         | ipratropium bromide .....               | 98  |
| GENGRAF .....                           | 88     | hydromorphone hcl .....               | 12, 13     | ipratropium-albuterol .....             | 100 |
| GENTAK .....                            | 94     | hydroxychloroquine sulfate ..         | 40         | irbesartan .....                        | 56  |
| gentamicin in saline .....              | 14     | hydroxyurea .....                     | 33         | irbesartan-hydrochlorothiazide<br>..... | 61  |
| gentamicin sulfate .....                | 14, 94 | hydroxyzine hcl .....                 | 49         | IRESSA .....                            | 36  |
| GENVOYA .....                           | 46     | hydroxyzine pamoate .....             | 49         | ISENTRESS .....                         | 46  |
| GILENYA .....                           | 66     | <b>I</b>                              |            | ISENTRESS HD .....                      | 46  |
| GILOTRIF .....                          | 36     | ibandronate sodium .....              | 92         | ISIBLOOM .....                          | 80  |
| glimepiride .....                       | 51     | IBRANCE .....                         | 36         | ISOLYTE-P IN D5W .....                  | 72  |
| glipizide .....                         | 51     | IBU .....                             | 11         | ISOLYTE-S PH 7.4 .....                  | 70  |
| glipizide er .....                      | 51     | ibuprofen .....                       | 11         | isoniazid .....                         | 32  |
| glipizide-metformin hcl .....           | 51     | icatibant acetate .....               | 86         | isosorbide dinitrate .....              | 63  |
| global alcohol prep ease .....          | 69     | ICLEVIA .....                         | 80         | isosorbide mononitrate .....            | 64  |
| GLUCAGEN HYPOKIT .....                  | 52     | ICLUSIG .....                         | 36         | isosorbide mononitrate er .....         | 63  |
| glucagon emergency .....                | 52     | IDHIFA .....                          | 33         | isotretinoin .....                      | 66  |
| glyburide-metformin .....               | 51     | ILEVRO .....                          | 95         | isradipine .....                        | 58  |
| glycopyrrolate .....                    | 74     | imatinib mesylate .....               | 36         | ISTURISA .....                          | 77  |
| granisetron hcl .....                   | 28     | IMBRUVICA .....                       | 36         | itraconazole .....                      | 29  |
| griseofulvin microsize .....            | 29     | imipenem-cilastatin .....             | 19         | ivermectin .....                        | 39  |
| griseofulvin ultramicrosize ..          | 29     | imipramine hcl .....                  | 27         | IXIARO .....                            | 90  |
| guanfacine hcl .....                    | 56     | imiquimod .....                       | 69         | <b>J</b>                                |     |
| guanfacine hcl er .....                 | 64     | IMOVAX RABIES .....                   | 90         | JAKAFI .....                            | 36  |
| <b>H</b>                                |        | IMVEXXY MAINTENANCE<br>PACK .....     | 79         | JANTOVEN .....                          | 55  |
| halobetasol propionate .....            | 68     | IMVEXXY STARTER PACK<br>.....         | 79         | JANUMET .....                           | 51  |
| haloperidol .....                       | 42     | INBRIJA .....                         | 41         | JANUMET XR .....                        | 51  |
| haloperidol decanoate .....             | 42     | INCASSIA .....                        | 84         | JANUVIA .....                           | 51  |
| haloperidol lactate .....               | 42     | INCRELEX .....                        | 78         | JARDIANCE .....                         | 51  |
| HAVRIX .....                            | 90     | indapamide .....                      | 62         | JASMIEL .....                           | 80  |
| heparin sodium (porcine) .....          | 55     | indomethacin .....                    | 11         | JUBLIA .....                            | 29  |
| HIBERIX .....                           | 90     | indomethacin er .....                 | 11         | JULEBER .....                           | 80  |
| HUMIRA .....                            | 89     | INFANRIX .....                        | 90         | JULUCA .....                            | 47  |
| HUMIRA PEDIATRIC<br>CROHNS START .....  | 88     | INLYTA .....                          | 36         | JUNEL 1.5/30 .....                      | 80  |
| HUMIRA PEN .....                        | 88     | INQOVI .....                          | 33         | JUNEL 1/20 .....                        | 81  |
| HUMIRA PEN-CD/UC/HS<br>STARTER .....    | 88     | INREBIC .....                         | 36         | JUNEL FE 1.5/30 .....                   | 81  |
| HUMIRA PEN-PEDIATRIC<br>UC START .....  | 89     | INTELENCE .....                       | 47         | JUNEL FE 1/20 .....                     | 81  |
| HUMIRA PEN-PS/UV/ADOL<br>HS START ..... | 89     | INTRALIPID .....                      | 72         | JUXTAPID .....                          | 63  |
| HUMIRA PEN-PSOR/UVEIT<br>STARTER .....  | 89     | INTRAROSA .....                       | 80         | <b>K</b>                                |     |
| hydralazine hcl .....                   | 63     | INTRON A .....                        | 87         | KALYDECO .....                          | 99  |
| hydrochlorothiazide .....               | 62     | INTROVALE .....                       | 80         | KARIVA .....                            | 81  |
| hydrocodone-acetaminophen               | 12     | INVEGA HAFYERA .....                  | 43         | KATERZIA .....                          | 58  |
| hydrocodone-ibuprofen .....             | 12     | INVEGA SUSTENNA .....                 | 43         | kcl in dextrose-nacl .....              | 70  |
|                                         |        | INVEGA TRINZA .....                   | 43         | kcl-lactated ringers-d5w .....          | 70  |
|                                         |        | INVIRASE .....                        | 48         | KELNOR 1/35 .....                       | 81  |
|                                         |        | INVOKAMET .....                       | 51         | KELNOR 1/50 .....                       | 81  |
|                                         |        |                                       |            | KESIMPTA .....                          | 66  |
|                                         |        |                                       |            | ketoconazole .....                      | 29  |

|                                        |                                        |                                 |
|----------------------------------------|----------------------------------------|---------------------------------|
| ketorolac tromethamine.. 11, 95        | LENVIMA (14 MG DAILY DOSE) .....36     | lithium carbonate .....50       |
| KINRIX .....90                         | LENVIMA (18 MG DAILY DOSE) .....37     | lithium carbonate er .....50    |
| KISQALI (200 MG DOSE) .36              | LENVIMA (20 MG DAILY DOSE) .....37     | LIVALO .....62                  |
| KISQALI (400 MG DOSE) .36              | LENVIMA (24 MG DAILY DOSE) .....37     | LIVMARLI.....74                 |
| KISQALI (600 MG DOSE) .36              | LENVIMA (4 MG DAILY DOSE) .....37      | LIVTENCITY .....45              |
| KISQALI FEMARA (400 MG DOSE) .....33   | LENVIMA (8 MG DAILY DOSE) .....37      | LOKELMA.....72                  |
| KISQALI FEMARA (600 MG DOSE) .....33   | LESSINA.....81                         | LONSURF .....33                 |
| KISQALI FEMARA(200 MG DOSE) .....33    | letrozole .....34                      | loperamide hcl .....74          |
| KLOR-CON .....70                       | leucovorin calcium .....33             | lopinavir-ritonavir.....48      |
| KLOR-CON 10 .....70                    | LEUKERAN .....32                       | lorazepam .....50               |
| KLOR-CON M10.....70                    | LEUKINE.....55                         | LORAZEPAM INTENSOL .50          |
| KLOR-CON M15.....70                    | leuprolide acetate.....85              | LORBRENA.....37                 |
| KLOR-CON M20.....70                    | LEVEMIR .....53                        | LORYNA .....81                  |
| KLOXXADO .....14                       | LEVEMIR FLEXTOUCH ...53                | losartan potassium .....56      |
| KORLYM.....52                          | levetiracetam .....22                  | losartan potassium-hctz .....61 |
| KOSELUGO .....36                       | levetiracetam er .....21               | loteprednol etabonate.....95    |
| KURVELO.....81                         | levobunolol hcl .....95                | lovastatin.....62, 63           |
| KYNMOBI.....41                         | levocarnitine .....72, 73              | LOW-OGESTREL .....81            |
| <b>L</b>                               | levocetirizine dihydrochloride .....97 | loxapine succinate .....42      |
| labetalol hcl .....58                  | levofloxacin .....20                   | lubiprostone .....73            |
| lactulose.....73                       | levofloxacin in d5w .....20            | LUMAKRAS.....37                 |
| lamivudine .....45, 47                 | LEVONEST .....81                       | LUMIGAN .....96                 |
| lamivudine-zidovudine.....47           | levonorgest-eth estrad 91-day .....81  | LUPKYNIS .....89                |
| lamotrigine .....21                    | levonorgestrel-ethinyl estrad 81       | LUPRON DEPOT (1-MONTH) .....85  |
| lamotrigine er .....21                 | levonorg-eth estrad triphasic 81       | LUPRON DEPOT (3-MONTH) .....85  |
| lamotrigine starter kit-blue...21      | LEVORA 0.15/30 (28).....81             | LUPRON DEPOT (4-MONTH) .....85  |
| lamotrigine starter kit-green .21      | LEVO-T.....84                          | LUPRON DEPOT (6-MONTH) .....85  |
| lamotrigine starter kit-orange .....21 | levothyroxine sodium .....84           | LUTERA .....81                  |
| LAMPIT .....40                         | LEVOXYL .....84                        | LYBALVI.....43                  |
| lansoprazole.....75                    | LEXIVA .....48                         | LYLEQ.....84                    |
| LANTUS .....53                         | LIALDA .....92                         | LYNPARZA.....33, 34             |
| LANTUS SOLOSTAR .....53                | lidocaine .....13                      | LYSODREN.....32                 |
| lapatinib ditosylate .....36           | lidocaine hcl .....13                  | LYZA .....84                    |
| LARIN 1.5/30.....81                    | lidocaine viscous hcl .....13          | <b>M</b>                        |
| LARIN 1/20.....81                      | lidocaine-prilocaine .....13           | magnesium sulfate .....70       |
| LARIN FE 1.5/30.....81                 | linezolid.....15                       | malathion .....69               |
| LARIN FE 1/20.....81                   | LINZESS .....73                        | maraviroc .....48               |
| LARISSIA .....81                       | liothyronine sodium.....85             | marlissa.....81                 |
| latanoprost .....96                    | lisinopril.....57                      | MARPLAN.....25                  |
| LATUDA .....43                         | lisinopril-hydrochlorothiazide .....61 | MATULANE.....32                 |
| LEENA.....81                           | lithium .....50                        | MAVYRET .....45                 |
| leflunomide.....86                     |                                        | MAYZENT.....66                  |
| LENVIMA (10 MG DAILY DOSE) .....36     |                                        | MAYZENT STARTER PACK .....66    |
| LENVIMA (12 MG DAILY DOSE) .....36     |                                        | meclizine hcl.....28            |

|                                         |     |                                         |        |                                         |    |
|-----------------------------------------|-----|-----------------------------------------|--------|-----------------------------------------|----|
| medroxyprogesterone acetate .....       | 84  | minoxidil .....                         | 64     | NEUPRO .....                            | 41 |
| mefloquine hcl .....                    | 40  | mirtazapine .....                       | 25     | nevirapine .....                        | 47 |
| megestrol acetate .....                 | 84  | misoprostol .....                       | 75     | nevirapine er .....                     | 47 |
| MEKINIST .....                          | 37  | MITIGARE .....                          | 30     | NEXAVAR.....                            | 37 |
| MEKTOVI .....                           | 37  | M-M-R II.....                           | 91     | niacin er (antihyperlipidemic)<br>..... | 63 |
| meloxicam .....                         | 11  | modafinil .....                         | 101    | nicardipine hcl .....                   | 59 |
| memantine hcl .....                     | 24  | moexipril hcl.....                      | 57     | NICOTROL .....                          | 14 |
| memantine hcl er .....                  | 24  | molindone hcl .....                     | 42     | nifedipine .....                        | 59 |
| MENACTRA .....                          | 90  | mometasone furoate .....                | 68, 97 | nifedipine er .....                     | 59 |
| MENEST .....                            | 79  | montelukast sodium.....                 | 97     | nifedipine er osmotic release           | 59 |
| MENQUADFI.....                          | 90  | morphine sulfate .....                  | 13     | NIKKI.....                              | 82 |
| MENVEO.....                             | 90  | morphine sulfate (concentrate)<br>..... | 13     | nilutamide .....                        | 32 |
| mercaptopurine.....                     | 33  | morphine sulfate er .....               | 12     | NINLARO .....                           | 34 |
| meropenem .....                         | 19  | MOVANTIK .....                          | 73     | nitazoxanide.....                       | 40 |
| mesalamine.....                         | 92  | moxifloxacin hcl.....                   | 20, 94 | nitisinone .....                        | 76 |
| mesalamine er.....                      | 92  | moxifloxacin hcl in nacl .....          | 20     | NITRO-BID.....                          | 64 |
| MESNEX .....                            | 34  | MULTAQ.....                             | 57     | nitrofurantoin macrocrystal ..          | 15 |
| metformin hcl .....                     | 51  | mupirocin.....                          | 70     | nitrofurantoin monohyd macro<br>.....   | 16 |
| metformin hcl er .....                  | 51  | mupirocin calcium.....                  | 70     | nitroglycerin .....                     | 64 |
| methadone hcl .....                     | 12  | mycophenolate mofetil .....             | 89     | nizatidine .....                        | 75 |
| methazolamide .....                     | 96  | mycophenolate sodium.....               | 89     | NOC DURNA .....                         | 78 |
| methenamine hippurate .....             | 15  | MYRBETRIQ .....                         | 76     | NORA-BE .....                           | 84 |
| methimazole .....                       | 86  | <b>N</b>                                |        | norethin ace-eth estrad-fe ....         | 82 |
| methocarbamol .....                     | 101 | nabumetone .....                        | 11     | norethindrone.....                      | 84 |
| methotrexate .....                      | 89  | nadolol .....                           | 58     | norethindrone acetate.....              | 84 |
| methotrexate sodium .....               | 89  | nafcillin sodium.....                   | 18     | norethindrone acet-ethinyl est<br>..... | 82 |
| methotrexate sodium (pf) .....          | 89  | naloxone hcl .....                      | 14     | norethindrone-eth estradiol...82        |    |
| methyl dopa.....                        | 56  | naltrexone hcl .....                    | 13     | norgestimate-eth estradiol ....82       |    |
| methylphenidate hcl .....               | 65  | NAMZARIC.....                           | 24     | norgestim-eth estrad triphasic<br>..... | 82 |
| methylprednisolone .....                | 77  | naproxen .....                          | 11, 12 | NORTREL 0.5/35 (28).....                | 82 |
| metoclopramide hcl .....                | 74  | naproxen sodium .....                   | 12     | NORTREL 1/35 (21).....                  | 82 |
| metolazone .....                        | 62  | naratriptan hcl.....                    | 31     | NORTREL 1/35 (28).....                  | 82 |
| metoprolol succinate er .....           | 58  | NARCAN .....                            | 14     | NORTREL 7/7/7 .....                     | 82 |
| metoprolol tartrate .....               | 58  | NATACYN .....                           | 94     | nortriptyline hcl .....                 | 27 |
| metoprolol-<br>hydrochlorothiazide..... | 61  | nateglinide .....                       | 51     | NORVIR.....                             | 48 |
| metronidazole .....                     | 15  | NATPARA .....                           | 93     | NOVOLIN 70/30.....                      | 53 |
| metronidazole in nacl .....             | 15  | NAYZILAM.....                           | 23     | NOVOLIN 70/30 FLEXPEN<br>.....          | 53 |
| metyrosine .....                        | 61  | nebivolol hcl .....                     | 58     | NOVOLIN N .....                         | 53 |
| mexiletine hcl .....                    | 57  | NECON 0.5/35 (28) .....                 | 82     | NOVOLIN N FLEXPEN ....                  | 53 |
| MICROGESTIN 1.5/30 .....                | 81  | nefazodone hcl.....                     | 26     | NOVOLIN R .....                         | 53 |
| MICROGESTIN 1/20 .....                  | 81  | neomycin sulfate.....                   | 14     | NOVOLIN R FLEXPEN.....                  | 53 |
| MICROGESTIN FE 1.5/30..                 | 82  | neomycin-bacitracin zn-<br>polymyx..... | 94     | NOVOLOG .....                           | 54 |
| MICROGESTIN FE 1/20.....                | 82  | neomycin-polymyxin-<br>dexameth .....   | 93     | NOVOLOG FLEXPEN.....                    | 53 |
| midodrine hcl.....                      | 56  | neomycin-polymyxin-<br>gramicidin.....  | 93     | NOVOLOG MIX 70/30 .....                 | 53 |
| miglitol .....                          | 51  | neomycin-polymyxin-hc                   | 93, 96 |                                         |    |
| miglustat.....                          | 76  | NERLYNX.....                            | 37     |                                         |    |
| MILI .....                              | 82  |                                         |        |                                         |    |
| minocycline hcl .....                   | 21  |                                         |        |                                         |    |

|                                  |            |  |
|----------------------------------|------------|--|
| NOVOLOG MIX 70/30                |            |  |
| FLEXPEN .....                    | 53         |  |
| NOVOLOG PENFILL .....            | 54         |  |
| NOXAFIL .....                    | 29         |  |
| NUBEQA .....                     | 32         |  |
| NUCALA .....                     | 100        |  |
| NUEDEXTA .....                   | 65         |  |
| NUPLAZID .....                   | 43         |  |
| NUTRILIPID .....                 | 73         |  |
| NYAMYC .....                     | 29         |  |
| NYLIA 1/35 .....                 | 82         |  |
| NYLIA 7/7/7 .....                | 82         |  |
| NYMYO.....                       | 82         |  |
| nystatin .....                   | 29, 30     |  |
| nystatin-triamcinolone.....      | 69         |  |
| NYSTOP .....                     | 30         |  |
| <b>O</b>                         |            |  |
| OCELLA .....                     | 82         |  |
| octreotide acetate .....         | 85         |  |
| ODEFSEY .....                    | 47         |  |
| ODOMZO .....                     | 37         |  |
| OFEV .....                       | 99         |  |
| ofloxacin.....                   | 20, 94, 96 |  |
| olanzapine.....                  | 43         |  |
| olanzapine-fluoxetine hcl ....   | 25         |  |
| olmesartan medoxomil .....       | 56         |  |
| olmesartan medoxomil-hctz .      | 61         |  |
| olmesartan-amlodipine-hctz .     | 61         |  |
| olopatadine hcl .....            | 94         |  |
| omega-3-acid ethyl esters.....   | 63         |  |
| omeprazole .....                 | 75         |  |
| OMNITROPE.....                   | 78         |  |
| ondansetron .....                | 28         |  |
| ondansetron hcl .....            | 28         |  |
| ONUREG .....                     | 33         |  |
| OPSUMIT .....                    | 99         |  |
| ORFADIN .....                    | 76         |  |
| ORGOVYX.....                     | 34         |  |
| ORKAMBI.....                     | 99         |  |
| orphenadrine citrate er.....     | 101        |  |
| ORSYTHIA.....                    | 82         |  |
| oseltamivir phosphate.....       | 49         |  |
| OSPHENA .....                    | 82         |  |
| oxacillin sodium .....           | 18         |  |
| oxacillin sodium in dextrose     | 18         |  |
| oxandrolone.....                 | 78         |  |
| oxaprozin.....                   | 12         |  |
| oxazepam.....                    | 49         |  |
| oxcarbazepine.....               | 23         |  |
| oxybutynin chloride.....         | 76         |  |
| oxybutynin chloride er.....      | 76         |  |
| oxycodone hcl.....               | 13         |  |
| oxycodone hcl er .....           | 12         |  |
| oxycodone-acetaminophen... 13    |            |  |
| OZEMPIC (0.25 OR 0.5             |            |  |
| MG/DOSE).....                    | 51         |  |
| OZEMPIC (1 MG/DOSE)....          | 51         |  |
| <b>P</b>                         |            |  |
| paliperidone er.....             | 43         |  |
| PANRETIN .....                   | 39         |  |
| pantoprazole sodium.....         | 75         |  |
| PANZYGA.....                     | 86         |  |
| paricalcitol .....               | 93         |  |
| paromomycin sulfate .....        | 14         |  |
| paroxetine hcl .....             | 26         |  |
| PASER.....                       | 32         |  |
| PEDIARIX .....                   | 91         |  |
| PEDVAX HIB.....                  | 91         |  |
| peg 3350-kcl-na bicarb-nacl .    | 74         |  |
| peg-3350/electrolytes .....      | 74         |  |
| PEGASYS .....                    | 87         |  |
| PEMAZYRE .....                   | 37         |  |
| penicillamine .....              | 77         |  |
| penicillin g pot in dextrose ... | 18         |  |
| penicillin g potassium.....      | 18         |  |
| penicillin g procaine .....      | 18         |  |
| penicillin g sodium .....        | 18         |  |
| penicillin v potassium.....      | 18         |  |
| PENTACEL.....                    | 91         |  |
| pentamidine isethionate.....     | 40         |  |
| pentoxifylline er .....          | 61         |  |
| perindopril erbumine .....       | 57         |  |
| PERIOGARD .....                  | 66         |  |
| permethrin .....                 | 69         |  |
| perphenazine.....                | 42         |  |
| phenelzine sulfate .....         | 25         |  |
| phenobarbital .....              | 22         |  |
| phenytoin.....                   | 23         |  |
| phenytoin sodium extended.       | 23,        |  |
| 24                               |            |  |
| PIFELTRO .....                   | 47         |  |
| pilocarpine hcl .....            | 66, 96     |  |
| pimecrolimus.....                | 68         |  |
| pimozide .....                   | 42         |  |
| PIMTREA .....                    | 82         |  |
| pindolol.....                    | 58         |  |
| pioglitazone hcl .....           | 52         |  |
| pioglitazone hcl-glimepiride.    | 52         |  |
| pioglitazone hcl-metformin hcl   |            |  |
| .....                            | 52         |  |
| piperacillin sod-tazobactam so   |            |  |
| .....                            | 19         |  |
| PIQRAY (200 MG DAILY             |            |  |
| DOSE) .....                      | 37         |  |
| PIQRAY (250 MG DAILY             |            |  |
| DOSE) .....                      | 37         |  |
| PIQRAY (300 MG DAILY             |            |  |
| DOSE) .....                      | 37         |  |
| PIRMELLA 1/35 .....              | 82         |  |
| piroxicam.....                   | 12         |  |
| PLASMA-LYTE 148 .....            | 71         |  |
| PLASMA-LYTE A .....              | 71         |  |
| podofilox.....                   | 69         |  |
| polymyxin b-trimethoprim ...     | 93         |  |
| POMALYST.....                    | 32         |  |
| PORTIA-28 .....                  | 83         |  |
| posaconazole.....                | 30         |  |
| potassium chloride.....          | 71         |  |
| potassium chloride crys er ....  | 71         |  |
| potassium chloride er.....       | 71         |  |
| potassium chloride in dextrose   |            |  |
| .....                            | 71         |  |
| potassium chloride in nacl ....  | 71         |  |
| potassium citrate er.....        | 71         |  |
| pramipexole dihydrochloride      | 41         |  |
| prasugrel hcl .....              | 56         |  |
| pravastatin sodium.....          | 63         |  |
| prazosin hcl.....                | 56         |  |
| prednicarbate .....              | 68         |  |
| prednisolone .....               | 77         |  |
| prednisolone acetate .....       | 95         |  |
| prednisolone sodium phosphate    |            |  |
| .....                            | 77, 95     |  |
| prednisone.....                  | 78         |  |
| PREDNISONE INTENSOL.             | 78         |  |
| preferred plus insulin syringe   |            |  |
| .....                            | 54         |  |
| pregabalin .....                 | 65         |  |
| PREMARIN .....                   | 79         |  |
| PREMASOL.....                    | 73         |  |
| PREMPHASE.....                   | 83         |  |
| PREMPRO .....                    | 83         |  |
| prenatal .....                   | 73         |  |
| PREVIFEM .....                   | 83         |  |
| PREVYMIS .....                   | 45         |  |
| PREZCOBIX.....                   | 48         |  |
| PREZISTA .....                   | 49         |  |
| PRIFTIN .....                    | 31         |  |
| primaquine phosphate.....        | 40         |  |
| primidone.....                   | 22         |  |

|                                |        |                               |    |                                |        |
|--------------------------------|--------|-------------------------------|----|--------------------------------|--------|
| PRIVIGEN .....                 | 86     | repaglinide .....             | 52 | SELZENTRY .....                | 48     |
| probenecid .....               | 30     | REPATHA.....                  | 63 | SEREVENT DISKUS .....          | 98     |
| PROCALAMINE .....              | 73     | REPATHA PUSHTRONEX            |    | sertraline hcl .....           | 26     |
| prochlorperazine.....          | 28     | SYSTEM .....                  | 63 | SETLAKIN.....                  | 83     |
| prochlorperazine maleate ..... | 28     | REPATHA SURECLICK ....        | 63 | sevelamer carbonate .....      | 73     |
| PROCTO-MED HC .....            | 68     | RESTASIS.....                 | 94 | SHAROBEL .....                 | 84     |
| PROCTO-PAK.....                | 68     | RESTASIS MULTIDOSE ...        | 94 | SHINGRIX .....                 | 91     |
| PROCTOSOL HC .....             | 68     | RETACRIT .....                | 55 | SIGNIFOR.....                  | 85     |
| PROCTOZONE-HC.....             | 68     | RETEVMO.....                  | 37 | sildenafil citrate .....       | 99     |
| progesterone .....             | 84     | REVLIMID .....                | 33 | silodosin.....                 | 77     |
| PROGRAF .....                  | 89     | REXULTI.....                  | 44 | silver sulfadiazine .....      | 69     |
| PROLASTIN-C .....              | 76     | REYATAZ .....                 | 49 | SIMBRINZA .....                | 96     |
| PROLIA .....                   | 93     | REZUROCK .....                | 89 | simvastatin.....               | 63     |
| PROMACTA.....                  | 55     | RHOPRESSA.....                | 96 | sirolimus .....                | 89     |
| promethazine hcl .....         | 28     | ribavirin .....               | 45 | SIRTURO .....                  | 32     |
| propafenone hcl .....          | 57     | rifabutin .....               | 31 | SKYRIZI .....                  | 87     |
| propranolol hcl .....          | 30, 58 | rifampin .....                | 32 | SKYRIZI (150 MG DOSE) ..       | 87     |
| propranolol hcl er .....       | 30, 58 | riluzole.....                 | 65 | SKYRIZI PEN.....               | 87     |
| propylthiouracil .....         | 86     | rimantadine hcl .....         | 49 | sodium chloride .....          | 71     |
| PROQUAD.....                   | 91     | RINVOQ .....                  | 87 | sodium fluoride.....           | 71     |
| PROSOL.....                    | 73     | risedronate sodium .....      | 93 | sodium polystyrene sulfonate   |        |
| protriptyline hcl .....        | 27     | RISPERDAL CONSTA .....        | 44 | .....                          | 72     |
| PULMOZYME.....                 | 99     | risperidone .....             | 44 | sofosbuvir-velpatasvir .....   | 45     |
| PURIXAN .....                  | 33     | ritonavir .....               | 49 | solifenacin succinate.....     | 76     |
| pyrazinamide .....             | 32     | rivastigmine .....            | 24 | SOLIQUA.....                   | 54     |
| pyridostigmine bromide .....   | 31     | rivastigmine tartrate.....    | 24 | SOLTAMOX .....                 | 33     |
| <b>Q</b>                       |        | rizatriptan benzoate .....    | 31 | SOMAVERT .....                 | 85     |
| QINLOCK.....                   | 37     | ROCKLATAN .....               | 96 | sotalol hcl.....               | 58     |
| QUADRACEL .....                | 91     | ropinirole hcl .....          | 41 | sotalol hcl (af).....          | 57, 58 |
| quetiapine fumarate .....      | 44     | rosuvastatin calcium .....    | 63 | SPIRIVA HANDIHALER ...         | 98     |
| quetiapine fumarate er ....    | 43, 44 | ROTARIX .....                 | 91 | SPIRIVA RESPIMAT .....         | 98     |
| quinapril hcl.....             | 57     | ROTATEQ .....                 | 91 | spironolactone.....            | 62     |
| quinapril-hydrochlorothiazide  |        | ROZLYTREK .....               | 37 | spironolactone-hctz.....       | 61     |
| .....                          | 61     | RUBRACA.....                  | 37 | SPRINTEC 28 .....              | 83     |
| quinidine sulfate .....        | 57     | rufinamide .....              | 24 | SPRITAM.....                   | 22     |
| quinine sulfate .....          | 40     | RUKOBIA.....                  | 48 | SPRYCEL.....                   | 38     |
| <b>R</b>                       |        | RYBELSUS.....                 | 52 | SPS .....                      | 72     |
| RABAVERT .....                 | 91     | RYDAPT .....                  | 38 | SRONYX.....                    | 83     |
| raloxifene hcl.....            | 93     | RYTARY.....                   | 41 | SSD.....                       | 69     |
| ramipril .....                 | 57     | <b>S</b>                      |    | STELARA .....                  | 87     |
| ranolazine er .....            | 61     | SANTYL .....                  | 69 | STIVARGA .....                 | 38     |
| rasagiline mesylate .....      | 41     | sapropterin dihydrochloride . | 76 | STRIBILD .....                 | 46     |
| RAVICTI.....                   | 76     | SAVELLA.....                  | 65 | SUBOXONE .....                 | 14     |
| RECLIPSEN.....                 | 83     | SAVELLA TITRATION             |    | sucralfate.....                | 75     |
| RECOMBIVAX HB .....            | 91     | PACK .....                    | 65 | sulfacetamide sodium .....     | 94     |
| RECTIV .....                   | 64     | SCEMBLIX.....                 | 34 | sulfacetamide sodium (acne) 20 |        |
| REGRANEX .....                 | 69     | scopolamine.....              | 28 | sulfacetamide-prednisolone ..  | 94     |
| RELENZA DISKHALER ....         | 49     | SECUADO .....                 | 44 | sulfadiazine.....              | 20     |
| RELI-ON INSULIN                |        | selegiline hcl.....           | 41 | sulfamethoxazole-trimethoprim  |        |
| SYRINGE.....                   | 54     | selenium sulfide.....         | 68 | .....                          | 20     |

|                                 |        |                                 |        |                           |        |
|---------------------------------|--------|---------------------------------|--------|---------------------------|--------|
| sulfasalazine .....             | 92     | TEPMETKO.....                   | 38     | TRECTOR.....              | 32     |
| sulindac.....                   | 12     | terazosin hcl.....              | 56     | TRELEGY ELLIPTA.....      | 100    |
| sumatriptan.....                | 31     | terbinafine hcl.....            | 30     | TRELSTAR MIXJECT.....     | 85     |
| sumatriptan succinate.....      | 31     | terbutaline sulfate.....        | 98     | TRESIBA.....              | 54     |
| sumatriptan succinate refill .. | 31     | terconazole.....                | 30     | TRESIBA FLEXTOUCH.....    | 54     |
| sunitinib malate.....           | 38     | teriparatide (recombinant) .... | 93     | tretinoin.....            | 39, 66 |
| SUNOSI .....                    | 101    | testosterone.....               | 79     | TREXALL.....              | 89     |
| SUPREP BOWEL PREP KIT           |        | testosterone cypionate.....     | 78     | triamcinolone acetonide.. | 66, 69 |
| .....                           | 74     | testosterone enanthate.....     | 78     | triamterene-hctz.....     | 61     |
| SUTAB.....                      | 74     | tetrabenazine.....              | 65     | trientine hcl.....        | 72     |
| SYEDA.....                      | 83     | tetracycline hcl .....          | 21     | TRI-ESTARYLLA.....        | 83     |
| SYMDEKO.....                    | 99     | THALOMID.....                   | 33     | trifluoperazine hcl.....  | 42     |
| SYMLINPEN 120.....              | 52     | theophylline er.....            | 99     | trifluridine.....         | 46     |
| SYMLINPEN 60.....               | 52     | thioridazine hcl.....           | 42     | trihexyphenidyl hcl.....  | 40     |
| SYMPAZAN.....                   | 23     | thiothixene.....                | 42     | TRIKAFTA.....             | 99     |
| SYMTUZA.....                    | 46     | TIADYLT ER.....                 | 59     | trimethoprim.....         | 16     |
| SYNAREL.....                    | 85     | tiagabine hcl .....             | 23     | TRI-MILI.....             | 83     |
| SYNJARDY.....                   | 52     | TIBSOVO.....                    | 38     | trimipramine maleate..... | 27     |
| SYNJARDY XR.....                | 52     | TICOVAC.....                    | 91     | TRINTELLIX.....           | 27     |
| SYNRIBO.....                    | 34     | tigecycline.....                | 16     | TRI-NYMYO.....            | 83     |
| SYNTHROID.....                  | 85     | timolol maleate.....            | 58, 95 | TRI-SPRINTEC.....         | 83     |
| <b>T</b>                        |        | timolol maleate (once-daily)    | 95     | TRIUMEQ.....              | 48     |
| TABLOID.....                    | 33     | tinidazole.....                 | 16     | TRIVORA (28).....         | 83     |
| TABRECTA.....                   | 38     | TIVICAY.....                    | 46     | TRI-VYLIBRA.....          | 83     |
| tacrolimus.....                 | 68, 89 | TIVICAY PD.....                 | 46     | TROPHAMINE.....           | 73     |
| TAFINLAR.....                   | 38     | tizanidine hcl .....            | 45     | trospium chloride.....    | 77     |
| TAGRISSO.....                   | 38     | TOBI PODHALER.....              | 99     | trospium chloride er..... | 76     |
| TAKHZYRO.....                   | 86     | tobramycin.....                 | 94, 99 | TRULICITY.....            | 52     |
| TALZENNA.....                   | 38     | tobramycin sulfate.....         | 14     | TRUMENBA.....             | 91     |
| tamoxifen citrate.....          | 33     | tobramycin-dexamethasone..      | 94     | TRUSELTIQ (100MG DAILY    |        |
| tamsulosin hcl.....             | 77     | tolterodine tartrate.....       | 76     | DOSE).....                | 38     |
| TARGRETIN.....                  | 39     | tolterodine tartrate er.....    | 76     | TRUSELTIQ (125MG DAILY    |        |
| TARINA FE 1/20 EQ.....          | 83     | tolvaptan.....                  | 72     | DOSE).....                | 38     |
| TASIGNA.....                    | 38     | topiramate.....                 | 31     | TRUSELTIQ (50MG DAILY     |        |
| TAVNEOS.....                    | 87     | topiramate er.....              | 31     | DOSE).....                | 38     |
| tazarotene.....                 | 66     | toremifene citrate.....         | 33     | TRUSELTIQ (75MG DAILY     |        |
| TAZORAC.....                    | 66     | torsemide.....                  | 62     | DOSE).....                | 38     |
| TAZTIA XT.....                  | 59     | TOUJEO MAX SOLOSTAR             |        | TUKYSA.....               | 38     |
| TAZVERIK.....                   | 38     | .....                           | 54     | TURALIO.....              | 38     |
| TDVAX.....                      | 91     | TOUJEO SOLOSTAR.....            | 54     | TWINRIX.....              | 91     |
| TEFLARO.....                    | 17     | TPN ELECTROLYTES.....           | 73     | TYBOST.....               | 48     |
| TEGSEDI.....                    | 76     | tramadol hcl.....               | 13     | TYMLOS.....               | 93     |
| TEKTURN HCT.....                | 61     | tramadol-acetaminophen.....     | 13     | TYPHIM VI.....            | 91     |
| telmisartan.....                | 56     | trandolapril.....               | 57     | <b>U</b>                  |        |
| telmisartan-hctz.....           | 61     | tranexamic acid.....            | 55     | UBRELVY.....              | 31     |
| temazepam.....                  | 101    | TRANSDERM-SCOP.....             | 28     | UKONIQ.....               | 38     |
| TEMIXYS.....                    | 48     | tranylcypramine sulfate.....    | 25     | UNITHROID.....            | 85     |
| TENIVAC.....                    | 91     | TRAVASOL.....                   | 73     | ursodiol.....             | 74, 75 |
| tenofovir disoproxil fumarate   |        | travoprost (bak free).....      | 96     | <b>V</b>                  |        |
| .....                           | 48     | trazodone hcl.....              | 26, 27 | valacyclovir hcl.....     | 46     |



|                               |    |                         |    |                            |     |
|-------------------------------|----|-------------------------|----|----------------------------|-----|
| VALCHLOR.....                 | 32 | VIRACEPT .....          | 49 | XPOVIO (60 MG ONCE         |     |
| valganciclovir hcl .....      | 45 | VIREAD .....            | 48 | WEEKLY) .....              | 34  |
| valproic acid .....           | 22 | VITRAKVI.....           | 39 | XPOVIO (60 MG TWICE        |     |
| valsartan .....               | 57 | VIVITROL .....          | 13 | WEEKLY) .....              | 34  |
| valsartan-hydrochlorothiazide |    | VIZIMPRO.....           | 39 | XPOVIO (80 MG ONCE         |     |
| .....                         | 61 | voriconazole .....      | 30 | WEEKLY) .....              | 34  |
| VALTOCO 10 MG DOSE ...        | 23 | VOSEVI .....            | 45 | XPOVIO (80 MG TWICE        |     |
| VALTOCO 15 MG DOSE ...        | 23 | VOTRIENT .....          | 39 | WEEKLY) .....              | 34  |
| VALTOCO 20 MG DOSE ...        | 23 | VRAYLAR.....            | 44 | XTANDI.....                | 32  |
| VALTOCO 5 MG DOSE ....        | 23 | VYFEMLA.....            | 83 | XULTOPHY .....             | 52  |
| vancomycin hcl .....          | 16 | VYLIBRA .....           | 83 | XURIDEN .....              | 76  |
| VAQTA .....                   | 91 | VYNDAMAX .....          | 76 | XYREM.....                 | 101 |
| varenicline tartrate .....    | 14 | <b>W</b>                |    | XYWAV .....                | 101 |
| VARIVAX .....                 | 92 | warfarin sodium.....    | 55 | <b>Y</b>                   |     |
| VARUBI (180 MG DOSE) ..       | 28 | WELIREG .....           | 39 | YF-VAX .....               | 92  |
| VASCEPA.....                  | 63 | <b>X</b>                |    | YONSA .....                | 32  |
| VELIVET .....                 | 83 | XALKORI .....           | 39 | <b>Z</b>                   |     |
| VELPHORO.....                 | 73 | XARELTO .....           | 55 | zafirlukast .....          | 98  |
| VEMLIDY .....                 | 45 | XARELTO STARTER PACK    |    | zaleplon.....              | 101 |
| VENCLEXTA.....                | 38 | .....                   | 55 | ZARXIO .....               | 55  |
| VENCLEXTA STARTING            |    | XATMEP.....             | 34 | ZEJULA .....               | 39  |
| PACK .....                    | 39 | XCOPRI .....            | 22 | ZELBORAF .....             | 39  |
| venlafaxine hcl .....         | 27 | XCOPRI (250 MG DAILY    |    | ZEMDRI.....                | 15  |
| venlafaxine hcl er .....      | 27 | DOSE) .....             | 22 | ZENPEP .....               | 76  |
| VENTOLIN HFA.....             | 98 | XCOPRI (350 MG DAILY    |    | zidovudine .....           | 48  |
| verapamil hcl .....           | 60 | DOSE) .....             | 22 | ZIEXTENZO .....            | 55  |
| verapamil hcl er .....        | 60 | XGEVA .....             | 93 | ziprasidone hcl .....      | 44  |
| VERQUVO .....                 | 61 | XIFAXAN .....           | 16 | ziprasidone mesylate ..... | 44  |
| VERSACLOZ .....               | 45 | XOFLUZA (40 MG DOSE) .. | 49 | ZIRGAN .....               | 45  |
| VERZENIO.....                 | 39 | XOFLUZA (80 MG DOSE) .. | 49 | ZOLINZA.....               | 34  |
| VESTURA .....                 | 83 | XOLAIR.....             | 87 | zolmitriptan.....          | 31  |
| VICTOZA .....                 | 52 | XOSPATA.....            | 39 | zolpidem tartrate .....    | 101 |
| VIENVA.....                   | 83 | XPOVIO (100 MG ONCE     |    | zonisamide .....           | 22  |
| vigabatrin.....               | 23 | WEEKLY).....            | 34 | ZOVIA 1/35 (28).....       | 83  |
| VIIBRYD .....                 | 27 | XPOVIO (40 MG ONCE      |    | ZYDELIG .....              | 39  |
| VIIBRYD STARTER PACK          |    | WEEKLY).....            | 34 | ZYKADIA.....               | 39  |
| .....                         | 27 | XPOVIO (40 MG TWICE     |    | ZYPITAMAG.....             | 63  |
| VIMPAT.....                   | 24 | WEEKLY).....            | 34 | ZYPREXA RELPREVV .....     | 44  |

This formulary was updated on 04/18/2022. For more recent information or other questions, please contact Alterwood Advantage Choice Member Service at 1-866-267-3144 toll-free (TTY users should call 711), 24 hours 7 days a week, or visit [www.alterwoodadvantage.com](http://www.alterwoodadvantage.com).

**Please review this document to make sure that it contains the drug(s) you take.** The formulary may change at any time. You must generally use network pharmacies to use your prescription drug benefit.

Benefits, formulary, pharmacy network, provider network, premiums, and/or copayments/coinsurance may change on January 1 each year and updated from time to time during the year. For Alterwood Advantage Choice members, your premiums, deductible, and copays/coinsurance may vary depending on the “Extra Help” you receive.



This formulary was updated on 04/18/2022. For more recent information or other questions, please contact Alterwood Advantage Member Services, at 1-866-267-3144 or for TTY users, 711, 24 hours a day, 7 days a week, or visit [www.AlterwoodAdvantage.com](http://www.AlterwoodAdvantage.com).

Alterwood Advantage is an HMO and HMO SNP with a Medicare contract and a State of Maryland Medicaid contract. Enrollment in Alterwood Advantage depends on contract renewal.

The Formulary may change at any time. You will receive notice when necessary.

Benefits, formulary, pharmacy network, provider network, premium and/or co-payments/coinsurance may change on January 1 of each year. For Alterwood Advantage Dual Secure member premiums, co-pays, co-insurance, and deductibles may vary based on the level of Extra Help you receive. Please contact the plan for further details.

This information is available for free in other languages. Please call our Member Services number at 1-866-267-3144 or, for TTY users, 711, 24 hours a day, 7 days a week. Member Services also has free language interpreter services available for non-English speakers.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.